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In this thesis I examined the potential of Bio-Oligomers such as peptoids, peptides 




A series of peptoid analogs have been designed and synthesised using solid phase 
synthesis. These peptoids have been subjected to biological evaluation to determine 
structure-activity relationships that define their antimicrobial activity. In total 13 
peptoids were synthesised. Out of 13 different peptoids, only one peptoid called 
Tosyl-Octyl-Peptoid (TOP) demonstrated significant broad-spectrum bactericidal 
activity. TOP kills bacteria under non-dividing and dividing conditions. The 
Minimum Inhibitory Concentrations (MIC) values of TOP for S. epidermidis, E. coli 
and Klebsiella were 20 µM, whereas Methicillin-resistant Staphylococcus aureus 
(MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA) were 40 µM. The 
highest MIC values were observed for Pseudomonas aeruginosa (PAO1) at 80 µM. 
The selectivity ratio (SR) or Therapeutic index (TI) was calculated, by dividing the 
10% haemolysis activity (5 mM) by the median of the MIC (50 µM) yielding a TI for 
TOP as 100. This TI is well above previously reported peptidomimetics TI of around 
20. TOP demonstrates selective bacterial killing in co-culture systems and 




In the second part of my thesis, I investigated aptamer and peptide-based molecular 
probes to detect MRSA. As well as screening aptamers and peptide probes against 
whole MRSA, I over-expressed and purified PBP2A protein. This purified protein 
was used as a target for aptamer and peptide probes to detect MRSA.  
 
Two different aptamer libraries were initially screened for utility. In-vitro conditions 
for SELEX were optimised. Biopanning with a phage derived peptides was also 
performed. Target sequences for both methods were identified and chemically 
synthesised. Evaluation of fluorescently labelled sequences with flow cytometry and 
confocal imaging showed no specificity for MRSA detection with either method. The 
Bio-Oligomers and the in-vitro selection methodology require further refinement to 
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Chapter 1:   Introduction 
Chapter 1: Introduction 
 
In my PhD, I have focused on two thematic research areas in bacteriology; 
antibacterial drug development and molecular diagnostics. Therefore in the first part 
of my work, I have investigated the antibacterial properties of peptoid molecules for 
therapeutic purposes. The rest of my research work focused on efforts to develop 
methicillin-resistant S. aureus (MRSA) diagnostic molecular probes using Aptamers 
and Peptide derived peptides. The thesis hence encompasses the following two 
investigations; 
 
(a) Study and characterisation of peptoids as a novel antimicrobial agents. 





1.1.1. Introduction to antibiotics 
 
Antimicrobial drugs or antibiotics are biologically active molecules that act against 
microorganisms. Most antibiotics for use in humans are natural products, secreted by 
one species of microbes (bacteria or fungi) as chemical defence mechanisms to kill 
microbes in the neighbouring microenvironment. Semisynthetic modifications of 
those have produced second, third and fourth generations of antibiotics. They have 
different modes of action but the majority inhibit essential microbial functions such 
as protein synthesis, DNA replication and cell-wall synthesis. Antibiotics are the 
most successful form of chemotherapy developed and applied in the past century in 
medicine (Wright, 2010; Gualerzi, 2014).  
 
After the introduction of antibiotics in 1940s and 1950s patients with bacteraemia 
had improved chance of survival and decreased mortality due to infection (Ekdahl, 
1995). New classes of antimicrobial agents rapidly entered the market in the 1950s 
and 1960s and this led to over-confidence that infectious disease would be 
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eradicated. In addition to that research into discovering new broad-spectrum 
antimicrobial drugs with previously unexploited modes of action was discouraged by 
pharmaceutical companies due to the large costs of research (Beutler, 2009). This 
includes the discovery and development of new drugs as it is a long and increasingly 
expensive process until approval is obtained. Once the new compounds finally reach 
the market it is difficult to recover the cost invested in the development. Therefore 
mostly the discovery efforts are concentrated in chemical synthesis and the 
development of large combinatorial libraries for automated high-throughput 
screening (HTS), this may reduce the time and expense involved in natural product 
discovery (Beutler, 2009; Li and Vederas, 2009). However despite having 
technological advances particularly in the area of molecular biology, genomics, 
combinatorial chemistry HTSs have provided highly efficient tools to expedite, 
increase, and improve drug discovery, here has been little success in identifying new 
leads for the development of new classes of antibiotics approved for human use. This 
failure reflects the particular challenges of antibiotic discovery (Livermore, 2011). 
 
No new classes of antibiotics were produced in the 37 years between the introduction 
of nalidixic acid in 1962 and linezolid in 2000 (Bax et al., 1998) (Figure 1.1).  All of 
the antibacterial agents that entered the market during this period were modifications 
of existing molecules. Therefore more than 20 novel classes of antibiotics were 
produced between 1930 and 1962 and only four new classes of antibiotics were 
marketed. However none of these new classes were really novel: daptomycin, 
approved in 2000, was discovered in the early 1980s; linezolid, approved in 2000, 
derives from a synthetic lead discovered in the 1970s; pleuromutilins, approved in 
2007, have been widely used for about 30 years in veterinary medicine; fidaxomicin, 
approved in 2011, was first reported in the 1970s (Endimiani et al., 2009; Houghton 
et al., 2010; Sutcliffe, 2011). During this window period bacteria exploited this 
opportunity and progressively developed resistance to all commonly used antibiotics 
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Figure 1.1: Timeline of the discovery of the most important antibiotic classes. Illustrating the 
innovation gap, between 1962 and 2000, no major classes of antibiotics were introduced 
(Fischbach and Walsh, 2009). 
 
Now every country in the world has antibiotic-resistant bacteria. In some regions, 
25% of the most common cause of community acquired pneumonia, Streptococcus 
pneumoniae, are resistant to penicillin (Thornsberry et al., 2002) and more than 70% 
of bacteria that give rise to hospital-acquired infections in the United States resist at 
least one of the main antimicrobial agents that are typically used to fight infection 
(Brinsley et al., 2005). Until the recent development of new antimicrobial agents, the 
antibiotic vancomycin was the ‘antibiotic of last resort’ for the treatment of multiple 
drug-resistant Staphylococcus aureus, and now the first case of fully vancomycin-
resistant S. aureus has been reported (Sievert, 2002). The scale of the problem 
become much severe due to many Western countries prescribing antimicrobial drugs 
by community doctors at the rate of 4–5 courses per person each year and 20% of all 
patients who enter hospital have or acquire an infection an increased rate of 
nosocomial infection  (Bryskier, 2000).  
 
Approximately 50 percent of antimicrobial agents are also used in veterinary 
medicine and agriculture and there has been increasing concern that such practise is 
contributing to the emergence of antibiotic resistance. The use of antibiotics as 
growth promoters in animal food is  particularly controversial and several antibiotics 
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or their close relatives are considered to be particularly important for human health 
such as avoparcin, which is very similar to vancomycin, have been banned from use 
in animal foods (Office, 1999). In Denmark in 1994, 24,000 kg of a vancomycin 
derivative called avoparcin was used for animal health, 1,000 times higher than the 
24 kg of vancomycin used to treat human infections in the same year (Witte, 1998). 
When pigs treated with avoparcin were analysed for vancomycin-resistant 
enterococci (VRE) strains, they contained the same five gene operons that encode 
vancomycin resistance in enterococci isolated from nonresponsive human patients. 
This lead to restriction on the use of avoparcin as an additive to animal feed (Office, 
1999). 
 
1.1.2. Discovery strategies and sources of classes of antibacterial 
 
Antibiotics have been discovered by empirical screening or phenotypic screening. 
The empirical screening was practised to screen chemicals that kill or inhibit growth 
of bacteria without prior knowledge of mechanism of action. In contrast to 
phenotypic screens, more specifically, whole-cell screens that detect the inhibition of 
a desired target or function, in a way corresponding to selecting genetic mutants by 
their demonstration of an expected phenotype (Wong et al., 2012). 
 
The rationale behind the discovery strategies employed since the 1960s have not 
been very productive in bringing drugs to market. The successful era of empiric 
screening involved screening for inhibition of cell growth without knowing the 
mechanism of action coincided with the Golden Age of natural product (NP) 
discovery (from the 1940s to the late 1960s). Most classes of antibacterial drugs for 
human and animal health were indeed discovered by empirical screening of NPs. The 
screening used freshly fermented broths or extracts as opposed to the current 
methods involve rapid chemical fractionation and identification and comparison to 
databases of known NPs (Wong et al., 2012; Gualerzi, 2014). Table 1.1 shows the 
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Table 1.1: Sources of clinically used classes of antibacterial drugs. (Gualerzi, 2014) 
 
Drug class  Source Discovery strategy 
β-lactams  
 
NP-Fungi, actinomycetes Empirical; also by 
spheroplasting (cell wall) 
Glycopeptides  NP- Actinomycetes Empirical 
Fluoroquinolones  Synthetic-Quinine analogs Empirical 
Aminoglycosides  NP-Actinomycetes Empirical 
Tetracyclines  NP-Actinomycetes Empirical 
Oxazolidinones  Synthetic-Industrial library Empirical 
Macrolides  NP-Actinomycetes Empirical 
Lincosamides  NP-Actinomycetes Empirical 
Streptogramins  NP-Actinomycetes Empirical 
Chloramphenicol  NP-Actinomycetes Empirical 
Metronidazole  Synthetic-Azomycin analogs Empirical 
Polymyxin  NP-Bacillus Empirical 
Daptomycin  NP-Actinomycetes Empirical 
Pleuromutilin  NP-Fungi Empirical 
Trimethoprim  
 
Synthetic-Pyrimidines Target-based for DHFR 
inhibition 
Sulfamethoxazole  Synthetic-Azo-dyes Empirical in limited 
Rifampicin  NP-Actinomycetes Empirical 
Mupirocin  NP-Pseudomonas Empirical 
Fosfomycin  
 
NP-Actinomycetes Phenotypic by 
spheroplasting (cell wall) 
Fusidic acid  NP-Fungi Empirical 
Fidaxamicin  NP-Actinomycetes Empirical 
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1.1.3. Antibacterial targets 
 
The fundamental requirement for an antibacterial target is that it is important for 
growth and viability of the pathogen. The vast majority of current antibiotics target 
similar cellular processes as their natural or synthetic predecessors. The range of 
these targets is limited to the components of protein synthesis, cell wall biosynthesis, 
DNA/ RNA metabolism and some other cellular processes. Antibiotic, such as 
ciprofloxacin are synthetic antibiotic structures that kill bacteria by targeting the 
enzyme DNA gyrase the enzyme responsible for uncoiling the intertwined circles of 
double-stranded bacterial DNA that arise after each round of DNA replication 
(Hooper and Wolfson, 1993). The RNA and protein machinery of the prokaryotic 
ribosomes is sufficiently distinct from the analogous eukaryotic machinery that there 
are many inhibitors of protein synthesis, targeting different steps in ribosome action, 
with selective antibacterial action. With the extensive range of genomes sequenced, it 
becomes possible to implement the idea in a more elaborate way, with essential 
targets defined much more precisely at the molecular level. This needs to be 
complemented by the availability of chemically diverse compound collections to 
screen for the target/ drug combination (Payne et al., 2007; Aminov, 2010). 
 
There are five major modes of action of antibiotics involved in bacterial killing as 
describe below (Morar and Wright, 2010; Gualerzi, 2014) (Figure 1.2 and Table 1.2); 
   
1 Interference with cell-wall synthesis. 
2 Inhibition of protein synthesis. 
3 Interference with nucleic acid synthesis. 
4 Inhibition of cofactor biosynthetic pathways. 
5 Membrane pore formation. 
 
Identifying the novel drug/ target combinations in pathogens is important for future 
discovery of antimicrobials. For example suppression of an important virulence 
factors, bacterial secretion systems (Negrea et al., 2007), inhibition of the histidine 
sensor kinase, virulence gene expression in several pathogens (Rasko et al., 2008), 
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inhibiting an important enzyme involved in Staphylococcus aureus virulence, as a 
candidate drug target to control MRSA (Chia et al., 2008). Other potential targets for 
intervention in bacterial metabolism include fatty acid biosynthesis (Su and Honek, 
2007), cell division (Lock and Harry, 2008), biosynthesis of tRNAs (Schimmel et al., 
1998), quorum sensing (Njoroge and Sperandio, 2009), bacterial two-component 
signal transduction (Gotoh et al., 2010), and proton motive force (Diacon et al., 
2009). Antibiotic resistance mechanisms themselves such as efflux pumps or β-
lactamases can also be targeted to restore the efficacy of antibiotics, which is 



















Figure 1.2: Bacterial targets of the most common antibiotics. Antibiotics target essential 
bacterial physiology and biochemistry, causing microbial cell death or the stop growth. There 
are five major antibiotic targets: the bacterial cell wall, the cell membrane, protein synthesis, 
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Table 1.2: Targets of clinically used classes of antibacterial drugs (Morar and Wright, 2010). 
 
Drug class  Pathway Target Use 
β-lactams  Cell-wall synthesis PBPs SYSMT 
Glycopeptides  Cell-wall synthesis Lipid II SYSMT 
Fluoroquinolones  DNA replication DNA Gyr/Topo IV SYSMT 
Aminoglycosides  Protein synthesis 16S rRNA SYSMT 
Tetracyclines  Protein synthesis 16S rRNA SYSMT 
Oxazolidinones  Protein synthesis 23S rRNA SYSMT 
Macrolides  Protein synthesis 23S rRNA SYSMT 
Lincosamides  Protein synthesis 23S rRNA SYSMT 
Streptogramins  Protein synthesis 23S rRNA SYSMT 
Chloramphenicol  Protein synthesis 23S rRNA SYSMT 
Metronidazole   DNA SYSMT 
Polymyxin   Cell membrane SYSMT 
Daptomycin   Cell membrane SYSMT 
Pleuromutilin  Protein synthesis 23S rRNA Topical therapy 
Trimethoprim  Folate synthesis DHFR (FolA) Systemic in combination 
Sulfamethoxazole  Folate synthesis FolP Systemic in combination 
Rifampicin  RNA synthesis RNA polymerase Systemic in combination 
Mupirocin  Protein synthesis Ile tRNA synthetase Topical therapy 
Fosfomycin  Cell-wall synthesis MurA Systemic UTI 
Fusidic acid  Protein synthesis Ef-G Systemic UTI 
Fidaxamicin  
 
RNA synthesis RNA polymerase Oral (nonabsorbed) 
for C. difficile 
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1.1.4. Antibiotics and resistance 
 
Microbial infectious diseases in human and farmed animals contribute significant 
morbidity and mortality throughout history. This significantly improved when 
penicillin and other classes of antibiotics were discovered and used to treat infectious 
diseases. However, almost as soon as antibacterial drugs were introduced in clinics, 
bacterial resistance spread resulting huge burden to the economy (Abraham and 
Chain, 1940; Tenover, 2006). 
 
Molecular basis of antimicrobial resistance; 
(A) Intrinsic resistance 
(B) Acquired resistance 
1 Mutation 
2 Horizontal gene transfer 
 
If the microorganisms become resistant above their previously predefined threshold 
minimum inhibitory concentration (MIC) values, then they are classified as drug 
resistant.  Bacterial resistance is very important for medical, social, and economical 
viewpoint and often results in treatment failure and this implies an added cost on 
healthcare (Cosgrove and Carmeli, 2003). However it is fascinating and important in 
biology, molecular evolution of drug resistant strains and selection of fine 
mechanisms that allow survival under unfavourable circumstances (Gualerzi, 2014).  
 
The evolution of drug resistant strains is common in pathogenic and non-pathogenic 
bacteria under the selective pressure of antibiotics. The concept of ‘‘resistome’’ was 
introduced to understand the evolution of resistance genes within microbial 
populations and the spread of these genes between species and genera (Wright, 
2007). The function of the resistome genetic elements is to counteract with toxic 
effects of antibiotic drugs. Furthermore, the resistome also comprises the collection 
of genes, called proto-resistance genes, which have the potential to evolve into 
resistance elements against antibiotic drugs (Morar and Wright, 2010). Many 
resistance genes have been isolated from clinically relevant strains and non-
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pathogenic organisms as well. Antibiotic-producing environmental bacteria are likely 
the original source reflecting the continuous evolution of antibiotic resistance strains 
pressure to survive in their environment (Baltz, 2008; Morar and Wright, 2010).  
 
This hypothesis is supported by the presence of drug resistance elements in 
antibiotic-producing bacteria that have orthologs in clinical isolates (Benveniste and 
Davies, 1973; Walsh, 2000; Hubbard and Walsh, 2003; Wright, 2005). However, 
antibiotic-producing bacteria could not be the sole source of resistance genes. In fact, 
bacterial genomes contain an unexpected number of genes encoding putative 
resistance proteins (Draker et al., 2003), which could have originated through 
amplification and random mutation of genes but not originally involved in antibiotic 
resistance (Sandegren and Andersson, 2009).  
 
Primary sequence analysis of resistance proteins revealed that the molecular 
mechanisms and the three-dimensional structures are homologous to known 
metabolic and signalling enzymes with no antibiotic-resistance activity (Morar and 
Wright, 2010). Therefore it is possible that resistance genes originally derived from 
elements having other metabolic functions similar to housekeeping genes encoding 
enzymes with modest and accidental resistance properties evolved into resistance 
enzymes as a result of selective pressure of antibiotic exposure. The fact that 
resistance genes are so widespread in the environment and that even resistance to 
synthetic antibiotics can be readily selected reveals the adaptable  nature of the link 
between molecular evolution and resistome (D'Costa et al., 2011). 
 
Bacterial resistance to antibacterial drugs manifests itself through a restricted range 
of molecular events (Figure 1.3). Pseudomonas aeruginosa is an opportunistic 
pathogen showing intrinsic resistance to antibiotics. In particular, some bacterial 
species are considered intrinsically resistant to a class of antibiotics because the drug 
cannot reach its cellular target or because the drug is not able to recognize its target 
which possesses the same function but a different structure. Intrinsic resistance is 
attributed to the low permeability of cellular envelopes together with the presence of 
chromosomally encoded multidrug efflux pumps or antibiotic-inactivating enzymes 
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that resemble those present in transposable elements and usually acquired by 
horizontal transfer. However, further intrinsic mechanisms act in synergy as many 
chromosomal genes that contribute to β-lactam resistance of P. aeruginosa were 
identified using a comprehensive library of transposon-tagged insertion mutants 
















Figure 1.3: Schematic representation of major resistance strategies. Resistance to antibiotics 
occurs through four general mechanisms: target modification; efflux; immunity and bypass; 
and enzyme-catalyzed destruction (Gualerzi, 2014). 
 
In contrast, susceptible bacteria may become resistant to a class of antibiotics 
through two types of genetic events: 
1 Random spontaneous mutation. 
2 Acquisition of the genetic information encoding resistance from other 
bacteria. 
In susceptible bacteria that acquire resistance by spontaneous mutations resistance 
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1 Modification or loss of the target with which the antibiotic interacts (The 
mecA gene encodes the penicillin-binding protein 2a (PBP2A) a 
transpeptidase membrane protein that possesses a low affinity for β-lactam 
antibiotics, such as methicillin and penicillin, and is responsible for β-lactam 
resistance in methicillin resistant S. aureus (MRSA) (Rice, 2012). 
2 Up regulation of enzymes that inactivate the antimicrobial agent (e.g., β-
lactamases that destroy the β-lactame antibiotics) or that modify the antibiotic 
target (e.g., ribosomal methylase in Staphylococci preventing erythromycin 
binding) (Abraham and Chain, 1940). 
3 Down regulation or inactivation of the outer membrane protein channel 
required by the drug for cell entry (e.g., in Escherichia coli) (Goessens et al., 
2013).  
4 Up regulation of pumps that expel the drug from the cell (e.g., efflux of 
fluoroquinolones in Staphylococcus aureus) (Costa et al., 2011). 
 
In all these cases, strains of bacteria carrying chromosomal mutations conferring 
resistance survive and grow under the selective pressure of antibiotic use, which 
instead kills the susceptible strains and promotes spreading of resistant genotypes. 
This kind of selection is named vertical evolution because resistance-associated 
genetic elements are transmitted from cell to cell through cell duplication (McManus, 
1997; Tenover, 2006).   
 
Bacteria also develop resistance through the acquisition of new genetic material from 
resistant organisms. This kind of selection is termed horizontal evolution and may 
occur in an intra- or interspecific way or even among different genera and may be 
facilitated via transposable elements such as transposons, which contain resistance 
genes (McManus, 1997). Genetic exchange mechanisms include events such as 
conjugation, transduction, and transformation (McManus, 1997; Tenover, 2006). 
During conjugation plasmid carrying resistance genes transfer to a recipient in gram 
negative bacterium through a mating bridge, this joins the two bacteria. In gram-
positive bacteria exchange of DNA by conjugation is usually triggered by sex 
pheromones, which facilitate the clumping of donor and recipient cells. During 
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transduction, resistance genes are transferred via bacteriophage. Finally, the so-called 
competent bacteria may acquire and incorporate resistance genes from other bacteria 
that have released their DNA into the environment after cell lysis, by transformation 
(McManus, 1997; Tenover, 2006). Through genetic exchange mechanisms, many 
bacteria become resistant to multiple classes of antibacterial agents, and these are 


















Figure 1.4: Schematic representation of the genetics and spread of drug resistance. The drug 
resistance is mobile and the genes for resistance traits can be transferred among bacteria of 
different taxonomic and ecological groups by means of mobile genetic elements such as 
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1.2. Antimicrobial peptides 
 
1.2.1. Their History and Evolution 
 
Antimicrobial peptides (AMP) are heterogeneous groups of relatively small 
molecules usually containing less than a hundred amino acids produced by almost all 
living organisms. The identification of these peptides can be traced back to the 
discovery of lysozyme by Alexander Fleming in 1921 (Fleming, 1922). Another 
well-known AMP has been documented in 1939 by discovering gramicidins in 
prokaryotic cells. They were isolated from Bacillus brevis. They had activity both in-
vitro and in-vivo against a wide range of Gram-positive bacteria (Dubos, 1939) were 
















Figure 1.5: The antimicrobial peptides discoveries each year from 1970 to 2012. Data were 
obtained from the antimicrobial peptide database (http://aps.unmc.edu/AP) (Wang and Wang, 
2004; Wang et al., 2009). 
 
With the discovery of penicillin and streptomycin in 1943 during the “Golden Age of 
antibiotics,” the interest in AMPs declined. This led to less interest in the therapeutic 
potential of natural host antibiotics such as lysozyme and its importance in immune 
defence strategies (Bentley, 2009; Zaffiri et al., 2012). However at the end of the 
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“Golden Age of antibiotics” and with the rise of multidrug-resistant microbial 
pathogens in the early 1960s there was a resumed interest in host defence molecules 
(Katz et al., 2006). This was prompted in the 1950s and 1960s, (Figure 1.5) by the 
discovery of cationic peptides and their ability to kill bacteria via oxygen-
independent mechanisms in human neutrophils (Zeya and Spitznagel, 1966). 
 
The isolation of inducible cationic antimicrobial proteins P9A and P9B in 1981 by 
injecting bacteria into the pupae of the silk moth, Hyalophora cecropia, was 
generally considered a landmark study the first major AMPs (Steiner et al., 1981; 
Steiner et al., 2009). Subsequently in 1987, another landmark study (Zasloff, 1987) 
isolated and characterized cationic AMPs from the African clawed frog, Xenopus 
laevis, called peptides magainin. A few years later, β-defensins and θ-defensins, 
which differ from α-defensins with respect to their cysteine pairings, were 
characterized, from bovine granulocytes (Selsted et al., 1993) and leukocytes of the 
rhesus monkey respectively (Tang et al., 1999). In the mid-1990s, the first anionic 
AMPs was discovered in X. laevis (Brogden et al., 1997) and several other such 
peptides were characterised in ruminants, including sheep and cattle (Brogden et al., 
2003).  
 
The early studies on AMPs have been extensively studied in plants, insects and other 
invertebrate organisms that lack an adaptive immune system (Bulet et al., 2004). 
However most of the current understanding of AMPs has been obtained from studies 
on those isolated from amphibian skin secretions, which is a rich source of these 
peptides (Nicolas and El Amri, 2009). These studies established that AMPs exist in 
virtually all multicellular organisms and these peptides play an important role in 
immunity in all organisms, including humans (Pasupuleti et al., 2012). AMPs have 
been identified at most sites of the human body normally exposed to microbes such 
as the skin and mucosae and are produced by a number of blood cell types, including 
neutrophils, eosinophils, and platelets (Malik and Batra, 2012). Studies suggest that 
AMPs can produce either constitutive or induced by inflammation or injury to 
protect the organism from infection. For example, α-defensins and dermcidin (the 
precursor of AMPs involved in skin defence) tend to be produced constitutively, 
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whereas the majority of β-defensins are inducible (Schittek et al., 2001; Auvynet and 
Rosenstein, 2009). 
 
More than 2,000 natural AMPs have been found in eukaryotes and in bacteria 
(Thomas et al., 2010; Piotto et al., 2012)  and the availability of databases has 
allowed comparison between AMPs and to postulate structure–function relationships 
and mechanisms of antimicrobial action. The diversity of these AMPs may have in 
part resulted from random substitutions involving the operation of a mutagenic error-
prone DNA polymerase similar to that reported for some bacteria (Nicolas et al., 
2003; Janion, 2008). Developing new AMPs with an ability to combat new or altered 
microbial pathogens would likely have an evolutionary advantage. Indeed, it has 
been suggested that AMPs and microbial resistance mechanisms have co-evolved. 
This leads to a transient host-pathogen balance that has shaped the existing range of 
these peptides found in nature (Peschel and Sahl, 2006). For example, plants and 
humans are susceptible to different pathogens and thus their defences are exposed to 
different selective pressures. In general plants are much more susceptible to fungi 
compared to other microbes, fungal pathogenicity would select for survivors with 
antifungal defensins. However, humans are more susceptible to bacteria than fungi 
and thus bacterial pathogenicity would select for survivors with antibacterial 
defensins (Stotz et al., 2009). 
 
1.2.2. The antimicrobial peptide database 
 
The antimicrobial peptide database (APD) also enables users to obtain the statistical 
parameters of peptides such as length, net charge, hydrophobic content and structure 
type for a single peptide or a group of candidates (Wang and Wang, 2004). The 
distribution of all the AMPs as a function of peptide length is given in Figure 1.6 
(A). It is clear that the majority of (88%) AMPs possess 11–50 amino acids with the 
most variable lengths of 21–30 residues. Considering the peptide at neutral pH at 7 in 
solution, the net charge of an AMP involves acidic amino acids aspartic acid (D), 
glutamic acid (E), and basic arginine (R) and lysine (K). The charge distribution of 
AMPs suggests that 86% of AMPs have a net charge between 0 and +7 (maxima at 
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+2 and +3). The hydrophobic percentage is the ratio between the sum of the amino 
acids in the hydrophobic group and the total number of amino acids. A distribution of 
all the AMPs as a function of peptide hydrophobic percentage is given in Figure 1.6 
(C). The majority of AMPs (89%) contain a hydrophobic percentage in the range of 
31–70% (the maximum at 41–50%). In the APD database, the 20 standard amino 
acids are classified into four groups: hydrophobic (L, I, V, M, F, W, A, and C), PG 
(P and G), polar (S, T, N, Q, and Y), and charged (D, E, K, R, and H). To a large 
extent, the amino acid composition of AMPs determines peptide activity (Mishra and 
Wang, 2012). The APD is the first AMP database that allows users to calculate the 
amino acid composition profile for each peptide or a selected group of AMPs with a 
specific activity or property (Wang and Wang, 2004; Wang et al., 2009; Wang, 
2013). Figure 1.6 (D) is such a profile for all the AMPs, where on average amino 
acids L, G, and K have the highest frequencies.  
 
 
Figure 1.6: AMP characters and function distribution. The peptide length (A), the net charge 
(B), hydrophobic percentage (C) and the frequency of the 20 amino acids of AMPs in the APD 
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1.2.3. Other biological activities of AMPs 
 
The primary functions of AMPs are direct antimicrobial activities, but more recent 
studies have indicated that these peptides modulate immunity and immune-cell 
function under physiological conditions (Hancock et al., 2012) and that these 
activities are the primary role of these peptides in the host. The immunomodulatory 
properties of AMPs  influence innate immunity  and  include (i) reduction in the 
levels of pro-inflammatory cytokines produced in response to microbial signature 
molecules; (ii) modulation of the expression of chemokines, reactive oxygen species 
and reactive nitrogen species (for example, nitric oxide); (iii) stimulation of 
angiogenesis; (iv) enhanced wound healing; (v) leukocyte activation; and (vi) 
macrophage and leukocyte differentiation (Figure 1.7) (Nijnik and Hancock, 2009; 
















Figure 1.7: Overview of the biological activities of AMPs and Host Defence Peptides. Direct 
cytotoxic activities are shown in green, direct immunomodulatory properties are shown in blue 
and indirect immunomodulatory properties that are a consequence of direct 
immunomodulatory properties are shown in pink. ROS, reactive oxygen species; NO, nitric 
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1.2.4. Cationic Antimicrobial Peptides 
 
Cationic antimicrobial peptides (CAMPs) are important components of the innate 
immune systems in all living organisms including bacteria, fungi, plants and animals. 
These peptides are active against bacteria, fungi, viruses, and pests such as insects. 
They are generally between 12 and 50 amino acids, containing basic amino acids, 
with an overall net positive charge of +2 to +9 (Hancock and Diamond, 2000). In 
addition, approximately 50% of the amino acids are hydrophobic. The presence of 
basic and hydrophobic amino acids promotes folding of linear AMPs into 
amphipathic secondary structures upon contact with lipid bilayers (Hancock and 
Rozek, 2002). CAMPs use a variety of mechanisms to kill microbes but it is 
generally accepted that the interaction of these peptides with the membranes of target 
organisms is an important part of their mechanism of interaction. CAMPs show 
promise as candidates for development as novel antimicrobials (Phoenix et al., 
2013). 
 
CAMPs are consist of basic amino acids such as arginine and/or lysine (Wang et al., 
2009), which gives these peptides a net positive charge, despite having positively 
charged moieties such as a C-terminal amide group (Brogden, 2005; Dennison et al., 
2005). The presence of these basic residues and other charged moieties is generally 
accepted to be the primary driver underpinning the ability of CAMPs to target the 
membranes of bacteria, fungi, and other microbes. The vast majority of CAMPs also 
possess amphiphilic structures, revealed as a spatial segregation of hydrophobic and 
hydrophilic residues on their molecular surface, which allows them to partition into 
microbial membranes. On partitioning into membranes, CAMPs orientate such that 
their apolar regions interact with the membrane lipid core while their polar regions 
concomitantly engage in electrostatic interactions with the membrane lipid head-
group region (Stromstedt et al., 2010; Teixeira et al., 2012). 
 
CAMPs show great diversity and are classified into many subgroups depending upon 
the criteria chosen, including origin, size, structure, amino acid sequence, biological 
action, and antimicrobial mechanism (Hwang and Vogel, 1998; Wang et al., 2010). 
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There are three broad classes of CAMPs: those that adopt a (1) α-helical structure 
(eg. cathelicidins, magainin peptides), (2) β-sheet structure with a cysteine-stabilized 
architecture (e.g. defensins), and (3) extended peptides that are rich in specific 
residues (Nguyen et al., 2011). Less common are looped peptides (e.g. bactenecin) 
and extended structures rich in arginine, glycine, histidine, proline, and/or tryptophan 
(e.g. indolicidin) (Guani-Guerra et al., 2010; Steinstraesser et al., 2011). Structure-
function studies suggest that certain biological properties of AMPs are dependent on 
specific structural characteristics. However, out of 2000 AMPs listed, approximately 
3% possess more than one domain such as a α-helical and β-sheet structure while 
around 70% of these peptides cannot be classified or have not been structurally 
characterized (Wang et al., 2010). 
 
The mechanisms underpinning the antimicrobial activity of human defensins is not 
well understood, although cationicity and hydrophobicity have been shown to be 
important determinants for the antibacterial activity of both human α-defensins and 
β-defensins. It is generally believed that the antimicrobial activity of human 
defensins involves compromising microbial membrane integrity which leads to 
collapse of the membrane’s electrochemical potential and proton motive force, 
allowing the leakage of cellular contents and the entry of defensins into the cell to 
interact with cytoplasmic targets, including DNA and RNA (Ganz, 2003; Taylor et 
al., 2008; Hazlett and Wu, 2011; Lehrer and Lu, 2012). 
 
1.2.5. Models for the Membrane Interactions of Antimicrobial Peptides 
 
The cell membrane (CM) of cells is a complex network of lipids and proteins with a 
molecular organization that makes a major contribution to both maintaining the 
structural integrity of cells and the activities of proteins that are associated with the 
lipid bilayer. The lipid molecules within a lipid bilayer are dynamic and actively 
involved in biological functions, and scaffold for the activities of proteins and 
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The association of AMPs with CM lipid can lead directly to the inactivation of 
microbes via cell lysis (Nguyen et al., 2011; Guilhelmelli et al., 2013) or 
internalization of these peptides attack on intracellular targets (Marcos and Gandía, 
2009; Nicolas, 2009). However, in order to reach and interact with microbial CMs, 
AMPs have to negotiate and pass through a variety of enveloping structures (Figure 
1.8). These structures vary across target organisms in their physiochemical 
properties, permeability, and thickness, and therefore influence the susceptibility of 



















Figure 1.8: Structural features of the cell walls of Gram-positive, Gram-negative bacteria and 
fungus. KDO, 3-deoxy-D-manno-octulosonate; LPS, lipopolysaccharide; OMPA, outer 
membrane protein A Schematic representations of the cell envelopes of Gram-positive bacteria 
(a), Gram- negative bacteria (b), and fungi (c) (a and b adapted from (Lolis and Bucala, 2003); c 
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In general, cationic AMPs (CAMPs) are by far the best characterized AMPs. These 
peptides passage through the microbial envelope appears to involve low-affinity, 
electrostatic interactions between these peptides and a range of anionic moieties that 
promote the migration of these peptides to the CM of the microbe (Mayers, 2009). 
The affinity level of CAMPs for these anionic moieties appears to be crucial as low 
affinity can reduce the targeting efficacy but higher affinities can bind anionic 
envelope components sufficiently strongly to prevent their passing through to the 
microbial CM and thereby inhibit their antimicrobial action. This kind of inhibitory 
actions have been reported for the interaction of CAMPs with a variety of anionic 
cell surface moieties which bind and thereby reduce the toxicity of these peptides to 
erythrocytes, non-cancerous cells and transformed cells (Papo and Shai, 2005; Bucki 
et al., 2008; Fadnes et al., 2009). 
 
In fungi, CAMPs migrate through the cell envelope by interaction with a number of 
anionic components including chitin chains, (1-3)-β-glucan, and phosphomannans or 
related compounds (Figure 1.8) (Marcos and Gandía, 2009; De Brucker et al., 2011). 
CAMPs can pass through anionic exo-polysaccharides such as alginate (Batoni et al., 
2011) formed by fungi and bacteria that participate in biofilms. CAMPs interact with 
anionic Gram-positive bacterial cell wall components such as teichoic and 
lipoteichoic acids while migrating via peptidoglycan layer to interact directly with 
the CM (Figure 1.8) (Read and Duncan, 2011). It has been shown that interaction 
with these anionic polymers is important for the antimicrobial activity in some 
CAMPs, such as defensins, which are β-sheet peptides produced by eukaryotes, 
indeed reducing the negative charge in those bacteria decreases their susceptibility to 
defensins (Peschel and Collins, 2001).  
 
With Gram-negative bacteria, CAMPs first encounter the outer membrane, with 
anionic lipopolysaccharide (LPS) as the major component of its external leaflet 
(Figure 1.8) (Mayers, 2009). The majority of CAMPs have a high affinity for LPS, 
which allows these peptides to cross the outer membrane via a self-promoted uptake 
pathway. Essentially, these CAMPs interact with lipid A moieties of LPS, which 
serves as an anionic binding site, thereby competitively replacing Mg2+and Ca2+ ions 
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that help maintain cell surface stability via the cross-linking of carboxylated and 
phosphorylated head-groups of lipids. Removal of these ions leads to disruption of 
the outer membrane, and allows the peptides to migrate across the peptidoglycan 
layer and accumulate in the periplasmic space before interacting with components of 
the CM (Laverty et al., 2011). A further consequence of CAMPs binding to LPS and 
lipoteichoic acid is the neutralization of the endotoxic activity associated with these 
molecules in bacterial sepsis, thereby avoiding the exalted inflammatory response 
induced by the antibacterial activity of other antibiotics (Brandenburg et al., 2011). 
The generally held view is that the antimicrobial action of CAMPs does not involve 
the use of protein and lipid membrane receptors, although such use is well 
established for some prokaryotic AMPs (Zhao, 2011). Recent studies have suggested 
that some CAMPs with non-lytic antibacterial mechanisms utilize protein receptors 
for membrane translocation and interaction with cytoplasmic targets (Giralt, 2014). 
 
1.2.6. Cell membrane associated Factors That Affect the Antimicrobial 
Action of CAMPs 
 
The initial association of CAMPs with the microbial CM is driven by electrostatic 
interactions between the net positive charged peptides and net negative charged cell 
membranes (Stromstedt et al., 2010). The CMs of bacteria are generally rich in 
anionic phospholipids, primarily phosphatidylglycerol (PG) and cardiolipin (CL), 
which are either present at low levels or absent from mammalian cells (Figure 1.9) 
(Lohner and Prenner, 1999). Indeed, it is the possession of this net negative charge 
that is believed to underpin the selectivity of CAMPs for bacterial cells over 
eukaryotic cells, since the latter carry a net neutral charge due to the presence of 
zwitterionic lipids such as PE, sphingomyelin (SM), and phosphatidylcholine (PC) 
(van Meer et al., 2008). 
 
Nevertheless, there are considerable differences between the levels of anionic lipids 
found in the membranes of different bacterial species and classes as can be seen from 
Figure 1.9. The CMs of Gram-positive bacteria are primarily composed of lipids that 
are derived from PG, exemplified by that of Staphylococcus aureus, which contains 
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around 57% PG, 38% lysylated PG (LysylPG), and 5% CL, a dimer of PG (Figure 
1.9). In contrast, the CMs of Gram-negative bacteria are mainlycomposed of PE, 
typically that of Escherichia coli, which contains approximately 80% PE, 6% PG, 
and 12% CL (Figure 1.9). 
 
In general, anionic lipids constitute over 80% of the total lipid found in the 
membranes of Gram-positive bacteria, but less than 30% of the total lipid present in 
those of Gram-negative bacteria (Epand and Epand, 2011). It would therefore seem 
that varying levels of anionic lipid contribute to the differing bacterial specificities 
shown across CAMPs given that many of these peptides show a preference for either 
Gram-positive or Gram-negative bacteria (Wang et al., 2009). 
 
Figure 1.9: Lipid composition of phospholipids present in the cell membranes of different 
bacteria. Gram-positive bacteria (a), Gram-negative bacteria (b), and fungi (c). These lipids 
include cardiolipin (CL), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), lysylated 
phosphatidylglycerol (Lysl PG), phosphatidylinositol (PI), and phosphatidylserine (PS) 
(Ratledge and Wilkinson, 1988). 
 
Upon interaction with the microbial CM, a number of factors are able to modulate 
the activity of CAMPs and their ability to partition into these membranes. A major 
factor is the transmembrane potential, which results from differing extents and rates 
 
 25 
Chapter 1:   Introduction 
of proton flux across the membrane (Fjell et al., 2012). Mammalian membranes 
maintain a weak transmembrane potential, but due in part to their high levels of 
anionic lipids, the CM of fungi (Harris et al., 2009) and bacteria (Bradshaw, 2003) 
maintain a relatively strong transmembrane potential. This high transmembrane 
potential strongly attracts CAMPs and enhances both their selectivity and toxicity for 
microbial cells (Wang et al., 2010). A similar mechanism appears to underpin the 
ability of CAMPs to target cancer cell membranes, which exhibit loss of lipid 
asymmetry, resulting in the presence of relatively high levels of anionic lipid on their 
outer surfaces and an accompanying high transmembrane potential (Fadeel and Xue, 
2009). 
 
In contrast to bacteria, the CM of fungal cells tend to share similar properties to 
mammalian membranes, having a net neutral charge due to the presence of 
zwitterionic lipids including PC, PE, and SM (Figure 1.8) as well as possessing a 
number of fungal-specific lipids (Thevissen et al., 2003). In comparison to bacteria, 
there has been far less research into the antifungal mechanisms of CAMPs, but there 
is evidence to show that interaction of these peptides with anionic lipid and the 
fungal CM leads to membrane lysis and plays a role in their antifungal mechanisms 
(Qi et al., 2010). In addition, it has been observed that CAMPs with primarily 
antifungal activity tend to possess a high proportion of neutral polar residues, which 
led to the suggestion that the peptides that interact with the fungal CM may show 
different structure–activity relationships to those used by CAMPs in their other 
antimicrobial activities (de Oca, 2013), possibly involving an ability to form 
complexes with fungal lipids (Lopez-Garcia et al., 2004). However, other CAMPs 
show only a weak ability to permeabilize the fungal CM and appear to inactivate 
fungi by other mechanisms involving multiple activities such as facilitating the efflux 
of ATP from the cell (Tanida et al., 2006). Taken with the fact that, as described 
above, some CAMPs utilize lipid receptors to promote their antifungal action, these 
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1.2.7. Established Models for the Membrane Interactions of AMPs 
 
Over the last four decades, three major models have become established to study 
mechanisms of membrane invasion used by α-CAMPs to exert their antibacterial 
activity. These models are generally referred to as the barrelstave pore model, the 
toroidal pore model, and the carpet mechanism, and have been extensively reviewed 
elsewhere (Brogden, 2005; Jenssen et al., 2006; Huang et al., 2010). Here, an 
overview of these models is presented along with a discussion of variants that have 
been recently described. 
 
1.2.8. Models of intracellular killing 
 
Despite the fact that AMPs cause cell membrane rupture which eventually leads to 
the lysis of microbial cells, there is increasing speculation that these effects are not 
the only mechanisms of microbial killing. There is increasing evidence to indicate 
that antimicrobial peptides have other intracellular targets (Figure 1.10). Some 
antimicrobial peptide such as Bac7 fragments 1–16, 1–23 and 1–35 do not 
permeabilize E. coli but yet cause a 2–5 log reduction in the number of organisms 
(Gennaro and Zanetti, 2000). 
 
Cationic peptide Pep5 activates autolysin in Staphylococcus simulans in the presence 
of lipoteichoic and teichuronic acids, which might explain the lysis of treated cells 
(Bierbaum and Sahl, 1987). Interestingly, in the absence of lipoteichoic acids the 
activity of partially purified autolysins is also stimulated directly by Pep5. The 
activity of host-derived secretory phospholipase for liposomes that contain anionic 
phospholipids or phosphatidylcholine is markedly enhanced by magainin 2, 
indolicidin and temporins B and L in 5 μM Ca2+ (Zhao and Kinnunen, 2003).  
 
The translocation of peptides across the cytoplasmic membrane involves unique 
mechanisms. Buforin II, which is a linear α-helical peptide with a proline hinge 
penetrates and accumulates in the cytoplasm without permeabilizing the cytoplasmic 
membrane (Park et al., 2000). The mechanism by which this peptide is translocated 
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was revealed by fusing the proline-hinge region of buforin II with a non-cell-
penetrating peptide. With amino-terminal helix of magainin 2-the hybrid peptides 
readily penetrated bacterial cytoplasmic membranes and accumulated in the 
cytoplasm, with concomitant antimicrobial activity (Park et al., 2000). Arginine-rich 
peptide groups, such as arginine-rich peptides, RNA-binding peptides, DNA-binding 
peptides and polyarginine and arginine-rich antimicrobial peptides, all readily and 


















Figure 1.10: Mode of action for intracellular antimicrobial peptide activity. In this figure 
Escherichia coli is shown as the target microorganism (Brogden, 2005). 
 
Apidaecin, a short, proline-rich antibacterial peptide, is translocated by a 
permease/transporter-mediated mechanism (Casteels et al., 1993). Once in the 
cytoplasm, translocated peptides can alter the cytoplasmic membrane septum 
formation, inhibit cell-wall synthesis, inhibit nucleic-acid synthesis, inhibit protein 
synthesis or inhibit enzymatic activity (Brogden, 2005). Lantibiotics are 
antimicrobial peptides from Gram-positive bacteria that contain the thioether amino 
acid lanthionine. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis by 
interfering with membrane associated transglycosylation (Brötz et al., 1998). Buforin 
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II binds to E. coli DNA and RNA (Park et al., 1998), and tachyplesin binds in the 
DNA minor groove (Yonezawa et al., 1992). The α-helical peptides (pleurocidin and 
dermaseptin), proline- and arginine-rich peptides (indolicidin) and defensins block 
thymidine, uridine and leucine uptake in E. coli, showing that they inhibit DNA, 
RNA and protein synthesis (Lehrer et al., 1989; Boman et al., 1993; Subbalakshmi 
and Sitaram, 1998; Patrzykat et al., 2002).   
 
At their minimal inhibitory concentrations, pleurocidin and dermaseptin both inhibit 
nucleic acid and protein synthesis without damaging the E. coli cytoplasmic 
membrane (Boman et al., 1993; Patrzykat et al., 2002). Indolicidin (100 μg/ ml) 
completely inhibits DNA and RNA synthesis in E. coli but does not have any effect 
on protein synthesis. At concentrations of 150 and 200 μg/ ml, protein synthesis is 
markedly inhibited (Subbalakshmi and Sitaram, 1998). Histatins bind to  receptors on 
the fungal cell membrane, enter the cytoplasm and induce the nonlytic loss of ATP 
from actively respiring cells (Kavanagh and Dowd, 2004). Their action can also 
disrupt the cell cycle and lead to the generation of reactive oxygen species (Andreu 
and Rivas, 1998).  
 




AMPs have been actively studied for decades but they have not widely been used in 
the clinic (Hancock and Sahl, 2006). This is due in part to the vulnerability of these 
peptides to rapid in-vivo degradation and low bioavailability. AMPs have found 
difficulty in the transition of in-vitro activity into in-vivo efficacy (Hancock and Sahl, 
2006). This is due to their sensitivity to biologically relevant conditions such as high 
salinity of plasma, as divalent cations may compete with such peptides for binding 
sites on the negatively charged bacterial surface (Deslouches et al., 2005). Moreover, 
AMPs are susceptible to degradation by serum proteases (Knappe et al., 2010) as 
well as to protein binding (Yeaman et al., 2002). However, peptidomimetic polymers 
(peptide isomers) of AMPs can play a crucial role replacing peptides due to their 
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susceptibility to proteolytic enzymes while retaining their beneficial features 
(Chongsiriwatana et al., 2008; Dohm et al., 2011).  
 
The backbone of the peptidomimetic polypeptoid is identical to that of a polypeptide 
in protein, but the side chain is added to the amide nitrogen rather than the α-carbon 
in peptoids (Figure 1.11). This difference removes inter- and intrachain hydrogen 
bonding in the backbone and also eliminates the main-chain chirality (Rosales et al., 
2010; Rosales et al., 2012). They lack  backbone hydrogen bonding due to the 
absence of hydrogen bond donors and they cannot form β-sheets and due to this they 
do not aggregate as easily as peptides (Dohm et al., 2011). Peptoids can be 
considered essentially peptide isomers, but the seemingly simple shifting of the side 
chains to the amide nitrogen significantly changes the properties of the isomer 
peptoid relative to the peptide. The most biologically relevant consequence of this 
shift is protease resistance, which arguably increases their therapeutic potential 
(Dohm et al., 2011).  
 
Polypeptoids or poly-N-substituted glycines are known as peptidomimetic polymers. 
They offer many advantageous properties for studies in biochemistry, molecular 
biophysics, diagnostics, and medicine (Dohm et al., 2011; Zuckermann, 2011). 
Peptoids are synthesised using solid phase synthesis, a stepwise polymerization 
method is applied to grow polymer chain and it is anchored to a solid support while 
coupling reagents are iteratively passed over the matrix and adding one monomer at a 
time to afford a polymer with an exact monomer sequence and near absolute 
monodispersity (Figure 1.12). The submonomer polymerisations are simple chemical 
building blocks that can be used to assemble a monomer in the course of stepwise 
polymer formation in which the functional side chain is incorporated. This approach 
towards oligo- and polypeptoids has been pioneered by Bartlett and co-workers and 
later modified and refined in the groups of Zuckermann, Kirshenbaum, Barron, and 















Figure 1.11: Schematic representation of polypeptoids (Luxenhofer et al., 2013). 
 
 
Figure 1.12: Schematic representation of Solid-phase submonomer method. This allows the 
rapid synthesis of sequence-specific peptoids from cheap and readily available starting materials 
(amines and haloacetic acid submonomers), using a repeating two-step monomer addition cycle 
of acylation. Each two-step cycle is performed at or near room temperature and takes <1 h and 
can be performed manually or by automated synthesizers. DIC = N,N0-
diisopropylcarbodiimide, NMP =N-methylpyrrolidinone (Sun and Zuckermann, 2013). 
 
The microwave-assisted solid-phase synthesis of polypeptoids can reduce the 
reaction time dramatically (from ∼1 hour to just a few minutes per monomer 
addition) with high purity and yields of products as good as or even better than those 
achieved using standard methods (Fara et al., 2006; Messeguer et al., 2008). 
Additionally, the two-step submonomer cycle involves only the simple pipetting of 
stable reagent solutions at room temperature. Therefore, the entire procedure can be 
accomplished either manually or automatically and can be readily adapted to most 
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Peptoids are also called poly-N-substituted glycine monomers. These monomers can 
be variable depending on the amino acid side-chain attached to the N atom. From a 
synthetic point of view, polypeptoids are a class of highly designable polymers. They 
are particularly well suited for AMP mimicry because they are easily synthesized on 
solid phase (by using conventional peptide synthesis equipment) with access to 
diverse sequences at relatively low cost (Zuckermann et al., 1992; Chongsiriwatana 
et al., 2008). From a synthetic point of view, polypeptoids are a class of highly 
designable polymers. Any chemical functionality available as a primary amine can 
be incorporated via a submonomer synthetic method and therefore these peptoids are 
highly and finely tunable (Zuckermann et al., 1992). This method also gives precise 
control over the exact placement and choice of monomers with exceptionally fine 
degree of control over potential functional properties (Zuckermann et al., 1992; 
Rosales et al., 2010).  
 
1.3.2. Peptoids and their potential use 
 
In 1994, Zuckermann and co-workers discovered several potent peptoid trimmer 
ligands for G-protein coupled receptors (Zuckermann et al., 1994) and the urokinase 
receptor (Ross et al., 2008). They used large synthetic peptoid libraries of chemically 
diverse short oligomers and screened them for biological activities. This was one of 
the first demonstrations that a diverse combinatorial library of synthetic compounds 
could provide high-affinity ligands for pharmaceutically relevant receptors (Gibbons 
et al., 1996). This discovery inspired many groups in both biopharmaceutical 
industry and academic laboratories to investigate potential therapeutics from peptoid 
libraries (Garcia-Martinez et al., 2002; Mora et al., 2005). Many specific biologically 
active peptoid oligomers have been described. For example, a library of cationic and 
hydrophobic peptoids yielded novel compounds with antimicrobial activity. These 
peptoids are a promising class of antimicrobial therapeutics, as they exhibit broad-
spectrum antibacterial activity and low mammalian cytotoxicity (Chongsiriwatana et 
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Using combinatorial peptoid microarrays, the Kodadek lab developed a general 
method to identify diagnostically useful antibodies without the need for antigen 
identification. They demonstrated the discovery of potentially useful diagnostic 
biomarkers in humans via identification of candidate IgG biomarkers for Alzheimer's 
disease (Reddy et al., 2011). In addition to linear protein ligands, several cyclic 
peptoid ligands have also been explored. Peptoid fluorophore conjugates have also 
been prepared as reporters for intracellular delivery (Kwon and Kodadek, 2008; 
Dhaliwal et al., 2011) or for folding into secondary structures (Birtalan et al., 2011; 
Fuller et al., 2011). These examples demonstrate that peptoid libraries are a 
powerful, inexpensive, and convenient source of diverse ligands for a variety of 
biomedical applications. Peptoids could be improved if we could understand their 
pharmacokinetics parameters such as; (1) bioavailability, (2) excretion mechanisms, 
(3) are peptoids and (4) toxicity such as hepatotoxicity. However, very little has been 
published in this area, and such studies are critical for the development of peptoids as 
potential pharmaceuticals (Dohm et al., 2011).  
 
Peptoid polymers exhibit excellent biocompatibility and potent biological activities 
similar to polypeptides (Fowler and Blackwell, 2009; Lee et al., 2010). For example, 
they can fold into protein-mimetic secondary and tertiary structures (Lee et al., 2008) 
serve as an effective siRNA transfection reagent (Utku et al., 2006), diagnostic 
agents (Reddy et al., 2011), lung surfactant mimetics (Brown et al., 2008), 
antimicrobial agents (Chongsiriwatana et al., 2008) and other therapeutics 
(Zuckermann and Kodadek, 2009) and can be incorporated site-specifically into 
polypeptide sequences (Lee and Zuckermann, 2011) and exhibit stability to 
proteolysis (Miller et al., 1995). 
 
1.3.3. Antimicrobial peptoids 
 
Non-natural mimics of AMPs are needed to provide better structural stability and 
bioavailability as therapeutic candidates to treat bacterial infection (Bessalle et al., 
1990; Arnt and Tew, 2002; Sanborn et al., 2002). The in-vivo structural stability of 
peptoids affords them a great potential for development as effective antimicrobial 
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agents (Patch and Barron, 2003; Chongsiriwatana et al., 2008). Recently, Fowler and 
Blackwell (2009) reviewed the structure activity relationships of antimicrobial 
peptoids or “ampetoids” that were developed by Barron and co-workers in 2003. 
Peptoids have been developed to mimic the AMP, with an emphasis on N-terminal 
alkylation, cyclization, and reduction in hydrophobicity with the aim of improving 
activity while substantially reducing mammalian cytotoxicity. Strategies to 
incorporate a single peptoid residue into a peptide, creating a peptide-peptoid hybrid 
with improved therapeutic potential, are also presented. Finally, the in-vivo 
biocompatibility and efficacy of antimicrobial peptoids to treat bacterial infections 
have been discussed (Chongsiriwatana et al., 2008). 
 
Previous studies have shown that antimicrobial peptoids are both structural and 
functional mimics of AMPs (Patch and Barron, 2003). Ampetoids are mimics of the 
magainins, a class of AMPs that are relatively short, cationic, and α-helical, and have 
similar antimicrobial properties (Patch and Barron, 2003). A study in 2008 
determined that the selectivity of peptoids towards bacteria (E. coli ATCC 35218 and 
B. subtilis ATCC 6633) over mammalian cells (lung epithelial A549 cell line) was 
enhanced by net cationicity and moderate hydrophobicity, whereas haemolytic 
activity (red blood cell lysis) increased with high hydrophobicity and amphipathicity 
(Chongsiriwatana et al., 2008). In order for peptoids to be successful therapeutics, 
they must preferentially interact with bacteria over mammalian cells; when this 
criterion is met, peptoids are referred to as “selective”. Considering the  net 
cationicity, hydrophobicity, and amphipathicity, subsequent design and testing of 
several families of ampetoids in order to fully understand the effects of sequence 
length, hydrophobicity, helicity, and charge-to-length ratio on the activity and 
selectivity of ampetoids (Dohm et al., 2011). Notably, the reduction of 
hydrophobicity by removing hydrophobic residues made peptoids less haemolytic 
while retaining the antimicrobial activity (Dohm et al., 2011). 
 
Multi-drug resistant (MDR) microorganisms have been used to study the true 
antibacterial potential of the peptoids derived from pexiganan. Further studies based 
on the peptoids’ antimicrobial activities were scrutinised using computational model 
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prediction, their structures and sequences characters. The activities of the peptoids 
when predicted by the model were consistent with their corresponding activities 
witnessed in-vitro in cell-based assays, escalating the potential for computational 
studies to aid in the designing and testing of peptoids for this and other therapeutic 
applications (Dohm et al., 2011). 
 
An earlier study in the Shai lab showed that the presence of an alkyl tail is believed 
to enhance peptoid penetration into and transport through the bacterial membrane. 
Interestingly similar behaviour was observed for alkylated peptides (Shai, 2002). 
This is due to the formation of micellization or other form of association based on 
hydrophobic chain-chain interactions that could explain their increased antimicrobial 
activity relative to the unalkylated variant. The N-terminal alkylation study also 
demonstrated that peptoid cytotoxicity toward red blood cells did not increase, 
whereas alkyl tail made peptoid were more toxic. Therefore, it is difficult to say if N-
terminal peptoid alkylation would improve the therapeutic potential of peptoids; 
nevertheless, it is a promising technique to increase the therapeutic applicability of 
certain peptoids as drug candidates against certain bacterial strains (Dohm et al., 
2011). 
 
Another strategy put forth to reduce haemolysis of red blood cells by peptoids was to 
design cyclized peptoids. Studies revealed that cyclic linear peptoids have improved 
antimicrobial properties and selectivity. Since cyclization tends to reduce 
conformational flexibility by constraining the residues, it is believed that structural 
rigidity would increase the ability of peptoids to permeabilize the bacterial 
membrane (Unciti-Broceta et al., 2009). Successfully synthesized selective α-cyclic 
peptoids were created with better antibacterial and antifungal activity than linear 
peptoids. However, despite cyclization, the improvement in antibacterial activity was 
not comparable to the activity of previously reported linear peptoid-based mimics of 
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1.3.4. Peptoid-Peptide Hybrid Mimics 
 
Adding a peptoid residues or segments can improve the proteolytic stability of 
peptides, increase the antimicrobial activity and also reduce the cytotoxicity of 
AMPs. Engineering of a single amino acid in a peptide by a peptoid residue can 
introduce beneficial improvements to peptide. Shin and co-workers demonstrated 
that substituting Trp19 in the bee venom AMP melittin with “NTrp,” a Trp-based 
peptoid residue, significantly reduced the mammalian cytotoxicity of the melittin 
analogue while still retaining its antibacterial and antifungal properties (Zhu et al., 
2006; Dohm et al., 2011). In another study, the substitution of all Pro residues in 
Trp/Pro-rich AMPs such as indolicidin, tritrpticin-amide, and a symmetric tritrpticin 
analogue (all Arg’s substituted with Lys’s) with NLys residues afforded more 
activity against Gram-negative and Gram-positive bacteria (MIC ~ 0.5 – 8 μM) and 
less haemolysis (minimum concentration that produces haemolysis (MHC) > 200 
μM) (Zhu et al., 2007). 
 
Further studies replaced a single Arginine or Leucine residue with NArg and NLeu, 
respectively, in apidacin Ib, an AMP found in insects. Replacing cationic amino 
acids with cationic peptoid residues increased the proteolytic stability and reduced 
haemolysis, but with reduced antimicrobial activity (Gobbo et al., 2009). Introducing 
a single oligo-N-methoxyethyl-glycine (Nmeg) peptoid residue along with a spacer at 
the N-terminus of a peptide-based human respiratory syncytial virus (hRSV) fusion 
inhibitor, C20 peptide improved proteolytic stability and solubility, while retaining 
the peptide binding affinity (Park et al., 2011). These studies emphasize that 
incorporating a single peptoid residue or replacing positively charged amino acids by 
structurally similar peptoid residues improve the bioavailability and structural 
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1.3.5. Lysine-peptoid hybrids 
 
A novel class of antibacterial compounds called lysine-peptoid hybrids were studied 
to identify antibacterial activity. The study revealed several lysine-containing 
analogues which displayed antibacterial activity against S. aureus and E. coli; MIC 
values for the most active ranging from <2–8 μM and 4–20 μM, respectively (Ryge 
and Hansen, 2005). The best candidates have an activity profile that is fully 
comparable with previous literature reports on naturally occurring antibacterial 
peptides  like buforin II, cecropin P1, magainin II and nisin (Giacometti et al., 1999), 
antibacterial peptoids (Goodson et al., 1999) and peptide–peptoid hybrids 
(Shankaramma et al., 2003). Furthermore, they identified two analogues which 
showed a high selectivity toward S. aureus but not E. coli, and four analogues which 
were very active, but did not show any selectivity toward either of the bacterial 
strains tested (Ryge and Hansen, 2005). 
 
Secondly, the haemolytic activity of the analogues correlated well with the number 
of lysine residues present in the hybrids and that haemolytic activity reduced very 
significantly, while retaining antibacterial activity (Ryge and Hansen, 2005). All of 
the analogues containing four or more lysine residues, showed a very low haemolytic 
activity and good antibacterial activity. They conclude that the lysine-peptoid hybrids 
are promising lead structures for developing new antibacterial agents. 
 
In another study on lysine-peptoid hybrid, LP5 exerts a dual mode of action (MOA). 
At 1 × MIC the lysine-peptoid hybrid traverses the cytoplasmic membrane of S. 
aureus without causing lethal damage and binds the chromosomal DNA, inhibits 
topo IV and DNA gyrase and thereby the replication machinery by blocking the 
accessibility to DNA. The inhibitory effect on DNA replication induces the SOS 
response leading to inhibition of growth. At higher concentrations of 5 × MIC and 
above, LP5 also targets the cell membrane leading to leakage of intracellular 
compounds like ATP, resulting in cell death. These results add new information 
about the MOA of a new synthetic peptide, and advance our knowledge of these 
compounds as potential antimicrobial therapeutics (Gottschalk et al., 2013). 
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1.3.6. Lysine-like polypeptoids 
 
Based on the well-known cell penetrating HIV Tat protein, (Unciti-Broceta et al., 
2009) have designed low toxicity lysine-like cell-penetrating peptoid for cell 
labelling. Based on the comparative uptake studies on compounds measured via flow 
cytometry and confocal microscopy they concluded that the 9-mer repeating units of 
lysine-like peptoid have greater penetration into mammalian cells.  
 
The work presented by (Unciti-Broceta et al., 2009) was based on the lysine 
monomeric peptoids and proved to be a quite remarkable carrier for all the cell lines, 
showing good mammalian cell membrane penetrability. However bacterial 
membrane damage or bacterial killing was not studied with these novel peptoids and 
their derivatives. Therefore my studies have been focussed to understand the 
structure-activity relationships on bacterial killing and mammalian cell toxicity on 
those derivatives. 
 
The core structure of the whole peptoid library was a 9-mer lysine-like peptoid unit 
(Figure 1.13) and the peptoid derivatives made by; (i) changing the length of the 
carbon side chain (Figure 1.14); and (ii) N-terminus modifications (Figure 1.15). The 
three different side chain lengths were introduced to a 9-mer consisted of butyl (four-
carbon), hexyl (six-carbon) and octyl (eight-carbon) monomers. Further structural 
changes have been made to the N-terminus end of the polymer encompassing 
different chemical groups conjugated to the N-terminus end such as H-non modified, 
BnCO-Phenyl acetamide, Tosyl-Toluene sulfonamide, Suc-Succinic amide, Ac-
Acetamide and Fmoc-9-Fluorenemethanol (Figure 1.15 and Table 1.3). A number of 
different bio assays have been developed and carried out to study the structure-






















Figure 1.13: The core structure of 9-mer peptoid. All peptoids have nine repeats of a monomer 
unit and each monomer unit either has butyl, hexyl or octyl carbon chain length (highlighted in 
dotted line). Modifications were made on N-terminus (highlighted in continuous line). This 
figure shows the Tosyl-Octamer peptoid (TOP) (Unciti-Broceta et al., 2009). 
 
Figure 1.14: The chemical formula of lysine amino acid and peptide to peptoid modification. 
Substituting the carbon side chain from α-carbon to nitrogen increases the stability of the 
peptoids compared to peptides. Increasing the length of the side chain facilitates mammalian 
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Figure 1.15: Schematic diagram of the development and design of the peptoid library. Butyl, 
hexyl and octyl are defined the length of the carbon side chain. Each peptoids also has different 
N-terminus modifications of the 9-mer such as H-non modified, BnCO-Phenyl acetamide, Tosyl-
Toluene sulfonamide, Suc- Succinic amide, Ac- Acetamide and Fmoc-9-Fluorenemethanol,  
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Table 1.3: Summary table of the peptoid library. Three main groups as butyl-monomers (four-carbon), 
hexyl-monomers (six-carbon) and octyl-monomers (eight-carbon) represent the three different lengths 
of carbon side chain and each category also has different N-terminus modifications such as H-non 
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1.4. Optical strategies for bacterial detection 
 
Bacterial imaging is an emerging technology that has an important role in health and 
environmental applications (Bleeker-Rovers et al., 2004). Imaging bacterial 
pathogens to address quantity, growth kinetics, interactions and real-time monitoring 
within the host environment has the potential to provide important information for 
the choice of antibacterial drugs and to develop novel antimicrobial therapies 
(Coombes and Robey, 2010; Andreu et al., 2011; Bobard et al., 2011).  
 
Optical imaging of bacteria has recently gained significant attention due to its 
relative low cost, near-patient testing capability and potential sensitivity. Recent 
approaches include detecting bacteria using fluorescent tagged cationic probes that 
preferentially bind the anionic phospholipids found on the bacterial cell membrane 
rather than the relatively neutral eukaryotic cell surface. These compounds are 
predominantly based around synthetic Zinc (II)-dipicolylamine probes which bind to 
both gram-negative and gram-positive bacteria both in-vitro and in murine models of 
infection (Leevy et al., 2006; White et al., 2010). The specific detection of Gram 
positive bacterial infections has been reported achieving optical imaging using 
(optically labelled vancomycin) vanco-800CW in-vivo in a mouse myositis model. 
These authors have also tested vanco-800CW in a human post-mortem biomaterial-
associated infections (BAI) implant model, with the intent of developing a novel 
bedside tool for detecting soft tissue infections and BAI. They showed that the 
vanco-800CW as a very promising clinical optical imaging agent for the detection of 
Gram-positive bacterial infections (van Oosten et al., 2013).  
 
Previous studies have not successfully developed MRSA specific imaging probes. 
Therefore my research was focused on developing MRSA specific probes using both 
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1.4.1. Introduction to Staphylococcus aureus 
 
Staphylococcus (from the Greek; grape-berry) were first described and classified in 
1882 by the Scottish surgeon Sir Alexander Ogston (Wilson, 1987). S. aureus is a 
member of the Staphylococcaceae family and this organism appears as gram-positive 
cocci in clusters. S. aureus is distinguished from other staphylococcal species on the 
basis of the gold pigmentation of colonies and positive results of coagulase, mannitol 
fermentation and approximately 1 μm in diameter (Crossley and Archer, 1997). The 
golden pigmentation of S. aureus colonies is caused by the presence of carotenoids 
and has been reported to be a virulence factor protecting the pathogen against 
oxidants produced by the immune system (Liu et al., 2005). More than 130 years 
later, S. aureus remains a versatile and dangerous pathogen in humans. Treatment of 
these infections has become more difficult because of the emergence of multidrug-
resistant strains (Blot et al., 1998). The staphylococcal genome consists of a circular 
chromosome approximately 2800 base pairs in size including prophages, plasmids, 
and transposons. Genes governing virulence and resistance to antibiotics are found 
on the chromosome, as well as the extra chromosomal elements (Novick, 1990). 
These genes are transferred between staphylococcal strains, species, or other gram-
positive bacterial species through the extra chromosomal elements (Schaberg and 
Zervos, 1986).  
 
1.4.2. Importance of S. aureus infections 
 
S. aureus is a commonly isolated human microorganism that is able to colonise the 
anterior nares and other skin regions of healthy individuals. It has been estimated that 
50% of adults are either persistent or intermittent S. aureus carriers (Wertheim et al., 
2005). S. aureus is one of the main causes of hospital- and community-acquired 
infections which can result in serious consequences. This microorganism has become 
a versatile pathogen causing a broad spectrum of infections due to a large arsenal of 
virulence factors. S. aureus is an important cause of skin and soft tissue infections 
(SSTIs), endovascular infections, pneumonia, septic arthritis, endocarditis, 
osteomyelitis, foreign-body infections, and sepsis (Lowy, 1998). S. aureus ranks first 
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or second among bacterial pathogens causing bloodstream infections according to 
different studies (Biedenbach et al., 2004; Wisplinghoff et al., 2004), and is the 
leading cause of nosocomial pneumonia (Hoban et al., 2003). In addition, S. aureus 
causes infections of surgical wounds and prosthetic implants (Pantosti and Venditti, 
2009). 
 
In addition to the infections listed above, S. aureus is often responsible for toxin-
mediated diseases, such as toxic shock syndrome, scalded skin syndrome and 
Staphylococcal foodborne diseases (SFD). Hospitalized patients are particularly 
exposed to S. aureus infections due to their compromised immune system and 
frequent catheter insertions and injections (Lindsay and Holden, 2004). This 
pathogen is the leading cause of bloodstream, lower respiratory tract and skin/soft 
tissues infections in all regions surveyed (Diekema et al., 2001). The importance of 
this human pathogen, apart from its ability to cause life-threatening infections, is its 
remarkable potential to develop antimicrobial resistance. The mortality rate from 
severe MRSA infections is about 20% and it has been estimated that MRSA 
infections are the leading cause of death by a single infectious agent in the US, 
exceeding deaths caused by HIV/AIDS (Klevens et al., 2007). Furthermore, MRSA 
as opposed to MSSA infection is associated with significantly higher costs, due to 
prolonged stay in the hospital, and mortality (Hanberger et al., 2011). 
 
1.4.3. The emergence of MRSA 
 
S. aureus resistance to penicillin emerged in the 1940s (Barber and Rozwadowska-
Dowzenko, 1948). Penicillin resistance is due to the acquisition of genes producing 
penicillinase, a β-lactamase enzyme which was found even before the introduction of 
penicillin into clinical use (Abraham et al., 1940). This enzyme cleaves the β-lactam 
ring of β-lactam antibiotics such as penicillin and its derivatives. Indeed in the 1950s, 
penicillin-resistant strains of S. aureus were pandemic in hospitals and the 
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The semisynthetic antibiotic, methicillin was introduced to overcome penicillin-
resistant S. aureus. Methicillin is a semisynthetic antibiotic derived from penicillin 
resistant to β-lactamase inactivation. Methicillin was introduced by Beecham in 
1959. However one year later, methicillin-resistant S. aureus (MRSA) was detected 
in the United Kingdom (Jevons et al., 1963). Unlike resistance to penicillin, the 
mechanism underlying methicillin resistance protects the bacteria from the entire 
class of β-lactam antibiotics including penicillins, cephalosporins, and carbapenems. 
 
MRSA is defined by the presence of a large mobile genetic element called the 
staphylococcal cassette chromosome, (SCCmec). It carries the mecA gene that codes 
for an alternative penicillin binding protein, PBP2A, with low binding affinity to all 
β-lactams (Ito et al., 2012). MRSA strains were first described in hospital settings, 
after the introduction of β-lactamase-resistant penicillins into medical practice, and 
they continue to be a serious problem in health care due to their ability to acquire 
multidrug resistance determinants. Although outbreaks of diseases in a hospital may 
also be caused by methicillin sensitive S. aureus (MSSA) (Kurlenda et al., 2010), 
MRSA infections are especially easily spread throughout a hospital and, without 
implementation of a special surveillance program with control procedures, the risk of 
an epidemic in hospitals is high (Kurlenda et al., 2010). 
 
Today, many developed countries report that methicillin resistant strains account for 
at least 25 – 50% of infectious S. aureus isolates in hospitals (Diekema et al., 2001). 
In contrast, some countries such as The Netherlands and the Scandinavian countries 
historically have low MRSA infection rates (often < 1 %), most likely owing to rigid 
search-and-destroy surveillance policies, as well as restraint in antibiotic 
prescription. In fact, a recent Japanese study indicates that high antibiotic 
consumption rates led to increased MRSA burden over time (Nakamura et al., 2012). 
Initially MRSA infections were limited to hospitalized patients, the most recent 
epidemic MRSA wave, beginning in the mid to late 1990s, was characterized by the 
emergence of community-associated MRSA (CA-MRSA) with the capacity to infect 
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1.4.4. Genetics of methicillin resistance in S. aureus 
 
The staphylococcal cassette chromosome mecA (SCCmec) is responsible for 
methicillin resistance in staphylococci and this is due to the acquisition of a mobile 
genetic element (MGE) (Katayama et al., 2000). The DNA fragment SCCmec ranges 
from 21 to 67 kb in size, depending on the SCCmec type (Hiramatsu et al., 2001). 
The number of SCCmec types is constantly increasing with the discovery of new 
elements and there are currently 11. All SCCmec types include the mecA gene, which 
codes for the low-affinity penicillin binding protein PBP2A (Hartman and Tomasz, 
1981) and is responsible for methicillin resistance in MRSA. Resistance is due to the 
fact that β-lactam antibiotics cannot inhibit PBP2A, in contrast to other S. aureus 
PBPs. SCCmec elements vary in composition and they may contain additional 
antibiotic resistance genes (Queck et al., 2009).  
 
MRSA also have acquired resistance to other antibiotics, such as erythromycin, 
clindamycin, ciprofloxacin, tetracycline, etc. (Shorr, 2007). It is alarming that multi-
drug-resistant strains of S. aureus are often only susceptible to vancomycin, an 
antibiotic with considerably lower efficiency to β-lactams. Furthermore, rare cases of 
highly vancomycin-resistant MRSA strains (VRSA) have been reported. Fortunately, 
these did not spread substantially, possibly owing to increased fitness cost associated 
with high-level resistance to vancomycin. The majority of CA-MRSA strains have 
not acquired resistance to additional antibiotics, with the exception of limited 
outbreaks of multi-drug-resistant CA-MRSA (Diep et al., 2008). 
 
1.4.5. The mecA Gene 
 
The mecA gene originally identified in methicillin-resistant S. aureus (MRSA) (Beck 
et al., 1986; Matsuhashi et al., 1986) encodes a PBP of 668 amino acid residues 
which is responsible for beta-lactam resistance (Utsui and Yokota, 1985). The mecA 
gene is carried by SCCmec and has been identified in various staphylococcal species, 
such as S. aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, 
Staphylococcus saprophyticus, and Staphylococcus fleurettii (Tsubakishita et al., 
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2010). The mecA genes present in these species have 98% sequence identity with the 
mecA carried by the first fully sequenced prototype MRSA strain N315 (Kuroda et 
al., 2001). The first divergent mecA gene homologues were identified on the 
chromosomes of Staphylococcus sciuri subsp. sciuri, S. sciuri subsp. rodentius, and 
S. sciuri subsp. carnaticum. These homologues are very similar to each other and 
have approximately 80% nucleotide sequence identity to mecA of N315 (Wu et al., 
1996; Wu et al., 1998; Couto et al., 2003). A second group of mecA gene 
homologues identified in Staphylococcus vitulinus have about 90% nucleotide 
identity to mecA of N315 (Schnellmann et al., 2006). 
 
1.4.6. Regulation of mecA gene expression 
 
The expression of the mecA gene is regulated in analogous manner to that of the β-
lactamase gene, blaZ. Similar to blaZ, mecA is divergently transcribed from its two 
regulatory genes organized in an operon, mecI and mecR1. Homodimeric methicillin 
repressor, MecI, constitutively represses expression of mecA as well as transcription 
of the mecI-mecRI operon by binding to two palindromes contained within the 
promoter-operator region (Safo et al., 2006). Derepression occurs through cleavage 
of MecI upon activation of the metalloprotease domain of the mecRI sensor-
transducer by a β-lactam antibiotic. 
 
MecRI is a membrane protein that has an extracellular penicillin-binding domain 
that, when bound by β-lactams, undergoes a conformational change inducing 
autocleavage of the intracellular protease domain. The active MecRI cleaves MecI 
which leads to derepression of mecA as well as the mecI-mecRI operon (Mallorquí-
Fernández et al., 2004). In addition to regulation of mecA expression by its cognate 
MecI and MecRI regulators, it can also be regulated by structurally and functionally 
similar β-lactamase regulators, BlaI and BlaRI. Due to their structural and functional 
similarity, MecI and BlaI are able to bind as homodimers to the promoter-operator 
region of mecA (Gregory et al., 1997). The MecI or BlaI-mediated repression is only 
relieved by induction through homologous and not heterologous sensor-transducers, 
demonstrating the repressor specificity of induction. Induction of mecA expression 
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by the MecRI-MecI system is slower than the induction by BlaRI-BlaI and never 
leads to maximal mecA transcription (Potempa et al., 1991).  
 
1.4.7. The PBP2A protein 
 
PBP2A (Figure 1.16) belongs to the group of high molecular mass (78 kDa) family 
of PBPs and consists of a transpeptidase domain and a non-penicillin binding domain 
of unknown function (Goffin & Ghuysen, 1998). PBP2A is known to possess low 
affinity for β-lactams that allows MRSA strains to grow in antibiotic concentrations 
that inactivate all native PBPs (Gaisford and Reynolds, 1989). PBP2A is a poorly 
active enzyme, compared to other native PBPs that synthesize highly cross-linked 
peptidoglycan (de Jonge and Tomasz, 1993). Even when the transpeptidase activity 
of all native PBPs is inhibited by the presence of methicillin, PBP2A has been shown 
to rely on the transglycosylase, β-lactam-insensitive, domain of the native PBP2 to 
confer resistance (Pinho et al., 2001). 
 
The serine in the active site of the transpeptidase domain in PBP2A (Figure 1.16) is 
responsible for nucleophilic attack on both the β-lactam ring and the D-alanyl-D-
alanine substrate and is located in an extended narrow groove. The groove mediates 
non-covalent interactions with the β-lactam that place the β-lactam in an unfavorable 
position for interaction with the serine in the active site. As a result, the acylation 
between the β-lactam and the active site does not occur. PBP2A successfully 
balances the crucial transpeptidase activity with a decreased affinity toward β-lactam 
antibiotics. Therefore PBP2A is able to synthesize the cell wall at otherwise lethal 






























Figure 1.16: The structure of PBP2A. The bi-lobed N-terminal non-penicillin binding  domain is 
orange, with the N-terminal lobe coloured green. The transpeptidase domain is blue, with the 
position of the active site indicated by the red. The N- and C- termini are labelled N and C, 
respectively (Lim and Strynadka, 2002). 
 
1.4.8. Research objective to over-express the PBP2A protein 
 
Expression of PBP2A is the basis for the broad clinical resistance to the β-lactam 
antibiotics by MRSA. Hence, I aimed to clone, overexpress and purify PBP2A to 
generate sufficient protein to develop molecular probes targeting PBP2A. In the field 
of molecular imaging, detecting PBP2A protein associated with MRSA could be an 
important molecular target to develop novel molecular imaging agents to identify 
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1.5. Aptamer molecular probe development 
 
1.5.1. Introduction-Aptamer technology 
 
Aptamers are short, single-stranded oligonucleotides (DNA or RNA) discovered in 
the early 1990s and have found diverse applications in biotechnology (Gold et al. 
1995; Nimjee et al. 2005). Aptamers are isolated through a process called systematic 
evolution of ligands by exponential enrichment (SELEX) (Ellington and Szostak, 
1990; Tuerk and Gold, 1990) in which a starting library of oligonucleotides are 
screened for sequences that can bind specifically and with high affinity to a target of 
choice. The process itself is very versatile and the choice of targets to obtain 
aptamers can vary from small molecules (nucleotides, vitamins, amino acids, 
carbohydrates, dyes, antibiotics) (Fickert et al., 2006; Lorenz and Schroeder, 2006), 
peptides and proteins (Nimjee et al. 2005) to whole cells (Ye et al., 2012). 
Depending upon the requirements of the target, strategies for aptamer selections are 
adjusted and can vary widely. Aptamers are also described as chemical versions of 
antibodies and can inhibit their targets through specific and strong interactions that 
are superior to those of biologics and small molecule therapeutics. They also avoid 
the toxicity and immunogenicity concerns of these traditional agents due to their 
nucleic acid compositions (Nimjee et al., 2005). 
 
1.5.2. The SELEX process 
 
SELEX starts with a single stranded nucleic acid library of either RNA or DNA. The 
library contains aptamers which have a variable or randomised region in the middle 
flanked by two constant regions called primer binding regions (Ellington and 
Szostak, 1990; Tuerk and Gold, 1990). This randomised region can range from a few 
nucleotides to hundreds of nucleotides and can be continuous or found in blocks. 
Importantly, enough nucleotide sequence randomisation in the library needs to occur 
to generate various conformations from which aptamer diversity originates. The 
diversity of the aptamer library increases with the larger randomised region of the 
aptamer. For example a library with 40 randomised nucleotides could yield 
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approximately 1014 unique aptamer sequences (considering four nucleotides in 40 
randomised positions) for screening (Gold et al. 1995). 
 
SELEX begins with a randomised aptamer library incubated with a target molecule 
(purified protein target or cells). A number of partitioning strategies exist, including 
centrifugation, nitrocellulose binding, column chromatography, or immune 
precipitation. The aptamer molecules that bind to the target molecule are then eluted 
and amplified by PCR for DNA aptamer selection (Bayrac et al. 2011), or RT-PCR 
for RNA aptamer selection (Adler et al. 2008). This generates an enriched pool with 
increased binding affinity for the target from the first round to the following SELEX 
rounds. The process of incubation, partitioning, elution, and amplification comprises 
one round of SELEX (Fitzwater and Polisky, 1996) (Figure 1.17). This process is 
then repeated under increasingly stringent conditions to isolate specific aptamers 
(Adler et al. 2008) that bind with the highest affinity for the target.  Conditions can 
be created for promoting greater binding to the target by increasing the aptamer to 
target molecule ratio, increasing salt concentrations, or decreasing the overall amount 
of target molecule used. The number of rounds required to drive a selection to 
completion depends on both the target and how much stringency is increased in each 
round and selection can be completed in 8–18 rounds (Fitzwater and Polisky, 1996). 
The counter-SELEX method was introduced to increase the efficiency of aptamer 
selection by traditional SELEX (Figure 1.17) (Jenison et al., 1994). Compared to 
traditional SELEX, counter-SELEX has a pre-clearing step using closely related 
structural analogs of the target to effectively discard non-specific aptamer. This 































Figure 1.17: Aptamer library and a simplified schematic of systematic evolution of ligands by 
exponential enrichment (SELEX): The starting oligonucleotide library (RNA or DNA) is 
incubated with the target of interest in the binding-reaction. The bound oligonucleotide-target 
complexes are partitioned from the unbound oligonucleotides. Then the unbound 
oligonucleotides are discarded and the bound oligonucleotides are eluted from the target and 
amplified. The amplified oligonucleotide ‘‘pool’’ is incubated with the target protein in the next-
round of SELEX. This process is repeated with the counter selection step which can reduce non-
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1.5.2.1.   Cell-SELEX 
 
SELEX can target more than one individual molecule by applying cell-SELEX 
strategies. This utilises living cells as the SELEX target (Figure 1.17). Although 
traditional SELEX is typically carried out using purified target molecules, whole live 
cells are also employed as selection targets. Not only normal/abnormal mammalian 
cells such as virus-infected and cancer cells but also live pathogenic organisms such 
as bacteria and viruses have been utilised as cell-SELEX targets (Tang et al., 2009; 
Hamula et al., 2011). The aptamers generated are functional with an original 
conformation that binds the target molecule on live cells. Compared to aptamers 
selected using a purified target, a cell-SELEX-derived aptamer may have more 
control to be used directly for clinical applications. 
 
A screened aptamer resulting from cell-SELEX using abnormal cells can be used to 
detect disease or cancer cells. Furthermore, biomarkers can be developed that 
identify the aptamer target for a specific abnormality (Blank et al., 2001). Aptamers 
can be selected for host cell proteins if their expression levels are up-regulated upon 
viral infection. Lastly, stable cell lines can be generated that express viral protein as a 
cell-SELEX target and the aptamer obtained can be used to detect virus infected cells 
(Chen et al., 2007). Novel biomarkers can be discovered using the cell-SELEX 
technique because the target molecules of the may be previously unrecognised as 
cell-specific surface molecules. Thus, cell-SELEX can be applied for de-novo 
discovery of novel biomarkers for a desired cell by identifying the aptamer binding 
partner. The cell-SELEX concept can be extended for in-vivo selection, which was 
first demonstrated using a hepatic tumour xenograft mouse model (Mi et al., 2010). 
Oligonucleotides were injected intravenously, liver tumours were harvested, and the 
injected RNA molecules were extracted and amplified. A tissue-specific aptamer can 
be more easily screened through this in-vivo selection process. Therefore a screened 
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1.5.2.2.  Capillary Electrophoresis-SELEX 
 
The SELEX process has disadvantages in that it is time consuming to repeat the 
rounds of enriching molecular biology methods have been introduced to SELEX to 
overcome these disadvantages. Capillary electrophoresis-SELEX (CE-SELEX) was 
designed for selecting aptamers to reduce repeating rounds with low dissociation 
constants (Mosing et al., 2005). In this method, the nucleic acids that bind the target 
migrate with different mobilities than those of unbound sequences and allow them to 
be collected as separate fractions. Although traditional SELEX requires 6-12 rounds, 
CE-SELEX significantly reduces the number of rounds and increases binding affinity 
(Schneider et al., 1995). CE-SELEX decreases the time, effort and cost to screen a 
higher affinity aptamer compared to those of traditional SELEX. Based on CE 
technology a non-SELEX method that selects an aptamer without amplification was 
demonstrated (Berezovski et al., 2006). This procedure can be automated using a 
single commercially available capillary electrophoresis instrument. 
 
1.5.2.3.  One step MonoLEX 
 
The MonoLEX approach combines a single affinity chromatography step with 
subsequent physical segmentation of the affinity resin and one single final 
exponential amplification step of the bound aptamers (Nitsche et al., 2007). Using 
the Biomek 2000, an automatic SELEX device (Cox et al., 1998). They 
demonstrated that 10 rounds of selection against eight targets in parallel can be 
performed in 4-5 days. 
 
1.5.2.4. Microfluidic SELEX 
 
Microfluidic SELEX (mSELEX) was designed that combines traditional SELEX 
with a microfluidic system. Protein immobilisation is the most important aspect of 
mSELEX. In previous studies a mSELEX prototype device was developed and 
biotinylated lysozymes were immobilized to silica microline previously coated with 
streptavidin (Hybarger et al., 2006). It is possible to use magnetic bead-based 
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SELEX process with microfluidics technology and a continuous-flow magnetic 
activated chip based separation device was developed (Lou et al., 2009). Using this 
mSELEX method, an enriched aptamer pool was obtained that tightly bound to the 
light chain of recombinant Botulinum neurotoxin type A after a single round of 
selection with a 33 nM Kd value. Recently, a novel formulation of sol-gel protein 
microarray material was developed, which produced physical properties suitable for 
protein immobilization, protein-protein interactions, and immunoassays (Kim et al., 
2006). Based on sol-gel, the authors developed a microfluidic device and method for 
binding nucleic acids to immobilized proteins and efficiently eluted and recovered 
the intact nucleic acids (Park et al., 2009). The mSELEX system has enhanced 
selection efficiency and reduces time and effort compared to those of traditional 
SELEX. 
 
1.5.3. Aptamer modifications to increase stability 
 
RNA and DNA oligonucleotides are naturally unstable molecules and are rapidly 
degraded in biological fluids due the presence of endogenous nucleases. Therefore, 
nucleotide modification strategies are often utilised to increase resistance. In the case 
of RNA aptamers, modified bases are typically introduced in the starting library for 
selection to have increased nuclease resistance from the outset. A common 
modification is to alter the functional group on the 2’ ribose position of pyrimidines, 
including 2’-fluoro, 2’-amino, and 2’-O-methoxy substituted nucleotides (Keefe and 
Cload, 2008). These modifications can easily be incorporated during in-vitro 
transcription using a mutant form of T7 RNA polymerase (Chelliserrykattil and 
Ellington, 2004). After selection, internal modifications can be made to the aptamer; 
however these may influence structure and functionality of the aptamer. Therefore, 
most chemical modifications for enhancing the nuclease stability of the aptamers are 
incorporated at the beginning of selection. 
 
Other modifications yielding aptamers with higher stability include the use of L-
nucleotides and locked nucleic acids. Aptamers created with L-nucleotides are 
known as spiegelmers, from the German word for mirror (Sooter and Ellington, 
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2002; Klussmann, 2006). L-nucleotides are the mirror image or enantiomers of the 
naturally occurring D-nucleotides. However, being the L-nucleic acid, they are not 
the substrate for DNA or RNA polymerases. Thus, they are not substrates for 
enzymatic polymerisation and cannot be directly used to make aptamers using the 
standard SELEX process. Aptamers composed of natural D-oligonucleotides can be 
selected against mirror image targets (such as L-amino acid peptides, rather than 
natural D-amino acid peptides). Once the aptamers are isolated, they can be 
chemically synthesised as L-oligonucleotides (Spiegelmers), and will bind to the 
natural D-amino acid peptide targets. Because Spiegelmers are composed of 
unnatural monomers, they are not good substrates for nucleases and have been shown 
to be stable over 60 hours in biological fluids. So far, there are 2 such aptamers in 
clinical trials (Kulkarni et al., 2007; Kulkarni et al., 2009; Sayyed et al., 2009). 
 
Aptamers are low molecular weight; therefore they are rapidly cleared by the renal 
system. This can be reduced through the addition of polyethylene glycol (PEG) or 
cholesterol to the aptamer. These kinds of modifications are made post-selection. 
They increase the overall molecular weight of the aptamers without disrupting their 
structure and the therapeutic functions. This can increase the half-life of an aptamer 
from <10 min to >12 h depending on the specific aptamer modifications (Becker et 
al., 2005). An aptamer with a longer half-life can be administered less frequently and 
potentially outside the hospital setting. Aside from traditional intravenous 
administration, recent work has suggested that aptamers can also be administered 
subcutaneously, which can increase the half-life up to 6 days (Vavalle et al., 2012). 
 
1.5.4. Aptamer characteristics 
 
Aptamers have several characteristics that make them useful as potential therapeutic 
molecules and set them apart from small molecules and antibodies. Aptamers are 
relatively small (8–15 kDa) compared to antibodies (50–100 kDa), while still 
demonstrating high specificity and affinity for their target, with equilibrium 
dissociation constants in the low nanomolar to high picomolar range (Nimjee et al. 
2005). This specificity and affinity stem from the fact that aptamers fold into unique 
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three-dimensional structures and form specific contacts between functional groups on 
both nucleic acid and protein targets (Long et al., 2008). Since an aptamer covers a 
functional portion of the target protein, they tend to act as antagonists by blocking 
their interactions with either protein partners or their substrates that results in the 
inhibition of their enzymatic activity (Long et al. 2008). This loss in enzymatic 
activity of protein targets by the action of aptamers is reversible in most cases. This 
is important therapeutically because once aptamer activity is reversed; the target 
protein is able to function immediately (Becker et al., 2005).  
 
Another advantage of aptamers, over antibodies, is their stability during long-term 
storage; they can be refolded into their functional structure after multiple freeze-thaw 
cycles. A major benefit of aptamers is that they can be generated, in small or large 
scale in-vitro, by either solid-phase chemical synthesis or by in-vitro transcription, 
both of which are much faster than the in-vivo generation of antibodies (Becker et 
al., 2005).  
 
Furthermore, unlike antibodies, aptamers have not been shown to produce an 
immune response in animal and clinical studies and are well tolerated in the body 
and this allows for repeated administration (White et al., 2000). The synthetic 
oligonucleotides, containing modified nucleotides, possibly do not provoke the 
adaptive immune response and generally do not produce antibodies. In 2009, Yu et 
al. demonstrated that the oligonucleotides containing 2’-modified nucleotides (2’-O-
methylribonucleotides, 5-methyl-dC or 2’-O-methyl-5-methyl-C) inhibit the toll-like 
receptors (TLR7 and TLR9) activity. Some of these 2’-modified nucleotides like, 2’-
O-methylribonucleotides are regularly used to synthesise aptamer. It is possible that 
aptamers containing modified nucleotides inhibit TLRs and do not provoke the 
innate immune system. This might be the other possible reason for their non-
immunogenic nature. In clinical trials, the only known immune responses to aptamer 
administration were thought to be caused by antibody generation to the PEG 
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Another important characteristic for aptamers as therapeutic molecules is the ability 
to rapidly and effectively reverse an aptamer with either a sequence-specific antidote 
or a universal antidote that reverses aptamer activity independent of sequence (Oney 
et al., 2009). This is a characteristic not found in small molecule inhibitors or 
antibodies, and lends itself well to application in the clinic, as well as a tool for 
studying a target of interest. Since the development of the SELEX process in 1990, 
this process has been used to create designer ligands, or aptamers, to essentially any 
target. This has opened up the possibility of using aptamers not just for basic 
sciences, but also for diagnostics, therapeutics, imaging, and biosensing. Notably, 
aptamers have already made the transition from the bench to the clinic. For example 
nuclease-resistant RNA aptamer against vascular endothelial growth factor modified 
with PEG (pegaptinib or Macugen, Eyetech Pharmaceuticals) is now in clinical use 
for the wet form of age-related macular degeneration (Ng et al., 2006). For the list of 
aptamers that are currently in clinical trial please refer (see table 1.4). The number of 
publications with aptamer applications is rapidly increasing. There are a variety of 
applications of aptamers as both therapeutic molecules and as sensing molecules 
(diagnostics).   
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1.5.5. Applications of aptamer 
 
1.5.5.1.  Therapeutics 
 
Aptamers can be modified to create different functions and can be specifically 
tailored for many potential applications in biotechnology and molecular medicine. 
Aptamers can bind to their cognate protein and also efficiently inhibit the function of 
target as an antagonist. Many aptamer therapeutic studies have been conducted to 
treat certain diseases by inhibiting therapeutic target activity and decreasing the 
partner binding property (Siller-Matula et al., 2012; Vater et al., 2013) (Figure 1.18). 
The first FDA approved Macugen aptamer drug for age-related macular 
degeneration, is a typical antagonistic aptamer (Zhou and Wang, 2006). Macugen 
(pegaptanib) is a 28-base RNA oligonucleotide with two branched 20 kDa PEG 
moieties (Ruckman et al., 1998). It selectively binds to the vascular endothelial 
growth factor (VEGF)165 isoform when introduced intravitreally. Thus, the 
intracellular signal cascade is inhibited by the pegaptanib-VEGF165 complex, which 
cannot bind to the VEGF receptor. Thus, pegaptanib has the potential to inhibit 
growth of blood vessels and vascular leakage by inhibiting the intracellular signal 
cascade induced by the pegaptanib-VEGF165 complex. Diverse therapeutics based 
on antagonistic functions of aptamers are undergoing clinical trials (Table 1.4). They 
inhibit the signalling cascade by decreasing activity of the target protein or altering 
binding with the physiological binding partner.  
 
Aptamers may also function as agonists in certain biochemical reactions, e.g. 
agonistic use of an aptamer with 4-1BB, which is a major co-stimulatory receptor 
(McNamara et al., 2008). 4-1BB increased expansion and survival of activated T 
cells. Dimerization of the anti-4-1BB aptamer treated with the CD3 antibody not 
only increased T-cell activation and interferon-γ in-vitro but also tumour regression 
in-vivo. Moreover, Dollins et al. designed an aptamer-based agonist by dimerising 
the OX4 RNA aptamer, which targets one of the tumour necrosis factor receptor 
families (Dollins et al., 2008). Two 2′-fluoropyrimidine-modified RNA aptamers 
were selected that bind to CD28 (CD28Apt2 and CD28Apt7) (Pastor et al., 2013). 
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Figure 1.18: Applications of aptamer. Aptamer can be used as therapeutics, targeted drug 
delivery system (DDS) and imaging. These three parts can be put together using aptamers and 
conjugation in multifunctional probes (Kong and Byun, 2013). 
 
This study suggested that an agonistic dimerised anti-CD28 aptamer increases co-
stimulatory efficacy and reduces therapeutic dose and toxicity compared to 
conventional agonistic anti-CD28 antibodies. Similar research on aptamers for use as 
co-stimulatory agonistic molecules is being conducted (Suntharalingam et al., 2006; 
Romer et al., 2011). Moreover, not only homo-dimerisation of an aptamer for 
agonistic use but also hetero-dimerization of two individual aptamers that recognize 
different targets for dual purposes, specific targeting and stimulating, have been 
reported (Gilboa et al., 2013). Two individual aptamers were hetero-dimerized 
including a 4-1BB binding aptamer to stimulate the immune response and a prostate-
specific membrane antigen (PSMA) binding aptamer for prostate cancer targeting. 
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This bi-specific aptamer was developed to revert prostate tumours through the host 
immune response. A bi-specific aptamer is more effective and synergizes with 
vaccination strategies and exhibits a superior therapeutic index compared with non-
targeted co-stimulation with 4-1BB antibodies or 4-1BB aptamers. 
Agonistic/antagonistic aptamers offer significant advantages over antibodies in terms 
of synthesis, cost, and immunogenicity as well as conjugation chemistry. 
 
1.5.5.2.  Target drug delivery 
 
Aptamers exhibit many desirable properties for targeted drug delivery such as ease of 
selection and synthesis, high binding affinity and specificity, low immunogenicity, 
and versatile synthetic accessibility. The therapeutic agents that have been delivered 
using aptamers as the targeting ligands can be categorized into three major classes;  
drugs, toxins, and small interfering RNAs (siRNAs) (Figure 1.18) (Zhang et al., 
2011).  
 
Doxorubicin (Dox) used in chemotherapy for haematological malignancies, 
carcinomas, and soft tissue sarcomas can intercalate within the double-stranded CG 
sequences of DNA and RNA. Based on the intercalation property of Dox to the 
aptamer, targeted Dox delivery for targeting cancer and Dox mediated cancer therapy 
has been actively studied (Ling et al., 2012; Liu et al., 2012; Meng et al., 2012; 
Subramanian et al., 2012). A Dox intercalated aptamer that binds to prostate-specific 
membrane antigen (PSMA), which is abundantly expressed on the cell surface of a 
human prostatic adenocarcinoma (LNCaP) metastatic lesion has been studied. PSMA 
expressing LNCaP-specific cell death was observed by treatment with Dox-
intercalated PSMA-specifi c 2′-fluoropyrimidine aptamer, but not in PSMA-negative 
PC3 cells (Bagalkot et al., 2006). Covalent conjugation of aptamer harboring the 
drug is relatively stable such that drug release during transport is prevented before 
the drug localizes at its cellular target. Drugs can be chemically modified to form 
stable ester, amide, and disulfide bonds that serve to conjugate the drug to the 
aptamer. Other chemotherapy drugs such as daunorubicin, thalidomide, and 
dactinoimycin can also intercalate to double-stranded oligonucleotides. They are 
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expected to show a good therapeutic effect in specific cancers, and their application 
in various aptamers is actively sought. 
 
Liposomes, small lipid bilayer structures, can be adopted as an excellent drug 
delivery carrier for aptamers. Aptamer-tagged liposomes have been synthesised to 
contain the anticancer drug paclitaxel and a fluorescent dye (Nile Red) for tumour-
specific drug delivery and imaging (Aravind et al., 2012). In another study, Cy3-
labeled, carboxylated, thiolated oligonucleotide aptamer (thioaptamer) against E-
selectin (ESTA, E-Selectin ThioAptamer) was designed. This modified ESTA was 
coupled to an amino PEGylated stealth liposome to make the vasculature targeting 
ESTA-conjugated liposome (Mann et al., 2011), which achieved tumour vasculature-
specific drug delivery. Moreover, a photosensitizer-aptamer conjugate was 
developed for cancer specific delivery to be used in photodynamic cancer therapy 
(Yang et al., 2011; Han et al., 2013). 
 
Aptamers can be used to deliver siRNA to specific cells and the receptor-mediated 
endocytosis mechanism is involved in cellular uptake. In general, non-covalent 
conjugation through a connector and covalent linkage through formation of an 
aptamer-siRNA chimera are two major strategies for aptamer and siRNA 
conjugation. In 2006, two biotinylated anti-PSMA aptamers were linked to two 
biotinylated anti-lamin A/C siRNAs using streptavidin as the connector (Chu et al., 
2006). As a result, PSMA-positive prostate cancer cell-specific siRNA was 
internalised and siRNA-specific gene expression was inhibited in-vitro. However, the 
siRNA release mechanism has not been demonstrated in-vivo.  
 
1.5.5.3.  Aptamer based imaging 
 
Another application of aptamers is diagnosis via in-vivo and in-vitro imaging, using 
an aptamer that is conjugated to a fluorophore, quantum dots, or other material such 
as gadolinium, which is useful for magnetic resonance imaging (MRI) (Figure 1.18). 
Optical imaging is a cost-effective imaging method that typically uses fluorescent or 
bioluminescent molecules. Aptamer based optical imaging can be divided into direct 
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targeting and activatable probes (Hong et al., 2011). Direct conjugation with an 
aptamer and a fluorescent molecule is widely studied (Shi et al., 2010; Cui et al., 
2011; Talbot et al., 2011; Zhang et al., 2012; Song et al., 2013; Zhang et al., 2013). 
It is the simplest way to image via a visualised aptamer by fluorescence. Aptamers 
probes activated following conformational changes are particularly useful. They are 
designed such that fluorescence will “turn-on” when the aptamer binds to its target. 
Typically, a fluorescently labelled substrate is designed to be maximally quenched 
by a quencher in close proximity due to FRET (McIntyre and Matrisian, 2003; Tsien, 
2005). For example, Zhang et al., designed a bifunctional fluorescent oligonucleotide 
probe for the detection of adenosine triphosphate (ATP) and thrombin (Tmb). The 
molecular beacon contains two hairpin loops that serve as the sensing elements, and 
a fluorophore at one end and a quencher at the opposite end, as the reporter (Li et al., 
2013). This “Turn-on” fluorescence mechanism by quenching is widely used in 
aptamer-based biosensors. Compared to a conventional “always-on” probe, the 
activatable probe could substantially minimise the background signal originating 
from non-target tissues, thereby giving significantly enhanced image contrast (Hong 
et al., 2011). Not only optical imaging, but super paramagnetic iron oxide 
nanoparticle-aptamer conjugate have been used in MRI imaging (Yigit et al., 2007). 
Aptamers can also be applied for targeted ultrasound imaging using covalent 
conjugation of nanobubbles. These aptamer-conjugated nanobubbles can be 
harnessed to release a certain amount of drugs upon targeted ultrasound-trigger 
(Wang et al., 2011). 
 
1.5.6. Staphylococcus aureus aptamer 
 
Staphylococcus aureus specific ssDNA aptamer panels are developed by a whole 
bacterium-based SELEX procedure. After several rounds of selection with S. aureus 
as the target and Streptococcus pneumoniae and S. epidermidis as counter targets, a 
panel of aptamers to detect S. aureus was developed using cell-based SELEX by 
(Cao et al., 2009). They demonstrated that the simultaneous probing of several 
targets by a set of specific aptamers proved to be more efficient than probing by an 
individual aptamer in detection of S. aureus. Unlike single target SELEX which 
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generates an enriched pool of aptamers to the single target, the complex SELEX ends 
up with an enriched pool of aptamers to various targets on the cells (Wang et al., 
2003; Shangguan et al., 2007). 
 
In another study, a novel and sensitive fluorescence bioassay for the simultaneous 
detection of S. typhimurium and S. aureus was developed. This technique used 
aptamer-conjugated magnetic nanoparticles for both recognition and concentration 
elements and using nanoparticles as highly sensitive dual-colour labels (Duan et al., 
2012). The luminescent signal was effectively amplified with the help of both 
magnetic separation and concentration. This method demonstrates the first use of 
aptamer-conjugated magnetic nanoparticles as the capture and concentration element 
and the use of up-conversion nanoparticles as the fluorescence element for the 
simultaneous detection of two types of pathogenic bacteria. According to published 
literature, several studies have focused on developing S. aureus specific aptamers in-
vitro. However MRSA specific aptamer molecules have not been developed yet and 
currently we do not have reliable and sensitive technique to detect MRSA in-vivo 
over other Staphylococcus species. Hence my thesis focused on initiating the 
development of aptamer based molecular probes to detect MRSA.  
 
1.6. Peptidic-based molecular probe development 
 
1.6.1. Background and Principles of Phage-Displayed Peptide Library  
 
Bacteriophage (phage), are single-stranded DNA viruses that infect various bacteria, 
including E. coli. Phage display technology first introduced in 1985 by George 
Smith, has had great applications in biology. Unique and other structural and genetic 
characteristics of the filamentous phage make phage display an extremely powerful 
tool for bioengineering. The technique can be used for screening ligands, developing 
new drugs, designing vaccines, evolving molecules, diagnosing diseases, drawing 
genetic maps, delivering targeted drugs or biosensing (Brigati et al., 2004; Liu et al., 
2009; Mao et al., 2009). Numerous proteins and peptides with high specificity and 
affinity have been isolated from phage display libraries using affinity selection 
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(biopanning) and have been widely used in different fields (Takakusagi et al., 2010; 
Ueberberg and Schneider, 2010). 
 
Encoded proteins are expressed on the phage surface as a fusion product with one of 
the phage coat proteins (Figure 1.19), this is achieved by the introduction of defined 
exogenous protein sequences into a location in the genome of the phage capsid 
proteins. By applying this technology, phage display libraries containing up to 1010 
different proteins have been easily developed (Ueberberg and Schneider, 2010).  
 
 
Figure 1.19: Schematic structure of a phage displaying multiple copies of a single-chain 
antibody (VH = variable heavy chain, VL = variable light chain). The information for the single 
chain antibody was introduced in a location of the genome for the phage coat protein pIII, and 
thus the antibodies are displayed fused to the pIII coat protein on the phage surface. An 
alternative startegy would be to express the single-chain antibodies with the other coat proteins 
of the phage pVIII or pVII+pIX (adapted from Ueberberg and Schneider, 2010). 
 
Therefore Phage displayed peptide libraries are a heterogeneous mixture of such 
phage clones, each carrying a different foreign DNA and therefore displaying a 
different peptide on its surface (Smith and Petrenko, 1997). The foreign peptides to 
be displayed by phage are fused into phage coat proteins through random foreign 
DNA insertion into the phage genome, particularly in the N-terminus of pIII coat 
protein between the vector-insert and insert-vector junctions. Consequently, coat 
protein and foreign peptide become a hybrid fusion protein that is exposed to the 
exterior environment. pIII, a minor coat protein, is located at one tip of the phage 
with five copies. Hence, theoretically, foreign peptides fused with pIII protein are 
displayed in five copies as well. In addition to pIII, pVIII major coat protein and pVI 
minor coat protein have been used to fuse with the foreign peptides. Nonetheless, 
pIII display system is much more common because it allows different foreign DNA 
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insertion sites (N-terminus of pIII, middle of pIII or replaces N-terminal domain or C 
terminal via leucine zipper) while pVI only allows fusion of foreign peptide at C-
terminal and pVIII at N terminal. According to Smith and Petrenko (1997), 
numerous pVIII displayed peptides, comprise a substantial fraction of the phage’s 
mass and might dramatically alter the physical and biological properties of the phage. 
 
Selection of the antibacterial peptide begins through affinity biopanning using phage-
displayed peptide library. The target can react with the phage-displayed peptides in 
solution, followed by the affinity capture of phage-target complexes. After the first 
round of selection, only peptides with strong binding affinity to bacteria are captured 
while unbound phages are washed away. The captured phages are then eluted and 
amplified to generate more copies of each selected individual phage in order to 
secure ever-fitter subsets of peptides in further rounds of selection. At the end of the 
selection, the selected phages should be low in yield but high in stringency, with the 
specific and tight binding phage-displayed peptides (Zhang et al., 2012). Individual 
phage is subsequently isolated, followed by the DNA sequencing for the inserted 
DNA region that encodes the displayed peptide. Based on the DNA sequences, 
peptide sequences can be deduced. 
 
1.6.2. Phage Display 12 Peptide Library 
 
Phage display 12 amino acid peptide library consists of linear peptides with 12 amino 
acid residues. Phage display is not applicable to larger polypeptides in which the 
fusions might lead to detrimental effects on the function of coat protein (Christensen 
et al., 2001). According to New England BioLabs, each phage has short linker 
sequence (Gly-Gly-Gly-Ser) that connects the peptide to pIII coat protein. The phage 
displays 12 amino acids on the pIII minor coat protein with five copies per phage. It 
fulfils the minimum requirement of antibacterial peptide of 12-50 amino acids. 
Therefore, it is believed to have good binding efficacy to the target bacterial 
membrane. Ph.D 12 from New England Biolabs is supplied with large population of 
phage clone, approximately 109 phage clones each with unique displayed peptide and 
1011 phage particles in total. 
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1.6.3. Applications of Phage Display Technology in bacterial detection 
 
Short-synthetic peptides have been gaining importance as probes for microbial 
detection. Previous studies successfully identified at least one family of peptide 
ligands that binds spores of every Bacillus species examined (Turnbough, 2003) and 
to detect species specific peptide ligands for the detection of Bacillus anthracis 
spores (Williams et al., 2003). The microbial cell surface as a whole, displays unique 
molecular compositions made of lipids, carbohydrates and proteins that may alter the 
mechanism by which a peptide might interact with an epitope or receptor, thereby 
providing unique binding sites for peptide interaction (Yarbrough et al., 2010; 
Yarbrough et al., 2011). Phage-displayed peptides have been successfully used to 
identify Salmonella typhimurium (Olsen et al., 2003; Sorokulova et al., 2005; Olsen 
et al., 2006; Meyer et al., 2012), demonstrate E. coli using streptavidin conjugated 
quantum-dots (Edgar et al., 2006), and highlight the use of lytic phage for specific 
capture and detection of S. aureus (Balasubramanian et al., 2007) and Bacillus 
anthracis (Sainath Rao et al., 2010).  
 
Bishop-Hurley et al., (2005) described the utility of using live whole bacterial cells 
as a target for the isolation of antimicrobial phage displayed peptides. They targeted 
receptor(s) on Haemophilus influenza and described that peptides binding to bacterial 
surface structures isolated by phage display may prove of value in developing new 
antibiotics. In another study a subtractive phage-display protocol to select for 
peptides binding affinity to the cell surface of poultry isolate of Campylobacter 
jejuni was used with the aim of finding peptides that could be used to control this 
microorganism in chickens. In total, 11 unique clones were found to inhibit the 
growth of C. jejuni by up to 99.9% in-vitro, and one clone was bactericidal in-vitro. 
The phage peptides were highly specific (Bishop-Hurley et al., 2010). They 
completely inhibited the growth of two of the four poultry isolates of C. jejuni tested 
with no activity detected towards other Gram-negative and Gram-positive bacteria. 
Rao et al., (2013) studied an improved subtractive phage display approach to identify 
short peptides that can bind specifically to the cell surface of S. aureus. They 
envisioned that a synthetic peptide representing the consensus sequence of several of 
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these individual peptides that bound to the cell surface of S. aureus in combination 
with quantum dot nanocrystals can serve as a novel probe for the detection of S. 
aureus. 
 
Kaur et al., (2012) have investigated the effects of protein synthesis inhibiting 
antibiotics on the plaque size and morphology of staphylococcal phages and suggest 
developing MRSA-virulent phages as therapeutics. However this technology has not 
been addressed to develop MRSA specific peptides to detect MRSA. Therefore my 
studies were focused to develop phage derived peptide to detect MRSA. Two 
approaches have been used, 1) MRSA specific and 2) PBP2A specific peptide 
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1.7. Hypothesis and Aims 
 
Hypothesis 1: 
• Lysine monomeric peptoids are a novel class of antibiotic with antimicrobial 




• Study the structure-activity relationships on bacterial killing using clinically 
important gram positive and gram negative bacteria.  
• Study the mammalian cell toxicity on those derivatives using standard cell 
toxicity assays. 
• Study the effect of those peptoids on inflammatory response using human 
neutrophil. 
 
Hypothesis 2:  




• Purify PBP2A protein to develop aptamer and peptide probes targeting the 
protein.  
• Conduct experiments to enrich aptamer using SELEX procedure against 
whole MRSA bacteria and the purified PBP2A protein.   
• Conduct phage panning experiments against whole MRSA bacteria and the 
purified PBP2A protein.  
• Sequence the enriched aptamer and phage to synthesise aptamer and peptide 
molecular probes.  
• Study the binding ability on these probes against panel of clinically relevant 
bacterial species including MRSA.  
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Chapter 2:  Materials and Methods 
 
2.1. Materials  
 
2.1.1. Chemicals used in this study 
 
All chemicals were obtained from Sigma unless otherwise noted. 
1kb DNA ladder (NEB) 






Dextran T-500 (Amersham Pharmacia Biotech, Buckingham, UK) 
Diff-Quick (Gamidor, Didcot, UK) 
Dihydroethidium (DHE) (Invitrogen) 
DMEM media (Gibco) 
DNase-free water 
Ethanol 
Fetal bovine serum (FBS) 
GelRed (Cambridge Bioscience) 




Iscove's modified Dulbecco's medium (PAA, Pasching, Austria) 
Loading dye (Promega)  
Luria Bertani (LB)  
Lysostaphin  
Lysozyme 
MTS reagent (Promega) 




Ncol (CCATGG) and Xhol (CTCGAG) restriction enzymes Ncol (NEB) 
Ni-NTA (Qiagen) 
PBS 
PCR master mix (Promega) 
Penicillin-Streptomycin 
Percoll (Amersham Pharmacia Biotech), 
Propidium iodide (PI) (Invitrogen) 
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Roscovitine 
SDS-PAGE protein gel (Invitrogen) 
SOB media 
Sodium citrate solution (Phoenix Pharma Ltd., Gloucester, UK) 
Sytox-Orange dye (Invitrogen) 
T4 DNA ligase (NEB) 
Triton X-100 
 
2.1.2. The bacterial strains used in this study  
 
1. Methicillin Resistant Staphylococcus aureus (MRSA-ATCC252),  
2. Methicillin Sensitive Staphylococcus aureus (MSSA-ATCC 25923),  
3. Escherichia coli (ATCC 25922) 
4. Pseudomonas aeruginosa (PAO1) 
5. Staphylococcus epidermidis-clinical strain 
6. Klebsiella pneumonia (ATCC BAA1706) 
7. Burkholderia cepacia (ATCC25416) 
8. Staphylococcus aureus RN6390-plasmid pSB2030 (PxylA::gfp-luxABCDE) 




2.2.1.  Microbiology 
 
2.2.1.1. Bacterial growth inhibition assay in MHB 
 
The bacterial growth inhibition assays were carried out to assess the efficacy of 
peptoids against bacterial growth. This assay was carried out to screen the whole 
peptoid library initially at 200 µM peptoid (all 13 different peptoids) concentration 
and then TOP with the panel of bacteria at 100 µM concentration. The assay has 
been carried out in 96 well plates with peptoid in 100 µl of Mueller-Hinton broth 
(MHB). In test wells, 50 µl of bacterial inoculum (2x106 cfu/ ml) in MHB was added 
to 50 µl of peptoid solution in MHB. Positive controls contained 50 µl of inoculum 
and 50 µl of MHB without peptoid. The bacterial growth was measured by 
measuring the O.D. at 600 nm over 16 hrs of incubation at 37oC. The O.D. was 
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measured every 15 minutes using a spectrophotometer. The growth inhibition was 
determined as the concentration of peptoid that completely inhibited bacterial growth 
after incubation. The values reported were reproducible between three independent 
experimental replicates, each consisting of three parallel trials (Qazi et al., 2004; 
Chongsiriwatana et al., 2008). 
 
2.2.1.2. MIC and MBC determination 
 
MICs were using 96-well microtiter plate. In test wells, 50 µl of bacterial inoculum 
(2x106 cfu/ ml) MHB was added to 50 µl of peptoid solution in MHB (prepared 100, 
80, 60, 40, 20, 0 µM serial dilutions). Positive controls contained 50 µl of inoculum 
and 50 µl of MHB without peptoid. The MIC was defined as the lowest 
concentration of peptoid that completely inhibited bacterial growth after incubation 
at 37°C for 16 hrs. MIC values reported were reproducible between three 
independent experimental replicates, each consisting of three parallel trials. 
 
MBC was determined by calculating the absolute bacterial counts at the following 
day by enumerating an aliquot from the culture on LB agar plates. At the end of the 
16 hrs of incubation for MIC, took 10 µl of the samples and did the serial dilutions in 
LB broth, plated a 10 µl onto LB agar plates (three replicates). The viable bacteria 
were enumerated on the next day after incubating plates at 37oC. 
 
2.2.1.3. Killing kinetics non-growth phase bacterial killing-PBS 
killing assays 
 
This assay has been carried out to determine the bactericidal effect of peptoids on 
non-dividing, latent or slow-growing bacteria (Coates et al., 2002; Ooi et al., 2010). 
In this assay used 500 µl PBS instead of MHB and carried out in 1.5 ml eppendorf 
tubes. Bacteria were grown overnight in Luria Bertani (LB) broth at 37oC in an 
orbital shaker at 200 rpm, subcultured the next day for 3-4 hours and washed three 
times with PBS before the assay. Then 250 µl of bacterial inoculum (2x106 cfu/ ml) 
in PBS was added to 250 µl of peptoid solution (serial dilutions) in PBS. Incubated 
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for 5 hrs and each hour took 10 µl of the samples and did the serial dilutions in LB 
broth, plated 10 µl onto LB agar plates (three replicates). The viable bacteria were 
enumerated on the next day after incubating plates at 37oC.  
 
2.2.1.4. Transmission electron microscopy (TEM) analysis 
 
To visualise the ultra-structural damage caused by TOP, MRSA and PAO1 were 
incubated in 100 µM of TOP for 1 hour and the samples processed as below. For 
TEM, samples were fixed in 3% glutaraldehyde in 0.1M Sodium Cacodylate buffer, 
pH 7.3, for 2 hours then washed in three 10 minute changes of 0.1M Sodium 
Cacodylate.  Specimens were then post-fixed in 1% Osmium Tetroxide in 0.1M 
sodium cacodylate for 45 minutes, then washed in three 10 minute changes of 0.1M 
Sodium Cacodylate buffer.  These samples were then dehydrated in 50%, 70%, 90% 
and 100% normal grade acetones for 10 minutes each, then for a further two 10-
minute changes in analar acetone. Samples were then embedded in Araldite resin.  
Sections, 1μm thick were cut on a Reichert OMU4 ultramicrotome (Leica 
Microsystems (UK) Ltd, Milton Keynes), stained with Toluidine Blue and viewed in 
a light microscope to select suitable areas for investigation.  Ultrathin sections, 60nm 
thick were cut from selected areas, stained in Uranyl Acetate and Lead Citrate then 
viewed in a Phillips CM120 Transmission electron microscope (FEI UK Ltd, 
Cambridge, England).  Images were taken on a Gatan Orius CCD camera (Gatan 
UK, Oxon, England). 
 
2.2.1.5. Flow cytometry analysis of (Reactive Oxygen Species) ROS 
 
MRSA was treated with different peptoids (TOP, THP-Tosyl-hexyl and HHP-H-
hexyl) at 100 µM in a 96 well plate for 1 hour. Aliquots of bacterial cells were 
washed twice and stained with dihydroethidium (DHE). Cells were immediately used 
for flow cytometry analysis on a BD FACS Calibur (BD Biosciences, San Jose, CA). 
For each sample, 10,000 events were acquired, and analysis was done by gating 
intact cells using log phase controls. Epifluorescence microscopic images were taken 
at to show TOP induces ROS production in MRSA. 
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2.2.1.6. Phage Display library screening-General Experimental 
Design 
 
A 12-mer phage-display peptide library was panned against whole MRSA and 
PBP2A purified protein. A total of three rounds of solution bio-panning was carried 
out separately on bacteria and purified protein. Then 120 randomly selected phage 
clones from the third round of bio-panning were sequenced individually and deduced 
into peptide sequences. Bioinformatics analysis predicted the conserved sequences of 
peptides and two lead peptides were selected for synthesis. Bacterial binding assays 
were carried out to assess the specificity of the synthesised peptides against MRSA.   
 
2.2.1.7. Bacterial culture and reagents 
 
All bacterial strains used in this study were maintained and sub-cultured periodically 
on nutrient agar plates and stored at 4-8oC until tested. Stock cultures of all bacteria 
were stored in microbank beads (Pro-Lab Microbank) at -70oC. In all experiments, 
log-phase cultures of bacteria grown in Miller’s Luria–Bertani (LB) broth were 
centrifuged at 13,000 g, washed with PBS, pH 7.4 and serial ten-fold dilutions were 
prepared with PBS (Mediatech Inc., Herndon, VA). Bacterial titers were estimated 
by optical density and confirmed by plating and counting on nutrient agar plates after 
overnight incubation at 37oC. 
 
2.2.1.8. Study of aptamer as a therapeutic agent for bacterial 
infection 
 
The assay was carried out in 96 well plates with aptamers at 1µM concentration in 
100 µl of Mueller-Hinton broth (MHB). In test wells, 50 µl of bacterial inoculum 
(2x106 cfu/ ml) in MHB was added to 50 µl of aptamer solution in MHB. Controls 
contained 50 µl of inoculum and 50 µl of MHB without aptamer. Bacterial growth 
was measured by recording the optical density (O.D.) at 600 nm over 16 hrs of 
incubation at 35oC. The O.D. was measured every 15 minutes using a 
spectrophotometer. Growth inhibition was determined as the concentration of 
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aptamer that completely inhibited bacterial growth after incubation. Experiments 
were conducted in triplicate on three separate occasions (Qazi et al., 2004; 
Chongsiriwatana et al., 2008). 
 
2.2.1.9.  Bacterial biding assay  
 
A panel of bacteria were grown overnight and washed three times with PBS Then 
bacteria at 108 cfu/ ml and 10 µM FAM labelled peptide probes were co-incubated in 
1ml PBS for 30 minutes at 37oC on rotator shaker. Unbound peptides were washed 
off and bound peptides analysed using flow cytometry and confocal microscopy.    
 
2.2.1.10. Evaluation of MRSA and PBP2A-aptamer probe binding 
in-vitro bacterial binding assay 
 
A panel of bacteria were grown overnight and washed three times with PBS. A 
concentration of 108 cfu/ ml bacteria and the FITC labelled aptamer probes at 100 
nM were co-incubated in 1ml PBS for 30 minutes at 37oC on rotatory shaker. Excess 
unbound aptamer was washed off and analysed using flow cytometry and confocal 
microscopy.    
 
2.2.1.11. Bacteria Suspension Preparation and PBP2A coated Ni-
beads preparation 
 
A single colony of bacteria (MRSA, MSSA and PAO1) was added to 5 ml of LB 
medium and incubated overnight at 37ºC with 250 rpm agitation. The following day, 
the suspensions were sub-cultured for 3-4 hrs, and then centrifuged at 13,000 g at 
4ºC for 1 minute. The supernatant was discarded and the bacterial pellet washed with 
1 ml of PBS. Upon washing, the bacteria were resuspended with 1 ml PBS and kept 
at 4ºC. Serial dilution of the bacteria was performed. One hundred microlitres of the 
serially diluted bacteria was plated on MacConkey agar to determine the bacterial 
titer. Then 109 cfu bacteria were used for biopanning and counter selection carried 
out in 2 ml low-bind eppendorf tubes.  
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A 300 µl of Ni-NTA agarose beads (washed three times with 1 ml PBS) were 
incubated with 100 µg/ ml of PBP2A at room temperature for 1 hour on a rotary 
shaker and unbound proteins washed off. These protein coated beads were then used 
as target substrates for the phage panning experiments in 2 ml eppendorf tubes. 
2x109 clones of the 12-mer phage-displayed peptide library were used for 
biopanning.  
 
2.2.1.12. Phage Biopanning 
 
Counter selection was performed against bacteria (MSSA or PAO1) (109 cfu/ ml) 
resuspended in 1 ml of phage library (2x109) in 2 ml eppendorf tube. The bacteria-
phage mixture was incubated at room temperature with gentle agitation on a rotary 
shaker. After an hour, the bacteria-phage mixture was centrifuged at 13,000 g for 1 
minute. The supernatant was passed through a 0.22 µm filter to remove all bacteria 
and removed the unbound phage into a fresh eppendorf tube. The unbound 
supernatant was collected for biopanning against MRSA bacteria and PBP2A 
protein. A separate counter selection was carried out with BSA coated Ni-beads and 
the supernatant used for biopanning against PBP2A protein.  
 
PBS (with Ca+2 and Mg+2) with 1% BSA was used for biopanning solution 
throughout the experiments. Biopanning was carried out against MRSA with and 
without counter selection. After incubation at room temperature for 1 hour, the 
MRSA-phage were collected by centrifugation and washed 10 times with PBS to 
remove any unbound phages. To increase the stringency, 1 % Tween 20 was added 
during the second and third biopanning. PBP2A coated Ni-beads were also 
biopanned with and without counter selected phage libraries. PBP2A coated Ni-
beads described above (300 µl) resuspended in 1 ml of phage library (2x109) in 2 ml 
eppendorf tube for PBP2A protein biopanning and treated as same as above during 
the incubation and washing steps.  
 
After a final washing with PBS, 1 ml of elution buffer (0.2 M glycine-HCl, pH 2.2) 
was added to resuspend the pellet (MRSA-phage or PBP2A-phage). The tube was 
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incubated at room temperature on a rotary shaker for 10 minutes. Then 150 μl of 
neutralization buffer (1 M Tris-HCl, pH 9.1) was added immediately to the tube. 10 
µl of the phage elute was titered and the remaining phage were amplified to enrich 
the phage clones for subsequent rounds of biopanning. 
 
2.2.1.13. Phage Amplification and phage precipitation 
 
A loop of single colony of E. coli ER2738 was added into 5 ml of LB medium 
supplemented with tetracycline (20 mg/ ml) and incubated overnight at 37ºC. The 
next day, 200 μl of the overnight culture was added into 20 ml of fresh LB medium 
in 250 ml conical flask and incubated for 30 minutes in a shaking incubator until the 
O.D. reached 0.05 at 600nm. The remaining phage elute was added into E. coli for 
propagation at 37ºC, 200 rpm. After 5 hours incubation, the culture was transferred 
into a 50 ml polypropylene tube and centrifuged at 14,000 g, 4ºC for 10 minutes. The 
supernatant was transferred into a fresh tube and centrifuged, then 80% of the upper 
supernatant (16 ml) was transferred into a fresh tube that was filled with 1/6 volume 
of 20% (v/v) PEG/ 2.5 M NaCl (3 ml). The mixture was mixed well and incubated 
overnight at 4ºC to precipitate the phages. The next day, the mixture was centrifuged 
at 12,000 g, 4ºC for 15 minutes. The supernatant was discarded and the tube was 
centrifuged again to completely remove the residual supernatant. The precipitated 
pellet was resuspended with 1 ml of TBS and transferred to a fresh microcentrifuge 
tube. The suspended phage was centrifuged for 5 minutes at 14,000 g at 4oC to pellet 
residual cells. Supernatant containing amplified phage was transferred (80%) to a 
fresh tube and the phage has precipitated adding 1/6 of the volume (200 µl) of 20% 
PEG/ 2.5M NaCl. The tube was incubated on ice for one hour, followed by 
centrifugation at 14,000 g at 4ºC for 10 minutes. The supernatant was discarded and 
the tube was centrifuged. After removing the residual supernatant, the pellet was 
resuspended with 200 μl of TBS and centrifuged to remove any cells. Supernatant 
was transferred to new tube and 200 µl of sterile glycerol and stored at -20oC. This is 
the amplified elute. The pre-amplified elute and the amplified elute were titered to 
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2.2.1.14. Phage titering (quantification of phage number) 
 
The phage stocks were titered by diluting so that the multiplicity of infection (MOI) 
was < 1 prior to infection therefore each plaque contains one phage DNA sequence. 
A loop of single colony of E. coli ER2738 was added into 5 ml of LB medium 
supplemented with tetracycline (20 mg/ ml) in a 50 ml centrifuge tube and incubated 
for 5 hours in shaking incubator until the O.D. at 600 nm of the bacteria reached 0.5. 
Pre-amplified phage was serially diluted to 10-4 while amplified phage was diluted to 
10-10. Ten microlitres of the diluted phage from the last three dilutions  (10-2, 10-3 and 
10-4) from the pre-amplified phage eluate and 10-8, 10-9 and 10-10 from the amplified 
phage eluate, were added to 200 μl of E. coli ER2738 (O.D.~0.5). After 5 minutes of 
infection in room temperature, the phage-infected E. coli ER2738 was transferred to 
5 ml of melted top agar (7 g/ L agar) at 45oC and briefly mixed well before pouring 
onto LB agar supplemented with IPTG/ Xgal (1.25 g IPTG and 1 g Xgal in 25 ml 
dimethylformamide-DMF). The plate was incubated overnight at 37ºC. The number 
of blue plaques was counted and recorded as plaque forming unit (PFU)/ ml on the 
next day. 
 
2.2.1.15. Individual Phage Clones Stock Preparation 
 
Twenty colonies from each biopanning were selected at the third round and 
amplified individually. Small scale amplification was carried out to make individual 
phage clone stocks. Overnight E. coli ER 2738 was diluted 1:100 in LB medium. 
One millilitre of the diluted culture was aliquoted into a microcentrifuge tube. A 
single, well-separated blue plaque from pre-amplified phage titer plate was picked 
using sterilized cut blue tips by stabbing on the agar then slowly aspirated the agar 
over the plaque. The culture together with plaque was incubated at 37ºC, 200 rpm for 
5 hours. The culture was centrifuged at 14,000 g for 30 seconds. The supernatant was 
transferred into new microcentrifuge tube and centrifuged. The upper 600 μl of the 
supernatant was then mixed with 600 μl of 50% glycerol in another new tube. 




Chapter 2:   Materials and Methods 
2.2.2.  Cell biology  
 
2.2.2.1. Haemolytic activity and Therapeutic index for TOP 
 
Whole blood were isolated from healthy blood donor, using sodium citrate solution 
(Phoenix Pharma Ltd., Gloucester, UK) as an anticoagulant and resuspended to 20 
vol% in PBS (pH 7.4). In a 96-well microtiter plate, 100 µl of erythrocyte suspension 
was added to 100 µl of peptoid solution in PBS (prepared by 1:2 serial dilutions) or 
100 µl of PBS in the case of negative controls. One-hundred percent haemolysis 
wells contained 100 µl of blood cell suspension with 100µl of 0.2 vol% Triton X-
100. The plate was incubated for 1 h at 37°C, and then each well was diluted with 
150 µl of PBS. The plate was then centrifuged at 1,200 g for 15 min, 100 µl of the 
supernatant from each well was transferred to a fresh microtiter plate, and 
absorbance at 350 nm was measured. Percentage of haemolysis was determined as 
(A-A0)/(Atotal-A0)x100, where A is the absorbance of the test well, A0 the 
absorbance of the negative controls, and Atotal the absorbance of 100% haemolysis 
wells, all at 350 nm (Chongsiriwatana et al., 2008). 
 
The selectivity ratio (SR) or Therapeutic index (TI) was calculated, where TOP 
concentration has 10% haemolysis activity (5 mM) divided by the median of the 
MIC value (50 µM). The calculated TI for TOP was 100 which is higher than 
previously discovered peptidomimetic (TI were around 20) (Chongsiriwatana et al., 
2008). 
 
2.2.2.2. Bacteria and lung epithelial cell (A549) co-culture assay 
 
This co-culture assay was carried out to demonstrate the peptoids selective killing of 
bacteria over mammalian lung epithelial cells (A549). A549 cells were seeded at 104 
cells /well in 96-well microtiter plate and cultured in IMDM media with Penicillin-
Streptomycin (100 U/ ml). After 24 hrs was changed the IMDM media to no 
antibiotics (Penicillin-Streptomycin). The cells were cultured for further 24 hrs 
without antibiotics. At the end of the total 48 hrs of incubation, was removed the 
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media and added 100 µl of bacteria (1x106 cfu/ ml) in IMDM (no antibiotics). The 
plates were then centrifuged at 2500 rpm for 30 minutes to adhere the bacteria on to 
the A549 cells and the supernatant was replaced by fresh IMDM (no antibiotics). The 
cells and bacterial co-cultures were incubated with and without peptoid in IMDM (no 
antibiotics) for 8 hrs at 37oC.  
 
At the end of the 8 hrs incubation, bacterial growth was measured by calculating the 
absolute bacterial counts and measuring the gfp fluorescence (RN6390). The A549 
cell death was measured by staining the cells with Sytox-Orange dye (Invitrogen, 
final concentration 5 μM) which only labelled the nucleus of the cells with 
compromised cell membranes. Lysed cell-free supernatants were cultured overnight 
to confirm bacterial colony counts at the end of the assay.  
 
2.2.2.3. Confocal microscope live image of A549 cells with peptoids 
 
The cell permeability of the TOP was evaluated and visualised using confocal 
microscopy live image analysis. A549 cells were seeded at 108 cells/ coverslip 
(Fisher Scientific; Cat No: 0730.016) which were ethanol (70%) washed, dried and 
placed on the bottom of a 6 well microtiter plate (Corning Costar). A549 cells were 
grown to 80% confluence in DMEM media with Penicillin-Streptomycin (100 U/ ml) 
and 5% FBS for 24 hrs at 37oC with 5% CO2. Then A549 cells were incubated with 
TOP-TAMRA for 30 minutes and the excess peptoid washed off and imaged at 565/ 
580 nm.  
 
2.2.2.4. Intracellular bacterial killing assay 
 
For internalization assays, S. aureus (RN6390) were internalized into A549 cells and 
the assay performed and quantified as previously described (Qazi et al., 2004). 
Monolayers of A549 epithelial cells grown to confluence (80%) were co-incubated 
with 100 µl of (107 cfu/ ml) gfp S. aureus for 1 hour after 30 minutes of 
centrifugation (2500 rpm, for 30 minutes) to enhance bacterial epithelial interaction 
and subsequent internalization. The wells were then washed (3x in PBS) and 
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incubated for 1 hour (37oC, 5% CO2). Non-internalized bacteria were removed by 
subsequent treatment with lysostaphin (10 μg/ml, Sigma) in HEPES buffered DMEM 
(Gibco) for 20 min at 37°C. Plates were washed and co-cultures were then incubated 
in phenol red-free DMEM (37oC 5%CO2) along with TOP (50 μM) or control.  
Luminescence and gfp fluorescence were measured on a Biotek plate reader every 15 
minutes for 20 hours.  
 
2.2.2.5. Prophylactic treatment of TOP 
 
This assay was performed to elucidate the utility of the pre-treatment of TOP to 
prevent bacterial colonisation in lung epithelial cells. A549 cells were pre-treated 
with TOP (50 µM and 100 µM) for 1 hour and washed excess prior to internalisation 
of RN6390-gfp-lux S. aureus the intracellular bacterial growth was measured by gfp 
fluorescence. Extracellular bacteria were removed by using lysostaphin (10 μg/ ml) 
as before and the growth monitored by measuring the gfp fluorescence at 48 hrs.  
 
2.2.2.6. Isolation of human blood neutrophils 
 
Fresh human venous blood was collected from volunteers, according to University of 
Edinburgh (Scotland) Research Ethics Committee approval #1702/ 95/4/72 or UBC 
Clinical Research Ethics Board protocol C02-0091, using sodium citrate solution 
(Phoenix Pharma Ltd., Gloucester, UK) as an anticoagulant. For neutrophil isolation, 
blood was centrifuged at 300 g for 20 min at room temperature, platelet-rich plasma 
was removed, and cells were suspended gently in 1% Dextran T-500 (Amersham 
Pharmacia Biotech, Buckingham, UK) in 0.9% saline and sedimented for 30 min at 
room temperature. The leukocyte rich upper layer was then fractionated by using 
three-step discontinuous, isotonic Percoll gradients as described previously 
(Dransfield et al., 1994). Briefly, cells were centrifuged at 300 g for 6 min, 
resuspended in 55% isotonic Percoll (Amersham Pharmacia Biotech), layered on top 
of 68% and 81% isotonic Percoll layers, and centrifuged at 700 g for 20 min at room 
temperature. Neutrophils were collected, washed in phosphate-buffered saline (PBS) 
without calcium or magnesium, and resuspended in Iscoves’s Dulbecco’s modified 
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Eagle’s medium (IDMEM; Invitrogen, Paisley, UK, or Burlington, Ontario, Canada) 
with 10% (v/v) heat-inactivated Fetal bovine serum (FBS).  
 
2.2.2.7. Neutrophil apoptosis 
 
Figure 2.1 shows the microscopic images of normal and apoptotic neutrophils. The 
apoptotic neutrophils containing condensed nuclei compared to the fragmented 
nuclei in normal neutrophils. Freshly isolated human blood neutrophils were 
incubated at 37°C, 5 % CO2, for 6 h and 20 h, at 5x106 cells/ ml in Iscove's modified 
Dulbecco's medium (PAA, Pasching, Austria) with 10% (v/v) heat-inactivated FBS, 
flat bottom 96-well culture plates (total volume 150 µl) in the presence of TOP (50 
µM and 100 µM), Roscovitine from Sigma, Dorset, UK (apoptosis inducer- positive 















Figure 2.1: Representative microscopic images of normal and apoptotic neutrophils. Arrows 
indicate normal neutrophils and arrowhead indicates an apoptotic neutrophil containing 
condensed and fragmented nuclei (original magnification, ×1,000, May-Giemsa stain) 
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Apoptosis cells were analysed by flow cytometry with Annexin V-647 and 
counterstained with propidium iodide (PI) for necrotic cells. For the analysis, 50ul of 
cells were added to 250 µl of AnnexinV-647 (Invitrogen) (1:500 dilutions in HBSS 
with 2.5 mM Ca2+) and after 10 min of incubation at 4°C, 1 μl of PI (1 mg/ ml) was 
added to each sample before immediate analysis on a FACScan flow cytometer (BD, 
Oxford, UK).  Neutrophil apoptosis was confirmed by cyto-centrifugation of 80 μl of 
sample at 300 rpm for 3 min. Samples were then fixed with methanol and stained 
with Diff-Quick (Gamidor, Didcot, UK) before morphological analysis under the 
microscope. 
 
2.2.2.8. Study the interaction of TOP with known modulators of 
neutrophil apoptosis 
 
To investigate whether TOP can interact with and modulate the effects of known 
modifiers of neutrophil apoptosis pathways, cells were incubated with TOP in the 
presence or absence of QVD-OPh (Sigma, Dorset, UK) a potent pan-caspase 
inhibitor that protects cells from capsase-dependent apoptosis. The rest of the 
conditions are similar to section 2.2.2.7.  
 
This investigates whether the TOP induces the apoptosis induced cell death 
(secondary necrosis) or primary necrosis (cell injury). These assays have been 
carried out for 6 and 20 hours and the neutrophils labelled with Annexin V-647 and 
PI to evaluate the pattern of cell death. 
 
2.2.2.9. TOP-cytotoxicity activity on A549 cells 
 
MTS Assays; the CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega - Cat No: G5421) is a colorimetric method for determining the number of 
viable cells in proliferation or cytotoxicity assays. A549 carcinoma-derived lung 
epithelial cells (CCL-185; American Type Culture Collection) were cultured in 
DMEM. A peptoid solution plate (100 µl per well) was prepared by serial dilution of 
aqueous peptoid stocks in media. Peptoid solutions were transferred to a 96-well 
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plate of a day-old cell monolayers containing 100 µl per well media with ~5,000 
cells per well. MTS reagent (Promega) 40 µl per well was added to each well, and 
the plate was incubated at 37°C for 3h, after which absorbance at 490 nm was read. 
Percentage of inhibition = [1-(A- Atestblank)/(Acontrol- Ablank)] x 100, where A is the 
absorbance of the test well and Acontrol the average absorbance of wells with cells 
exposed to media and MTS(no peptoid).A test blank (media, MTS, and peptoid) and 
Ablank (media and MTS) were background absorbance measured in the absence of 
cells (Chongsiriwatana et al., 2008). 
 
2.2.2.10. Aptamer cytotoxicity studies on 3T3 cells 
 
To evaluate the potential cytotoxicity of the aptamers, the CellTiter-Glo® 
Luminescent Cell Viability Assay was carried out to determine the number of viable 
cells in culture based on quantitation of the ATP present, which signals the presence 
of metabolically active cells (Promega - Cat No: G7570). Mouse embryonic 
fibroblast cells (3T3) were cultured in a 96-well plate, with ~5,000 cells per well in 
DMEM. Aptamers (50 µM) were mixed with cell culture media and transferred (100 
µl) to one day old cell monolayers. For the positive control, 50 µM of H2O2 in 
DMEM was added. Cells were incubated for 24 hrs at 37oC with a humidified 
atmosphere of 5 % CO2. After 24hrs incubation, the plate was equilibrated at room 
temperature for 30 minutes. A 100 μl of CellTiter-Glo® Reagent was added to each 
well and the plate placed on an orbital shaker to induce cell lysis and allowed to 
incubate at room temperature for 10 minutes to stabilise the luminescent signal. The 
plate was then centrifuged at 1000 g to remove cell debris and supernatant 
transferred (150 µl) to a black 96-well plate and luminescence recorded. 
 
2.2.3. Molecular biology 
 
2.2.3.1. Lysine peptoid library synthesis  
 
The core structure of the whole peptoid library was based on 9-mer lysine-like 
peptoid unit (Figure: 1.13) and the peptoid derivatives have been made by; (i) 
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changing the length of the carbon side chain (Figure: 1.14); and (ii) N-terminus 
modifications (Figure: 1.15). The three different side chain lengths introduced to a 9-
mer consisted of butyl (four-carbon), hexyl (six-carbon) and octyl (eight-carbon) 
monomers. Further structural changes have been made to the N- terminus end of the 
polymer encompassing different chemical groups conjugated to the N-terminus end 
such as H-non modified, BnCO-Phenyl acetamide, Tosyl-Toluene sulfonamide, Suc-
Succinic amide, Ac-Acetamide and Fmoc-9-Fluorenemethanol (Figure: 1.15 and 
Table: 1.3). A number of different bio assays have been developed and carried out to 
study the structure-activity relationship on these peptoids on bacterial killing and 
potential mechanisms. 
 
All the peptoids were made in the department of chemistry university of Edinburgh 
in Mark Bradley’s group. All chemicals, solvents and biological materials were 
purchased from Sigma–Aldrich or Fischer. Peptoids were synthesised using solid 
phase synthesis, a stepwise polymerization method is applied to grow polymer chain 
and it is anchored to a solid support while coupling reagents are iteratively passed 
over the matrix and adding one monomer at a time to afford a polymer with an exact 
monomer sequence and near absolute monodispersity (Chongsiriwatana et al., 2008; 
Unciti-Broceta et al., 2009). Peptoids were HPLC purified and purity was 
determined using MALDI-TOF MS analysis. 
 
2.2.3.2. Bioinformatics data mining for mecA gene 
 
Bioinformatics data tools have been used to obtain information about the mecA gene. 
The ‘Comprehensive Microbial Resource’ was the main resource 
(http://cmr.jcvi.org/tigr-scripts/CMR/CmrHomePage.cgi). The genome search has 
been carried out using Staphylococcus aureus as the input. The General Information 
for S. aureus subsp. aureus MRSA252 was obtained. The Annotation Search Report 
for mecA was obtained using Gene Symbol as mecA for the search. The Primary 
Annotation Display and Primary Annotation Sequences for the mecA gene and the 
PBP2A protein were obtained browsing the locus SAR0039. This DNA sequence has 
been used for the primer designing to amplify the mecA gene in MRSA. 
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2.2.3.3. mecA gene specific primers designing   
 
mecA gene specific primers were designed to avoid a N-terminal membrane-
spanning segment which is the non-soluble fraction of the protein. The designed 
primers only amplify the soluble fraction of PBP2A protein (amino acid residues 24 
to 668aa). C-terminal His-tagged protein was designed to over express incorporating 
Ncol (CCATGG) and Xhol (CTCGAG) restriction enzymes (Table 2.1).   
 
 Table 2.1: Oligonucleotide primers used for cloning of mecA gene in this study 
 
2.2.3.4. PCR amplification of mecA gene and agarose gel 
electrophoresis 
 
Set up for 100 µl PCR amplification volumes as shown in below: 
PCR master mix (Promega cat # :M7502) 50 µl 
Jck12DC 1 µl 
Jck12BC 1 µl 
Chromosomal DNA   1 µl (10 ng) 
DNase-free water 47 µl 
 
Initial denaturation at 95oC for 2 min then: 
95oC for 30s 
60oC for 30s 
72oC for 2min  
PCR was run for a total of 30 cycles and then 72oC for 2 min for the final extension.  
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A 1% agarose gel was prepared and loaded as shown below. To visualise the DNA 
bands on the gel, GelRed (Cambridge Bioscience Cat#:41003) was added (5 µl/ 50 
ml) into the agarose gel preparation. 
 
 Positive (µl) Control (µl) Ladder (µl) 
Loading dye (Promega -Cat#:G1881) 1 1 1 
PCR products 5   
PCR negative control (only primers)   5  
1kb DNA ladder (NEB-Lot #: 0971104)   1 
H2O   4 
 
2.2.3.5. Restriction enzyme digestion and ligation 
 
For the restriction enzyme digestion the following volumes were added as shown 
below:  
Two enzymes, Ncol (NEB-Lot#: 0021106) and Xhol (NEB-Lot#: 0581101) were 
used for the restriction enzyme digestion of the vector pET21d(+) and PCR amplified 
mecA insert. Each restriction enzyme digestion was carried out separately and gel 
purified prior to the digested fragments being included in the second restriction 
enzyme digestion. 
 
 Volume (µl) 
DNA 10 µg 50 
BSA  5 
Buffer  5 
Enzyme each (Ncol & Xhol) 3 
 
Ligation of the insert and the vector was done using T4 DNA ligase (NEB-Lot#: 
0991102). The insert (mecA) and the vector pET21d(+) were mixed in a  3 to 1 ratio 
and incubated at 16oC for overnight with the 1 µl of T4 DNA ligase and 2 µl of 
ligase buffer in a total volume of 20 µl. The ligated products were precipated with 
ethanol and run on a 1% agarose gel to visualise the ligated products. 
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2.2.3.6. Transformation of cloned plasmid into E. coli BL21 cells 
 
PBP2A protein was over-expressed in E. coli BL21(DE3) (Sigma; cat# B2935) 
expression strain. E. coli BL21 cells were thawed on wet ice and 10 ng of cloned 
DNA vector added and gently mixed. BL21 cells and plasmid vector were incubated 
on wet ice for 30 minutes. Cells were heat shocked by incubating tubes at 37oC in a 
water bath for 45 seconds and returned to ice for 2 minutes. The mixture was added 
to warm (37oC) SOB media (450 µl) and incubated for 1hour at 37oC at 225 rpm. 
The cells were spread over LB agar plates containing ampicillin (50 µg/ ml) and 
incubated overnight at 37oC to grow the transformed colonies. 
 
2.2.3.7. Colony PCR 
 
Colony PCR was carried out on ten selected transformed colonies. These colonies 
were grown in 500 µl of LB for 5hrs with ampicillin (50 µg/ ml) at 37oC and washed 
three times in PBS. The cells were resuspended in 30 µl of water prior to extracting 
DNA by heating the cells up to 100oC for 5 min. The cell debris was spun down and 
supernatant containing DNA transferred to a fresh tube. 5 µl of this DNA product 
was used to run a PCR using mecA specific primers as detailed above. 5 µl of PCR 
products were run on 1% agarose gel to confirm the mecA gene amplification.       
 
2.2.3.8. Plasmid Midi preparation 
 
Plasmid extraction was carried with a Qiagen Plasmid Midi Kit (Qiagen Car# 12143) 
following instructions from the manufacturer. Four positive colonies from colony 
PCR were selected for plasmid preparation. Colonies were grown in 100 ml of LB 
broth with ampicillin (50 µg /ml) at 37oC overnight at 250 rpm.  The overnight 
cultures were centrifuged at 5500 rpm for 10 min at 4oC and supernatants discarded. 
The pellet was washed in 25 ml of PBS and pelleted at 5500 rpm for 10 min at 4oC 
and resuspended in 4 ml of lysis buffer P1, in which RNase A was added. 4 ml of 
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Four millilitres  of Buffer P3 was then added  and mixed immediately by inverting 4-
6 times and incubated on ice for 15 minutes to precipitate genomic DNA, protein and 
cell debris. To separate the plasmid DNA, the mixture was spun down at 9500 rpm 
for 30 minutes at 4oC. While spinning the QIAGEN-tips 100 was equilibrated by 
applying 4 ml of Buffer QBT and allowed to empty by gravity flow, 10 minutes 
before adding the sample.  
 
The QIAGEN-tips 100 were washed three times with 10 ml Buffer QC before eluting 
the plasmid DNA with 5 ml of Buffer QF into a new falcon tubes. The plasmid DNA 
was precipitated by adding 3.5 ml of Isopropanol and spun down at 9500 rpm for 30 
min at 4oC before decanting the supernatant. The DNA pellet was washed with 2 ml 
of 70% ethanol (at room temperature) and spun down at 9500 rpm for 30 min at 4oC. 
The DNA pellet was air dried overnight at room temperature and the plasmid DNA 
dissolved in 200 µl of water before storing at -20oC. The size of the plasmid DNA 
was determined by running a 1% agarose gel.  
 
2.2.3.9. Sequencing of cloned plasmids and ClustalW analysis  
 
Purified plasmids (5 µl) were sent for Sanger sequencing with 1µl of sequencing 
primers (3.2 pmol/ µl) premixed to a volume of 6 µl per sample. Plasmids were 






Received data were visualised using FinchTV DNA analysing software and 
sequences were analysed using ClustalW2 analyser to confirm alignment with the 
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2.2.3.10. Over-expression of the PBP2A protein 
 
Colony PCR data and sequencing data confirmed the accurate molecular cloning of 
the gene mecA into pET21d(+) vector. Two positive colonies (JCK138-34 and 35) 
were selected for the over expression of the protein PBP2A in E. coli BL21. The 
transformants were cultured in LB (5 ml) broth containing ampicillin (50 µg/ ml) at 
250 rpm at 37oC overnight. The following morning 5 ml of the overnight culture was 
added into 500 ml (1:100) of LB broth containing ampicillin (50 µg/ ml) in a 1L 
flask and grown for 5 hrs at 37oC at 250 rpm before over expression. Expression of 
the His-tagged PBP2A protein was induced by adding 0.5 mM of IPTG and the 
cultures were then incubated at 22oC at 250 rpm for an additional 24 hrs. Cells were 
harvested by centrifugation at 5,000 g for 20 min at 4oC and the pellet washed twice 
with phosphate buffer (0.1 M NaPO4, 0.5 M NaCl and pH 7.2) before freezing for 
purification.  
 
2.2.3.11. PBP2A protein purification Cell lysis and generation of 
cleared lysates 
 
The frozen bacterial cells were placed at room temperature and allowed to thaw for 
15 minutes. Thawed cells were resuspended in 10 ml of buffer NPI-10 (50 mM 
NaH2PO4, 300 mM NaCl and 10 mM Imidazole pH 8) and added to 1 ml lysozyme 
solution (10 mg/ ml). To the resuspended cells, 3 units of Benzonase were added for 
every ml of the original cell culture volume. The cells were mixed by pipetting up 
and down and incubated for 30 min at room temperature. The crude lysate was 
transferred into 50 ml falcon tubes and centrifuged for 30 min at 15,000 g at 4oC. 
The insoluble fraction was pelleted at the bottom and the supernatants containing 
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2.2.3.12. Protein purification under native conditions using gravity 
flow 
 
Ni-NTA superflow columns (1.5 ml) were drained by removing the seals at the outlet 
of the columns before opening the screw cap allowing them to drain by gravity flow 
on QIArack (cat# 19015). The column was equilibrated by adding 10 ml Buffer NPI-
10 into column and allowed to drain through completely by gravity flow. The cleared 
lysate was added into the equilibrated columns and allowed to drain by gravity flow. 
The column was washed twice by adding 10 ml Buffer NPI-20 (50 mM NaH2PO4, 
300 mM NaCl and 20 mM Imidazole pH 8) into the column. His-tagged protein 
PBP2A was eluted by adding 3 ml Buffer NPI-250 (50 mM NaH2PO4, 300 mM 
NaCl and 250 mM Imidazole pH 8) into a new tube. The buffer was replaced by PBS 
using 50,000 MW protein elution columns. The purity of the protein was evaluated 
by running SDS-PAGE protein gel and visualised by coomassie blue.  
 
2.2.3.13. SDS-PAGE protein gel 
 
Purified protein PBP2A was run on pre-cast 4-12% Bis-Tris polyacrylamide gels 
NuPAGE-Novex from Life technologies (Cat# NP0321BOX, Invitrogen) to visualise 
the protein purity and to determine the size of the protein. Protein sample was 
prepared by adding 20 µl of purified PBP2A protein, 5 µl of sample buffer 
(NuPAGE® LDS Sample Buffer Cat# NP0007, Invitrogen) and 2 µl of reducing 
agent (NuPAGE® Sample Reducing Agent Cat# NP0009, Invitrogen) before heating 
at 60oC for 5 min. Protein size was determined by running 8 µl of SeeBlue® Plus2 
Pre-Stained Standard (Cat# LC5925, Invitrogen). 
 
2.2.3.14. BCA protein quantification assay  
 
The Thermo Scientific™ Pierce™ BCA Protein Assay is a detergent-compatible 
formulation based on bicinchoninic acid (BCA) for the colorimetric detection and 
quantitation of total protein. This method combines the well-known reduction of 
Cu+2 to Cu+1 by protein in an alkaline medium (the biuret reaction) with the highly 
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sensitive and selective colorimetric detection of the cuprous cation (Cu+1) using a 
unique reagent containing bicinchoninic acid. The purple-colored reaction product of 
this assay is formed by the chelation of two molecules of BCA with one cuprous ion. 
 
A set of protein standards were prepared diluting the contents of one Albumin 
Standard (BSA) ampule into several clean vials, using the same diluent as the 
sample(s) for three replications of each diluted standard. The final concentrations of 
the standards were made to 2000, 1500, 1000, 750, 500, 250, 125, 25 (µg/ml) and the 
blank (no BSA).  Working Reagent (WR) was prepared by mixing 50 parts of BCA 
Reagent A with 1 part of BCA Reagent B (50:1, Reagent A: B).  
 
Microplate procedure was adopted according to the manufacturer’s instructions as 
below. Pipette 25 µl of each standard or unknown sample replicate into a microplate 
well. Added 200 µl of the WR to each well and mix plate thoroughly on a plate 
shaker for 30 seconds. Covered the plate and incubated at 37°C for 30 minutes. 
Cooled the plate to room temperature and measured the absorbance at 562 nm on a 
plate reader. A standard curve was plotted by the average Blank-corrected 562 nm 
measurement for each BSA standard vs. its concentration in µg/ ml. Used the 
standard curve to determine the protein concentration of each unknown sample of 
PBP2A.  
 
2.2.3.15. Penicillin binding protein (PBP2A) Latex Agglutination 
test 
 
This test is a rapid latex agglutination assay, detecting PBP2A protein in isolates of 
Staphylococcus. The Oxoid PBP2A Latex Test (Cat# DR0900) was used to detect the 
PBP2A protein.  
 
MRSA and MSSA strains were grown in LB agar plates overnight at 37oC. Bacterial 
colonies were grown separately in 500 µl of LB for 5hrs at 37oC at 250 rpm. The 
cells were harvested by centrifugation at 13,000 rpm for 1 minute and washed three 
times with PBS. The cells were resuspended in 4 drops of Extraction Reagent 1 in a 
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micro-centrifuge tube. The sample was boiled for three minutes and cooled down to 
room temperature before adding one drop of Extraction Reagent 2 into the tube and 
mixed well. The sample was spun at 13,000 rpm for 5 minutes and the supernatant 
used for the latex agglutination test.  
 
The Latex reagents were mixed by inversion several times, and one drop of Test 
Latex or Control Latex added to each labelled test circle of the test paper according 
to the manufacture instructions. Test samples of 50 µl of supernatant of MRSA, 
MSSA or PBP2A purified protein were added on the test circle and the control circle.  
Using mixing stick mixed the latex and samples in each circle thoroughly. Sample 
cards were rocked gently up to three minutes and agglutination observed under 
normal lighting conditions.  
 
2.2.3.16. Designing of Aptamer libraries 
 
Primers, PCR conditions and library were designed and adapted according to Sefah 
et al., (2010). PCR plays a major part of aptamer selection and therefore it was 
important to select primers and libraries to have high PCR amplification efficiency. 
The ‘sense’ strand of the primer was functionalised at the 5′ end with an amino group 
(NH2). The importance of the NH2 group was to increase the resistance against 
nuclease degradation. The ‘antisense’ strand was functionalised at the 5′ end with 
biotin. The presence of biotin helps to separate the sense and antisense strands after 
PCR by streptavidin-biotin interaction, followed by alkaline denaturation. The length 
of the randomised region determines the diversity of the library. It is only necessary 
to label the initial library with NH2. All oligonucleotide sequences were purified by 
high-performance liquid chromatography (HPLC) in 1µM scale. The primers and 
library sets are shown below in the Table 2.2. Fluorescein isothiocyanate (FITC) 
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Table 2.2: Eight aptamer libraries used in this study. 
 
G and M libraries different due to the variable primer binding sites as mentioned in 
the table. 
Variable region Library G 














-(30N)- G1 (74bp) M1 (66bp) 








G4 (74bp) M4 (66bp) 
 
Primer sequences:  
 
Jck11GA- Forward-AminoMod 5’CTACACGACGCTCTTCCGATCT3’ 
Jck11GB- Reverse-biotin 5’ TGCTGAACCGCTCTTCCGATCT 3’ 
Jck11GA- Forward-FAMMod 5’CTACACGACGCTCTTCCGATCT3’ 
Jck10MA- Forward-AminoMod 5’ ATACCAGCTTATTCAATT 3’ 
Jck10MB- Reverse-biotin 5’ AGATTGCACTTACTATCT 3’ 
 
2.2.3.17. PCR amplification of aptamer libraries 
 
To assess the correct PCR conditions, several PCR protocols were carried out and the 
optimum conditions were determined. Ten PCR cycles were applied to  primer set 
Jck11  above, using the following amplification conditions: hot start at 95°C for 2 
minutes, denaturation at 95°C for 30s, annealing at 60°C for 30s and elongation at 
72°C for 30s, followed by final extension for 4 min at 72°C. For the primer set 
Jck10, annealing temperature at 55°C was used and the rest of the conditions were 
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2.2.3.18. Agarose gel electrophoresis 
 
A 4% agarose gel was prepared with Tris-borate-EDTA (TBE)  buffer (Promega-Cat 
No: V4251) and GelRed (Cambridge Bioscience-Cat No: BT41003) (1:10,000) 
added to visualize the ssDNA. After making the gel, 5 µl of DNA sample was loaded 
with gel loading dye (1:6) and electrophoresis performed at 100 V for 40 min in TBE 
buffer. The bands were observed under UV light and images of the gels captured. 
 
2.2.3.19. Study of different buffers on the efficiency of SELEX 
protocol 
 
After optimising the PCR conditions to amplify the aptamer libraries, optimisation of 
selection buffers were studied. G and M libraries were utilised in this experiment and 
selection was carried out with (MRSA) and without bacteria (control). Four different 
buffers were evaluated; 
• PBS (with Ca+2 and Mg+2) 
• Buffer B (Tris–HCl-25 mM, KCl-50 mM, NaCl-200 mM, EDTA-0.2 mM,   
Glycerol-5% (v/v), DTT-0.5 mM) 
• Iscove's Modified Dulbecco's Media (IMDM) 
• Dulbecco's Modified Eagle Medium (DMEM) 
 
A 1 µl of the library (100 µM) was used in 1 ml of buffers and incubated for 30 
minutes at 37oC on a rotary shaker. Followed by three washes, the elution step was 
performed at 95oC for 10 minutes in 500 µl of water. Elutes were subjected to PCR 
amplification and 5 µl of the PCR products were applied and run on agarose gel as 









Chapter 2:   Materials and Methods 
2.2.3.20. Preparation of ssDNA from PCR products 
 
A 200 μl of Streptavidin Sepharose beads (GE Healthcare Life Sciences-Cat No: 17-
5113-01) were washed with 1 ml of water (molecular biology grade) and mixed with 
1 ml of PCR products in a 1.5 ml eppendorf tube and incubated for 5 minutes at 
room temperature on a rotary shaker and washed three times with water.  Single-
stranded aptamers (non-biotinylated strand) were separated from the immobilised 
complementary strand with a 5 minute incubation of 50 µl of fresh 200 mM NaOH. 
Supernatant was taken after centrifugation at 13,000 g for 1 minute (ssDNA 
aptamer). The supernatant was diluted into 1 ml of PBS-T, containing 10 µl of 200 
mM monobasic phosphate buffer to adjust the pH to 7.5. Finally, the material was 
heated to 95°C for 10 minutes then immediately placed at 4°C until the next round of 
SELEX. 
  
 2.2.3.21. Experimental design and SELEX procedure  
 
The SELEX procedure was carried out independently against MRSA (ATCC252), 
MSSA (ATCC 25923), PAO1-Pseudomonas aeruginosa, Kebsiella pneumonia 
(ATCC BAA1706) E. coli (ATCC 25922) and alveolar epithelial cell line (A549) for 
five rounds without counter selection. These aimed to generate aptamers against 
individual bacteria and eukaryotic cells but were not specific due to lack of counter 
selection. These ssDNA aptamers were sequenced using an Ion Torrent sequencing 
method. Non-specific aptamers were attempted to be eliminated at the sequence level 
(where the sequenced data was carefully analysed and common sequences shared 
with the other bacteria eliminated). 
 
For the purified PBP2A protein, 15 SELEX rounds were carried out before Ion 
Torrent sequencing with counter selection against BSA and FBS. No counter 
selection against whole bacteria was performed. The initial ssDNA library pool was 
prepared by adding 50 μl of 100 µM (5 nmol) DNA library (1015 different sequences) 
to 500 μl of SELEX buffer, mixed and heated at 95 °C for 5 min. The resulting 
mixture was snap-cooled on ice and kept on ice until ready to use later the same day. 
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Bacteria were grown in LB media overnight and washed with PBS three times before 
the incubation with ssDNA aptamer library (prepared above). For the purified protein 
(PBP2A) SELEX, the protein (0.1 mg/ ml) was coated on Ni-NTA Agarose beads 
(Qiagen-Cat No: 30210) (300 µl beads washed 3 times with PBS) for 1 hour at room 
temperature in water and excess protein washed off with PBS.    
 
Bacteria and PBP2A coated Ni-NTA beads were incubated separately with the 
ssDNA library pool in 1 ml of PBS, the binding buffer using low binding eppendorf 
tubes to minimise the non-specific binding to the tube. The aptamer library and the 
target molecules (bacteria and PBP2A) were incubated for 30 minutes at 37oC on a 
rotary shaker. After incubation, unbound aptamer was removed by washing three 
times and centrifuging the content at 13,000 g for 1 min at 4 °C and discarding 
supernatants.  
 
For the first round of selection, elution of the bound sequences was conducted by 
adding   500 μl of DNase-free water to the cell pellet. Bacteria were resuspended and 
transfered into a 1.5 ml microfuge tube. Only in the first round was DNA eluted in 
purified water. As the entire eluted pool was amplified by PCR, DNase-free water 
was used for the elution of the bound DNA sequences during the first round of 
selection.  If the DNA was eluted in PBS, high salt concentration affects the 
efficiency of PCR. The pellet mixture was heated at 95°C for 10 min, centrifuged at 
13,100 g for 5 min and supernatant containing eluted DNA collected. 
 
In subsequent rounds, DNA was eluted in binding buffer.  
PCR conditions for the first amplification are shown below: 
 
Reagents Reaction mixture (μl) 
PCR master mix (Promega-Cat No:M7502) 500 
Primer mixture 50 (0.5 μM final) 
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For  primer set Jck11, amplification conditions used: hot start at 95°C for 2 minutes, 
denaturation at 95°C for 30s, annealing at 60°C for 30s and elongation at 72°C for 
30s, followed by final extension for 4 min at 72°C. For the primer set Jck10: exactly 
same as primer set JcK11 except annealing temperature at 55°C. 
 
2.2.3.22. Ion Torrent sequencing and data analysis 
 
Seven DNA samples were transferred to The Institute of Genetics and Molecular 
Medicine, Western General Hospital, Edinburgh, UK for sequencing. The sequenced 
data was analysed using TextWrangler, text editor software which generated two 
probable aptamer probes called PBP2A specific and MRSA specific. The hairpin 
structures of MRSA and PBP2A aptamer probes were determined using the website 
at Integrated DNA Technologies (IDT), the OligoAnalyzer 3.1. To evaluate the 
binding efficacy of the aptamer probes, they have been re-synthesised with 5’ FITC 
modification by SIGMA-ALDRICH, UK.  
 
2.2.3.23. Evaluation of PBP2A-aptamer probe binding in-vitro; Ni-
NTA beads assay 
 
Ni-NTA agarose beads (washed three times with PBS, 300 µl) were incubated with 
100 µg/ ml of PBP2A, BSA, FBS and trypsin separately at room temperature for 1 
hour on a rotary shaker unbound proteins washed. These protein coated beads were 
used as target substrates for the FITC labelled PBP2A-aptamer probe to evaluate the 
efficacy of binding by using plate reader, confocal microscopy and fibre-based 
confocal microendoscopy (FCM-Cellvizio) after incubation for 30 minutes at 37oC. 
Before analysis the beads were washed three times with PBS to remove excess 
aptamer probes. For the plate reader analysis, 100 µl of labelled beads were loaded 
into 96 well plates (three wells) and fluorescence measured at 488/520 nm. The 
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2.2.3.24. DNA Extraction and Sequencing 
 
One millilitre of diluted overnight E. coli ER2738 was incubated with 100 μl of 
individual phage clone stock at 37ºC, 200 rpm for 4-5 hours. After centrifuging the 
culture at 14, 000 g for one minute at 4 ºC, 800 μl of the supernatant was then mixed 
with 200 μl of 20% (v/v) PEG/ 2.5 M NaCl. After one hour standing on ice, the 
mixture was centrifuged at 14,000 g for 10 minutes at 4ºC. Pellet was resuspended 
with 100 μl of iodide buffer by gently tapping the tube. Then 250 μl of absolute 
ethanol was added and mixed. The suspension was incubated at room temperature for 
20 minutes. Later the suspension was centrifuged and washed with 0.5 ml of cold 
70% ethanol. The supernatant was removed completely while the pellet was vacuum 
dried at 37ºC for 30 minutes and resuspended with 30 μl of TE buffer. 
 
The DNA was then analysed in 1% agarose gel electrophoresis at 100 V for 1 hour in 
1 X TBE buffer. The gel was stained with added GelRed and the DNA was viewed 
under UV light. Dense and uniform band was considered as purified DNA and 
compared with 0 .5 µg of purified single-stranded M13mp18 DNA (NEB #N4040). 
DNA was sequenced using 96 gIII sequencing primer 5´- HOCCC TCA TAG TTA 
GCG TAA CG-3´ by The Gene Pool, University of Edinburgh.  
 
2.2.3.25. Sequence Analysis 
 
The resulting DNA sequences were translated into an amino acid sequences using 
FinchTV software tool and the corresponding 12-mer peptide sequences were 
analysed by ClustalW online tool. The analysis data resulted in four groups (with and 
without counter selection against MRSA and PBP2A). The conserved region 
“ATGGGATTTTGCTAAACAACTTTCAACAGTTTCGGCCGA” of the phage 
genome was identified using ClustalW. The oligonucleotide that encodes the 
displayed peptide was located after the conserved region. The oligonucleotide was 
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2.2.3.26.  Peptide synthesis 
 
The sequence analysis and ClustalW data analysis elucidated high frequency hits for 
MRSA specific and PBP2A specific peptides. Therefore these FAM labelled peptides 
were synthesised alongside with control peptides (low frequency) to assess the 
efficacy of binding.  
 
2.2.4. Bio-distribution and bio-availability of aptamer in mouse model 
 
Naïve aptamer library was amplified using 5’-Cy5.5 conjugated forward primers and 
5’-biotinylated reverse primers (see section 2.2.3.17.). The PCR products were 
purified and ssDNA obtained using Streptavidin Sepharose beads (see section 
2.2.3.20.). 5’-Cy5.5 conjugated ssDNA aptamer (125 µg/ mice) were delivered into 
mice via intratracheal (IT) or intravenous (IV) routes. The distribution of 5’-Cy5.5 
conjugated aptamer were monitored at 20 minutes and 72 hours using IVIS Pre-
clinical In-Vivo Imaging Systems PerkinElmer (at 640/720 nm filters, 5 second 
exposure times and high binning).  Mice were continuously anaesthetised 
(metomidate/ ketamine) during imaging. Animals were sacrificed after 72 hrs and 
organs imaged separately. PCR was performed on supernatant of homogenised 
organs (Homogenise bags from Fisher Scientific; BAJ-820-010N) samples and 




All animal experimentation was performed with U.K. Home Office authorization and 




All statistical analysis was performed on GraphPad Prism (version 5). The results are 
represented as the mean±s.e.m. Data sets were compared using a two-tailed unpaired 
Student’s t-test. Statistical significance was set at P <0.05.  
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A collection of peptoid analogs have been designed and synthesised by collaborators 
in the University of Edinburgh, Department of Chemistry (Dr Jeff Walton & 
Professor Mark Bradley) using solid phase synthesis. These peptoids have been 
subjected to biological evaluation to determine structure-activity relationships that 
define their antimicrobial activity. Each peptoid consists of 9 repeating N-substituted 
glycine monomers (9-mer). The monomer units were synthesised possessing three 
different lengths of alkyl chains; butyl-monomers (four-carbon), hexyl-monomers 
(six-carbon) and octyl-monomers (eight-carbon). Hence a family of 9-mers were 
synthesised with 4, 6 or 8 carbons in the side chain. To further increase diversity, the 
analogues were synthesised in varying capping groups at the N-terminus. These were 
either capped with an amide (-CONH-), sulphonamide (-SO2NH-) or left uncapped. 
In total 13 peptoids were synthesised. Out of 13 different peptoids, only one peptoid 
called Tosyl-Octyl-Peptoid (TOP) demonstrated significant broad-spectrum 
bactericidal activity. TOP kills bacteria under non-dividing and dividing conditions. 
The Minimum Inhibitory Concentrations (MIC) values of TOP for S. epidermidis, E. 
coli and Klebsiella were 20 µM, whereas Methicillin-resistant Staphylococcus aureus 
(MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA) were 40 µM. The 
highest MIC values were observed for Pseudomonas aeruginosa (PAO1) at 80 µM. 
The selectivity ratio (SR) or Therapeutic index (TI) was calculated, by dividing the 
10% haemolysis activity (5 mM) by the median of the MIC (50 µM) yielding a TI for 
TOP as 100. This TI is well above previously reported peptidomimetics TI of around 
20. TOP demonstrates selective bacterial killing in co-culture systems and 
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3.2. Introduction 
 
Decades of widespread and indiscriminate usage of antibiotics in the healthcare 
sector has led to emergence of multidrug resistant bacteria such as vancomycin-
resistant Enterococci (Arias and Murray, 2012) and methicillin-resistant 
Staphylococcus aureus (MRSA) (Theuretzbacher, 2011); (Gould et al., 2012; 
Phoenix et al., 2013). Hardly any new antibiotics have been introduced within the 
last decade and most novel antibacterial drugs are designed through modification of 
existing scaffolds (Jabes, 2011; Livermore, 2011; Tomasini et al., 2013). Hence there 
is clearly an urgent need for new antibiotics with novel mechanisms of antimicrobial 
action.  
 
Antimicrobial peptides (AMPs) are a heterogeneous group of relatively small 
molecules containing less than 100 amino acids that are evolutionarily ancient 
molecules produced by nearly all living organisms.  They are an essential part of the 
innate immune response (Zasloff, 2002). In addition to their antimicrobial function, 
AMPs are involved in variety of other roles such as modulation of the innate and 
adaptive immune systems via their ability to function as chemotactic agents (Easton 
et al., 2009; Nijnik and Hancock, 2009; Zasloff, 2002). AMPs and bacteria have co-
evolved, hence few examples of resistance development have occurred in nature 
(Woolhouse et al., 2002). 
 
A major obstacle in the further development of  AMPs is difficulty in the transition 
of in-vitro activity into in-vivo efficacy (Hancock and Sahl, 2006). This is due to 
their sensitivity to biologically relevant conditions such as high salinity of plasma 
and divalent cations. Divalent cations compete with AMPs for binding sites on 
negatively charged bacterial surfaces (Deslouches et al., 2005). Moreover, AMPs are 
susceptible to degradation by serum proteases (Knappe et al., 2010) as well as to 
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In contrast to AMPs, Peptoids represent a class of peptidomimetic that are not found 
in nature. Peptoids have been generated to mimic the biological functions of 
naturally occurring cationic host defense peptides. They differ from peptides as the 
side chains are attached to the nitrogen atom instead of the α-carbon (Figure 1.13 and 
Figure 1.14) (Chongsiriwatana et al., 2008; Park et al., 2013). Due to this, peptoids 
are highly resistant to proteolysis. Peptoids have a wide range of potential biomedical 
applications such as cell target drug delivery, cell labelling and as antimicrobial 
agents (Park et al., 2013).Peptoids have recently been developed as antimicrobial 
agents (Park et al., 2013). In particular, similar to AMPs, peptoids have been 
generated to have both hydrophilic and hydrophobic properties.  Recent 
structure/function investigations of these ampetoids (antimicrobial peptoid 
oligomers) suggested a requirement for net cationic charge and moderate 
hydrophobicity for effective antimicrobial activity, with high hydrophobicity and 
strongly amphipathic structures inducing  haemolysis (Chongsiriwatana et al., 2008). 
 
The development of peptoids was based on the HIV-tat cell penetrating peptide, a 
basic peptide derived from human immunodeficiency virus (HIV)-1. The Tat protein 
(positions 48-60) translocates through cell membranes and accumulates in the 
nucleus, the properties of which have been utilized for the delivery of exogenous 
proteins into cells (Futaki et al., 2001). The sequence of the optimal region is 
RKKRRQRRR, comprising basic amino acids containing 6 arginine and 2 lysine 
residues within a linear sequence of 9 amino acids (Ruben et al., 1989). Hence, 
arginine and/ or lysine-rich cell penetrating peptides (CPPs) cargo have been 
extensively studied as intracellular delivery agents (Futaki et al., 2001; Mo et al., 
2012). Previous published data (Dhaliwal et al., 2011; Unciti-Broceta et al., 2009) 
based on the lysine monomeric peptoids demonstrated remarkable non-toxic 
mammalian cell membrane penetrability. However bacterial membrane damage or 
bacterial killing was not studied with these peptoids or derivatives. Therefore this 
chapter focussed on the structure-activity relationships that may determine bacterial 
killing and mammalian cell toxicity with derivatives of the original peptoid (Figure 
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In contrast to the requirements previously suggested for optimal antimicrobial 
activity (Chongsiriwatana et al., 2008), our peptoids are highly hydrophilic achiral 
cationic molecule with no amphipathicity. These properties were specifically 
designed to confer antimicrobial killing and efficient entry into eukaryotic cells 
without incurring host toxicity. The previous studies suggested that 9-mer lysine-like 
peptoids  facilitated efficient and rapid mammalian cell membrane penetration and 
entry with minimal toxicity (Unciti-Broceta et al., 2009). The core structure of the 
synthesised peptoid library was a 9-mer lysine-like peptidomimetic (Figure 1.13).  
Derivatives were made by;  
 
(i) Changing the length of the carbon side chain (Figure 1.14), three different side 
chain lengths consisted of butyl (four-carbon), hexyl (six-carbon) and octyl (eight-
carbon) monomers.  
 
(ii) N-terminus modifications (Figure 1.15). Different chemical groups have been 
conjugated to the N-terminus end such as H-non modified, BnCO-Phenyl acetamide, 
Tosyl-Toluene sulfonamide, Suc-Succinic amide, Ac-Acetamide and Fmoc-9-
Fluorenemethanol (Figure 1.15 and Table 1.3).  
 
A number of different bio assays have been developed and carried out to study the 
structure-activity relationship on these peptoids on bacterial killing and their 
potential mechanisms.  
 
3.3. Initial screening of peptoids – Bacterial growth inhibition 
 
Bacterial growth inhibition assays were conducted  to rapidly screen peptoids for 
antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA), 
methicillin-sensitive Staphylococcus aureus (MSSA), E. coli and Pseudomonas 
aeruginosa (PAO1) (Figure 3.1 and Figure 3.2). The assays were conducted in 96 
well plates with 200 µM of peptoid in 100 µl of Mueller-Hinton broth (MHB) over 
16 hrs. The growth of bacteria was assessed by measuring the Optical Density (O.D.) 
at 600 nm. Summary results are shown in the table 3.1. The data demonstrate that the 
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Tosyl-octamer peptoid (TOP) shows significant growth inhibition of MRSA, MSSA, 
PAO1 and E.coli.  Also there is some growth inhibition with H-octamer and BnCO-
octamer. This antibiotic activity screen indicated that the tosyl group and octamer 
carbon side chain are important structural determinants of antibacterial activity of the 

























Figure 3.1: TOP is the most antibacterial peptoid against Gram-negative bacteria. E. coli and 
PAO1 (106 cfu/ml) were incubated in MHB at 37oC for 16 hrs with library peptoids (200 µM) in 
96 well plates to assess the growth inhibition. Only Tosyl-Octyl peptoid (TOP) demonstrated 
bacterial growth inhibition at 16 hrs (Figures represent representative data of n=3). 
PAO1 200 µM
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Interestingly, the tosyl capping group in butyl and hexamer carbon chain peptoids 
confers no bacterial killing indicating that the importance of the octamer length of 
the carbon chain for bacterial killing. Based on this initial screen, the Tosyl-Octamer-


























Figure 3.2: TOP is the most antibacterial peptoid against Gram-positive bacteria. MRSA and 
MSSA (106 cfu/ml) were incubated in MHB at 37oC for 16 hrs with library peptoids (200 µM) in 
96 well plates to assess the growth inhibition. Only Tosyl-Octyl peptoid (TOP) demonstrated 
bacterial growth inhibition at 16 hrs (Figures represent representative data of n=3). 
MRSA 200 µM
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Table 3.1: The summary results of growth inhibition assay on bacterial killing.  











Tosyl-octyl (TOP) Yes* 
Suc-octyl No 
Ac-octyl No 
Yes*- No bacterial growth observed after 16 hrs of incubation at 37oC. 
Some- Observed some bacterial growth after 16 hrs of incubation at 37oC. 
No- Observed bacterial growth the same as the control. 
 
3.3.1. Killing kinetics non-growth phase bacterial killing-PBS killing 
assays 
 
Latent or slow-growing bacteria frequently exhibit tolerance to antibiotics that are 
active against rapidly dividing bacteria. This contributes to the prolonged treatment 
periods required for persistent infections and leads to emergence of multidrug 
resistant bacteria (Coates et al., 2002; Ooi et al., 2010). Hence a PBS killing assay 
has been performed to study the bactericidal effect of TOP on non-dividing bacteria 































Figure 3.3: PBS killing assay data demonstrates that TOP kills non-dividing gram-positive and 
gram-negative bacteria. Bacteria (106 cfu/ ml) were incubated in PBS (1.5 ml eppendorf tubes) 
with TOP and the viability of the bacteria were assessed by plating 10 µl of the samples on LB 
plates after serial dilutions. The viable bacteria were enumerated on the next day after 
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3.3.2. Killing kinetics on dividing bacteria-growth inhibition assay 
 
At present, most clinically used antibiotics target one of the classical metabolic 
pathways of DNA, RNA, protein or cell wall syntheses (Poole, 2012; Sass and Brotz-
Oesterhelt, 2013). Therefore antibacterial drug candidates are normally identified by 
screening libraries of natural, recombinant or chemically synthesized compounds 
against actively dividing bacteria targeting metabolic pathways (Sass and Brotz-
Oesterhelt, 2013). Extending the screening assays that were performed (Figure 3.4), 
and the antibacterial activities of TOP against clinically relevant bacterial strains 
were performed to evaluate TOP’s spectrum of activity.  
 
Eight clinically important bacterial strains including gram-positive and gram-
negative bacteria were incubated with and without TOP to study the effect of the 
peptoid on bacterial growth for 16 hrs. The results are shown in the figure 3.4. The 
TOP demonstrated bactericidal activity against most gram-positive and negative 











































Figure 3.4: TOP shows bactericidal effect on dividing bacteria in MHB. Clinically relevant 
bacteria (106 cfu/ml) were incubated with and without TOP in MHB in 96 well plates for 16 hrs 
at 37oC and the growth measured by serial recording of O.D. at 600 nm. The bottom graph 
shows the effect of TOP at 100 µM on bacterial growth where the top graph shows the growth 
curves without TOP. Aside from B.cepacia, the remaining seven bacterial strains show complete 




Bacterial growth curve in MHB with TOP























Bacterial growth curve in MHB
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3.4. Minimum inhibitory concentration (MIC) and Minimum Bactericidal 
Concentration (MBC) determination for TOP 
 
Following the initial screening at 100 µM (Figure 3.4), further assays were 
performed to determine MIC values for TOP. MIC is a laboratory test to determine 
the minimum concentration of an antibiotic that inhibits visible bacterial growth in 
MHB (Coates et al., 2002; Pompilio et al., 2011). Gram-positive and negative 
bacteria were grown in MHB with and without peptoid and the lowest concentration 
of TOP that completely inhibited the bacterial growth after incubation at 37oC for 16 
hrs were determined. The growth curves were generated by measuring the O.D. at 
600 nm for 16 hrs (Figure 3.5 and Figure 3.6). 
 
Minimum Bactericidal Concentration (MBC) was calculated at the end of the 16 hrs 
of incubation in MHB to determine the TOP concentration resulting in 0% bacterial 
survival (Coates et al., 2002). This was determined by calculating the absolute 
bacterial counts the following day by enumerating an aliquot from the culture on LB 




































Figure 3.5: MIC for TOP against gram-positive bacteria.  Serial dilutions of TOP were 
incubated with 106 cfu/ml bacteria in MHB and O.D. measured at 600 nm over 16 hrs at 37oC. 
Different bacterial strains showed different levels of growth inhibition. S. epidermidis showed 
higher susceptibility with growth inhibition at 20 µM and MRSA and MSSA showed  growth 




















































































































Figure 3.6: MIC for TOP against gram-negative bacteria.  Serial dilutions of TOP were 
incubated with 106 cfu/ml bacteria in MHB and O.D. measured at 600 nm over 16 hrs at 37oC. 
E. coli and Klebsiella show growth inhibition at 20 µM, whereas PAO1 showed growth inhibition 
at 80 µM (n=3; mean and SEM). 
 
Table 3.2: The summary table shows the MIC and MBC values for TOP 
Bacteria MIC (µM) (n=3) MBC (µM) (n=3) 
MRSA 40 60 
MSSA 40 80 
S.epidermidis 20 20 
RN6390-gfp-lux 60 100 
PAO1 80 100 
E.coli 20 60 
Klebsiella 20 40 
 
PAO1-Growth curve
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3.5. Haemolytic activity and Therapeutic index for TOP 
 
Haemolytic activity is conventionally used to assess eukaryotic membrane toxicity of 
antibacterial as red blood cells are extremely fragile (Ilker et al., 2004; Yang et al., 
2000). Cationic AMPs are thought to attach to negatively charged bacterial 
membranes and then ‘pore form’ in bacterial membranes through hydrophobic 
interactions. Unlike bacteria, mammalian cell membranes are charge neutral, 
therefore AMPs have reduced electrostatic attraction to mammalian cell membranes. 
However, the hydrophobic nature of many of the AMPs still results in eukaryotic cell 
membrane toxicity.  These characteristics of AMPs result in a selectivity ratio or 
therapeutic index defined as  (Ilker et al., 2004) the ratio of the AMP concentration 
resulting in  10% haemolytic activity (Haemolytic Dose 10%-HD10)  over the  MIC 
of AMP (Al-Ahmad et al., 2013; Brogden, 2005). Hence, the haemolytic activity of 














Figure 3.7: TOP haemolysis activity. TOP induces haemolysis in a dose dependent manner and 
it demonstrates less than 10% haemolytic activity at 5 mM level (n=3). Human red blood cells 
were incubated with different concentrations of TOP for 1 hour at 37oC and haemolysis 
determined by measuring the release of haemoglobin by spectrophotometric quantification. The 
percentage of haemolysis was calculated considering 100% haemolysis induced by incubating 
red blood cells with 0.2% tween.  
TOP-haemolysis
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The selectivity ratio (SR) or Therapeutic index (TI) was calculated using 10% 
haemolysis activity (5 mM) (Figure 3.7) divided by the median of the MIC value (50 
µM) (Table 3.2). The calculated TI for TOP was 100 (HD10-5000/MIC-50) which is 
well above previously discovered peptidomimetics (Table 3.3) (TI’s were around 20) 
(Chongsiriwatana et al., 2008).  
 
3.6. Bacteria and lung epithelial cell co-culture assay to determine selectivity 
of TOP 
 
A co-culture assay was developed and conducted to demonstrate TOP selective 
killing of bacteria over mammalian lung epithelial cells. The rationale of the assay 
was to model in-vitro bacteria-epithelial cell viability in the continued presence of 
TOP. Bacteria and A549 cells were incubated with TOP (50 µM) for 8 hrs in 96 well 




Figure 3.8: Schematic diagram shows the bacteria and A549 co-culture assay. 
 
At the end of the 8 hrs incubation, absolute bacterial numbers were determined by 
plating aliquots of supernatant and enumerating cfu/ml the following day alongside 
measuring the gfp fluorescence (RN6390). A549 cell viability was determined by 
staining the cells with Sytox-Orange dye (nuclear labelling dye that only labels in 
presence of permeable cell membranes) (Figure 3.9 and Figure 3.10). 
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Figure 3.9: TOP inhibits bacterial growth in co-culture assay. (A) The top graph shows the 
absolute bacterial counts with and without TOP (50 µM) after 8 hrs incubation. Figures 
represent mean values ± SEM of n=3. (B) The representative images of epifluorescence 
microscopic images show the RN6390-gfp-lux bacterial growth with and without TOP. The 
control image shows the A549 cells with RN6390-gfp-lux bacteria (left panel) vs TOP treated 
cells (right panel) where the bacterial growth has been inhibited, clearly shown by reduced gfp 
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Figure 3.10: A549 epithelial cells are protected by TOP in co-culture assay. (A) The top graph 
shows Sytox-Orange reads (dead cells), GFP-green bacteria. Figures represent mean values ± 
SEM of n=3. In-vitro TOP protects A549 epithelial cells from bacterial induced death. (B) The 
representative images of epifluorescence show RN6390-gfp-lux bacteria and MRSA with and 
without TOP. The TOP treated A549 epithelial cells are protected from bacterial invasion and 
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3.7. TOP rapidly enters lung epithelial cells-A549 
 
Previous studies demonstrated that 9-mer lysine-like peptoids rapidly cross 
mammalian cell membranes (Unciti-Broceta et al., 2009). To determine if the TOP 
could rapidly translocate through mammalian cell membranes, a fluorescent 
analogue of TOP was synthesised (TAMRA-TOP) to visualise TOP localisation with 
confocal microscopy.  Figure 3.11(a) shows live confocal image of A549 cells with 





















Figure 3.11(a): Confocal microscope live image of A549 cells after incubation with TAMRA-
control and TOP-TAMRA for 10 minutes at 100 µM.  The cell-permeant dye Calcein (488/520 
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Figure 3.11(b): Kinetics of TOP-TAMRA A549 cellular uptake. A549 cells were incubated at 
37oC with 5, 10, 50 µM concentrations of TOP-TAMRA for 1, 5 and 10 minutes. Washed cells 
were imaged and red the fluorescence intensity at 560/600 nm.  
 
3.8. TOP kills intracellular bacteria 
 
The intracellular ‘niche’ is a potential environment for antibiotic evasion (Qazi et al., 
2004) and bacterial persistence. In order to kill intracellular bacteria, antibiotics need 
to be capable of penetrating the eukaryotic cell membrane and accumulating 
intracellular to a sufficiently high concentration to be effective against intracellular 
bacteria (Qazi et al., 2004). To study the intracellular antimicrobial activity of TOP, 
S. aureus (RN6390) expressing a gfp-luxABCDE reporter operon under the control 
of a growth-dependent promoter was used. The dual luminescence and fluorescence 
reporters in the bacteria were used to track bacterial replication within the 













































































Figure 3.12: Schematic diagram of the internalisation assay and assessment of intracellular 
activity of TOP. A549 cells were grown to 80% confluence prior to addition of RN6390 
(approximately 106 cfu), centrifugation and incubation for 1 hour to permit internalisation. 
Following this, lysostaphin 10 µg/ ml was added to the well to kill non-internalised bacteria. The 
adhered A549 cells were extensively washed prior to addition of TOP and microplate reader 







































Figure 3.13: TOP demonstrates intracellular bacterial killing. TOP treated A549 cells (with 
intracellular bacteria) show significantly reduced luminescence (A) and gfp (B) indicating that 
TOP possesses intracellular bacterial killing ability (n=3; mean and SEM).  
 
3.9. Prophylactic TOP treatment of A549 cells reduces internalised bacterial 
growth 
 
The respiratory airway epithelium is continually exposed to bacteria. Prophylactic 
treatment of A549 cells with TOP was tested to confirm if subsequent bacterial 
growth within the intracellular niche was reduced. Following similar methods to 
those represented in Figure 3.12, the treated A549 cells with TOP prior to exposure 
to bacteria. Prophylaxis treatment of antibiotics has been recommended by American 
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(Capitano et al., 2001). This assay was performed to explain the utility of the pre-
treatment of TOP to prevent bacterial colonisation in lung epithelial cells. A549 cells 
were pre-treated with TOP and washed excess prior to internalisation of RN6390-
gfp-lux S. aureus the intracellular bacterial growth was measured by gfp 














Figure 3.14: TOP pre-treated A549 cells reduced intracellular RN6390-gfp-lux. A549 cells were 
pre-treated with 100 µM and 50 µM of TOP and washed before the internalisation of RN6390-
gfp-lux. The growth of bacteria was monitored by measuring gfp fluorescence over 48 hrs. 
Intracellular bacterial growth was reduced in TOP pre-treated A549 cells in a dose dependent 
manner (Panels represent mean values ± SEM for n = 5).  
 
3.10. TOP disrupts bacterial membrane 
 
AMPs disrupt bacterial membranes (Haney and Hancock, 2013) but it is not clear 
whether membrane disruption is the primary mechanism of killing that TOP uses to 
kill bacteria (Figures 3.1, 3.2). To visualise ultra-structural damage, TOP treated 
bacteria were subjected to Transmission electron microscopy (TEM) analysis. TEM 
clearly showed bacterial membrane disruption of (A) Gram positive and (B) Gram 
negative bacteria (Figure 3.15). 
 
           TOP pretreated A549 cells reduce the growth of











































Figure 3.15: TEM images demonstrate bacterial cell membrane disruption.  Bacterial 
membranes have ruptured with disruption and extrusion of bacterial contents (yellow arrows). 




3.11. TOP may induce reactive oxygen species production in bacteria 
 
Reactive oxygen species (ROS) production is a mechanism for antibiotic bactericidal 
activity  leading to DNA, protein and lipid damage (Vilchèze et al., 2013). Hence, 
the induction of ROS in bacteria after TOP addition was evaluated. MRSA was 
treated with different peptoids (TOP, THP-Tosyl-hexyl and HHP-H-hexyl) in a 96 
well plate for 1 hour followed by addition of Dihydroethidium (DHE) to measure 
ROS production (Figure 3.16). 
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Figure 3.16: TOP induces ROS production in MRSA. (A) The production of ROS in MRSA by 
TOP measured by the plate reader in 96 well plates. (Panels represent mean values ± SEM for n 
= 3) (B) Representative epifluorescence microscopy images showing TOP inducing ROS 
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3.12. TOP induced toxicity in mammalian cells 
 
Freshly isolated human neutrophils and mammalian lung epithelial cells (A549) were 
exposed to TOP for prolonged periods and neutrophil viability/apoptosis (flow 
cytometric) and epithelial cell mitochondrial function (MTS assay) assessed. 
Interestingly and surprisingly, TOP induced apoptosis and secondary necrosis in 
neutrophils in a caspase-dependent manner. TOP did not induce epithelial cell 
toxicity.  
 
3.12.1. TOP induced neutrophil apoptosis 
 
Neutrophil apoptosis is the process of programmed cell death with anti-inflammatory 
sequela. Conversely, primary necrosis results in pro-inflammatory sequela. Apoptosis 
prevents the release of neutrophil-toxic contents to the surrounding tissue and 
promotes the resolution of inflammation (Li et al., 2009). Resolution of the 
inflammatory response is a complex process and includes production of host-derived 
anti-inflammatory mediators and apoptosis of neutrophils.  Neutrophil apoptosis and 
removal of apoptotic neutrophils by macrophages facilitates the resolution of 
inflammation ( Savill et al., 1989; Kennedy and DeLeo, 2009; Moret et al., 2011).  
 
Given the pivotal role played by neutrophils in orchestrating the inflammatory 
response, TOP was incubated with neutrophils to delineate any toxicity. Surprisingly 
TOP induced neutrophil apoptosis and subsequent secondary necrosis. Neutrophils 
were incubated with TOP (50 µM and 100 µM), Roscovitine (Cyclin-dependent 
kinase inhibitor that induces neutrophil apoptosis) and control buffer in 96 well 
plates for 6 and 20 hrs. Neutrophil apoptosis and necrosis was analysed by flow 
cytometry with Annexin V and propidium iodide (PI) staining respectively (Figure 


































Figure 3.17: Induction of neutrophil apoptosis and necrosis by TOP at 6 hrs. (A) Representative 
FACS plots show PI and Annexin V labelling of neutrophils. (B) Representative images of 
neutrophils (magnification x40). (C) Graph shows the percentages of cell labelling. The control 
shows 90% healthy cells (Annexin V and PI negative) and no PI positive (no necrotic cells). 
Roscovitine (10 µM) causes apoptosis in neutrophils but not necrosis. Treatment with 50 µM 
TOP shows around 20% Annexin V and 20% Annexin V and PI positive cells indicating they 
are undergoing apoptosis and necrosis. This population increases with higher concentration of 
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Figure 3.18: Induction of neutrophil apoptosis and secondary necrosis by TOP at 20 hrs. (A) 
Representative FACS plots show PI and Annexin V labelling of neutrophils. (B) Representative 
images of neutrophils (magnification x40). (C) The graph shows the percentages of cell labelling. 
TOP induces neutrophil necrosis at 50 µM and 100 µM concentrations at 20 hrs compared to 
the control and Roscovitine (10 µM). (Panels represent mean values ± SEM for n = 4). 
 
To further clarify if TOP was inducing apotosis or necrosis as a primary process, 
neutrophils were incubated with TOP in the presence or absence of QVD-OPh a 
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chosen as it has  superior aqueous stability, cell permeability, and efficacy than 
fluoromethylketone (FMK)-based caspase inhibitors and displays no cytotoxic 
effects alone (Caserta et al., 2003). Experiments analogous to Figures 3.17 and 3.18 

























Figure 3.19: QVD blocks secondary necrosis induced by TOP at 6 hrs. (A) Representative FACS 
plots show PI and Annexin V labelling of neutrophils. (B) Representative images of neutrophils 
(magnification x40). (C) Graph shows the percentages of cell labelling. Neutrophils have been 
incubated with QVD and TOP for 6 hrsand labelled with Annexin V and PI and analysed by 
FACS. (Panels represent mean values ± SEM for n = 4). 
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Figure 3.20: QVD blocks secondary necrosis induced by TOP at 20 hrs. (A) Representative 
FACS plots show PI and Annexin V labelling of neutrophils. (B) Representative images of 
neutrophils (magnification x40). (C) Graph shows the percentages of cell labelling. Neutrophils 
were incubated with QVD 10 µM and TOP for 20 hrs and analysed by flow cytometric staining 
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To further investigate if TOP had a role in specifically inducing secondary necrosis 

























Figure 3.21: TOP induces rapid secondary necrosis of apoptotic neutrophils. (A) Representative 
FACS plots show PI and Annexin V labelling of neutrophils. (B) Representative images of 
neutrophils (magnification x40). (C) Graph shows the percentages of cell labelling. Neutrophils 
were aged for 20 hrs and then pulsed with TOP for 10 minutes before staining with the Annexin 
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3.12.2. TOP shows no toxicity to A549 cells 
 
MTS assays were carried out to observe TOP cytotoxicity on A549 cells at 3 hrs and 












Figure 3.22: TOP has low toxicity on A549 cells. A549 cells were incubated with four different 
peptoids including TOP at different concentrations for 3 hrs. MTS assay was performed at the 
end of the assay. Significance was assessed by one-way ANOVA with Bonferroni’s multiple 
comparison tests comparing each treatment with control. (Panels represent mean values ± SEM 











Figure 3.23: TOP toxicity on A549 cells at 24 hrs incubation. A549 cells were incubated with 
TOP at different concentrations for 24 hrs. MTS assay was performed at the end of the assay. 
TOP was toxic to A549 cells at 100 µM concentrations at 24 hrs but no significant toxicity lower 
than 80 µM. (Panels represent mean values ± SEM for n = 3; P=0.0068). 
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3.13. Discussion 
 
In the discussion summarises the TOP activity on bacterial killing, selectivity over 
mammalian cells, inflammatory response on neutrophils and evaluate the A549 cell 











TOP activity on gram positive and gram negative bacteria: 
 
Emergence of multidrug resistant bacteria such as vancomycin-resistant Enterococci 
and methicillin-resistant Staphylococcus aureus (MRSA) are major global challenges 
(Theuretzbacher, 2011; Arias and Murray, 2012; Gould et al., 2012; Phoenix et al., 
2013). Resistance is due to decades of widespread and indiscriminate usage of 
existing antibiotics Despite this,  most novel antibacterial drugs are designed through 
modifications of existing scaffolds resulting in the high likelihood of resistance 
emerging in even new drugs (Jabes, 2011; Livermore, 2011; Tomasini et al., 2013). 
Hence there is an urgent need for new antibiotics with novel mechanisms of 
antimicrobial action. AMPs show high potential to serve in this capacity. However 
the major obstacle in the further development of lead AMPs is difficulty in the 
transition of in-vitro activity into in-vivo efficacy (Hancock and Sahl, 2006). In 
contrast to AMPs, Peptoids represent a class of peptidomimetic that are not found in 
nature. Peptoids are highly resistant to proteolysis, providing vast opportunity for 
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A library of peptoids have been synthesised based on a group of achiral cationic 
peptoid polymers with the department of chemistry based on the previous published 
data (Unciti-Broceta et al., 2009; Dhaliwal et al., 2011) to study the structure-activity 
relationships (S.A.R) on bacterial killing. The core structure of the whole peptoid 
library was 9-mer lysine-like peptoids unit (Figure 1.13) and the peptoid derivatives 
have been made by; (i) changing the length of the carbon side chain; and (ii) N-
terminus modifications (Figure 1.15 and Table 1.3). 
 
This study evaluated the efficacy of TOP on gram negative and gram positive 
bacterial species including clinically isolated bacteria and multidrug resistance 
strains such as methicillin resistant Staphylococcus aureus (MRSA). However in 
future work it is important to investigate the effect of TOP on other clinically 
important bacterial/fungal/virus strains and species including vancomycin resistant 
enterococci (VRE), Mycobacterium tuberculosis and other multidrug-resistant 
microbes to study the full spectrum of the efficacy of this drug to be used in clinical 
settings.  
 
To investigate the antibacterial activity of these peptoids, growth inhibition assays 
have been carried out in MHB for 16 hrs on MRSA, MSSA, PAO1 and E. coli at 200 
µM peptoid concentrations. The summary results show that TOP has significant 
growth inhibition on MRSA, MSSA, PAO1 and E.coli compared to other peptoids 
tested (Figure 3.1 and Figure 3.2).  The octyl derivatives such as H-octamer and 
BnCO-octamer peptoids show variable bacterial growth inhibition leaving TOP as 
the ‘lead’ antibacterial candidate. This analysis further indicated that the tosyl group 
and octamer carbon side chain (long carbon chain) are important peptoid structures 
in order to retain antibacterial activity as a linear 9-mer peptoid. However the 
presence of tosyl groups with butyl and hexamer carbon chain shows no bacterial 
killing indicating that the importance of the length of the carbon side chain (octly) 
for bacterial killing. Therefore TOP was selected as the lead compound to carry out 
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According to the figure 3.1 and figure 3.2, the results show that some of the peptoids 
tested are supporting the growth of bacteria instead of killing them. All the bacterial 
strains tested for the initial screening of the peptoids show increase of bacterial 
growth compared to control with some of the peptoids tested. As example peptoid 
Suc-octyl induce the growth in PAO1, MRSA and MSSA, but not in E.coli. Peptoid 
H-hexyl shows similar effect on E.coli, MRSA and MSSA, however not in PAO1 
strain. This may be due to the probiotic effect of peptoids on bacterial species. 
Probiotic effects of peptides have been studied by (Janer et al., 2004) and (Azuma et 
al., 1984) concluded that casein macropeptide (CMP) can effectively stimulate 
growth for lactic acid bacteria. However the mechanism of action may be the effect 
of hydrolysis of these peptoids on the growth-promoting activity of these peptoids or 
may be an hormonal effect on bacterial growth.   
 
TOP has two major components; (i) lysine-like (octyl) 9-mer unit and (ii) N-
substitute-Tosyl (sulphonamide) group. Previous studies have identified that several 
lysine-peptide hybrids have broad-spectrum activity against clinically important 
bacteria and fungi (Ryge et al., 2008). Recent studies on the lysine-peptoid hybrid 
LP5 ([N-(1-naphthalenemethyl)glycyl]-[N-4-methylbenzyl)glycyl]-[N-
(1naphthalenemethyl)glycyl]-N-(butyl)glycin amide and 5 lysines) revealed that it 
traverses the cytoplasmic membrane of S. aureus without causing lethal damage to 
the membrane and binding to the chromosomal DNA inducing bacterial killing 
(Gottschalk et al., 2013).  
 
It has been postulated that the cationic and amphiphatic nature of AMPs selectively 
kill bacteria by penetrating the negatively charged cell membrane leading to 
membrane disintegration. However, AMPs may also act by other mechanisms 
without destruction of the cell membrane targeting intracellular enzymatic activities 
such as cell wall synthesis and RNA, DNA and protein synthesis (Hale and Hancock, 
2007; Jenssen et al., 2006). The inhibition of RNA, DNA and protein synthesis in 
bacteria may result from AMPs interacting with DNA repair by collapsing 
replication forks (Dubois et al., 2013; Gunderson and Segall, 2006). Higher 
concentrations of LP5 also target the cell membrane leading to leakage of 
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intracellular compounds like ATP, resulting in cell death (Dubois et al., 2013; 
Gottschalk et al., 2013).  
 
TOP has N-substitution sulphonamide group. Sulphonamides are one of the most 
frequently used antibacterial agents in veterinary medicine in Europe (Grave et al., 
2010; Zessel et al., 2013). A considerable number of sulphonamides are well known 
as antibacterial, anti-cancerous, and also as anti-inflammatory agents (Badr, 2008; 
Jain et al., 2013). Recent studies on sulphonamide have shown  their matrix 
metalloproteinase (MMP) inhibitory activity (Jain et al., 2013).  
 
According to the initial screening results with the growth inhibition assay, the 
presence of the sulphonamide groups on octyl-peptoid shows antibacterial activity. 
However, Hexyl and Butyl peptoids with the N-sulphonamide group did not show 
any antimicrobial activity on PAO1 (Tosyl-Butyl and Tosyl-Hexyl) and E. coli 
(Tosyl-Hexyl). But some growth inhibition was observed with MRSA and MSSA 
with Tosyl-Hexyl, indicating that the sulphonamide group synergises with octyl-9-
mer combination to promote the broad range of bactericidal activity on gram positive 
and negative bacteria. Previous studies on sulfonamide derivatives revealed that the 
given chain length of the lipophilic moiety and the nature of the hydrophilic group 
substituted at the amino nitrogen of the sulfonamide molecule had a marked 
influence on surfactant properties and mutual lipophilic and hydrophilic groups may 
have surface activity and bacterial effect (Badr, 2008). These studies suggest that the 
proper combination of different groups to the sulphonamide may have beneficial 
effects. 
 
Latent or slow-growing bacteria frequently exhibit tolerance to antibiotics that are 
active against rapidly dividing bacteria. These pathogens persist in the intracellular 
niche and multiply very slowly providing a residual bacterial niche in the host from 
which further growth, infection and spread may occur (Zeiler et al., 1985). Both the 
intracellular niche and the slower replication of these pathogens allow them to be 
relatively protected from conventional antimicrobial therapeutics (Yanmin et al., 
2010). Therefore the activity of TOP against non-multiplying cultures of MRSA and 
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PAO1 using well characterized techniques is important (Bahl et al., 1997). Under 
these conditions, TOP displayed dose-dependent antibacterial activity (Figure 3.3).  
 
The results of PBS killing assay data show that the TOP kills non-dividing gram-
positive MRSA within 3 hrs at 100 µM concentration and gram-negative bacteria, 
PAO1 with in 1hr at 50 µM concentration. These results indicate that the 
microbicidal mechanism of TOP may not be through interfering with  metabolic 
pathways such as DNA, RNA, protein or cell wall syntheses but rather through 
primary membrane damage (Coates et al., 2002; Ooi et al., 2010).  
 
The growth inhibition assays were carried out to investigate the bactericidal effect of 
TOP on dividing bacteria in MHB. The data revealed that killing of gram negative 
and positive bacteria was observed except in B.cepacia at 100 µM TOP 
concentrations. The PBS killing assay and growth inhibition assays suggests that the 
TOP may have multiple mechanisms of bacterial killing (Coates et al., 2002; Ooi et 
al., 2010). However the exact killing mechanisms remain to be elucidated. Since 
TOP has the two potent characters 9-mer-octyl lysine peptoid group and the 
sulphanilamide group, the killing may involve complex mechanisms. However 
cationic properties on 9-mer-octyl lysine group may also involve binding to the 
negatively charged bacterial surface (Dubois et al., 2013) and penetration into the 
bacteria. The sulphanilamide group may block the production of folic acid synthesis 
in the bacteria and proceed to death (Lascelles and Woods, 1952). The ability of the 
TOP to kill bacteria in non-dividing cultures suggests a mechanism that does not 
solely involve the synthetic machinery of the bacteria as well. Many AMPs possess 
hydrophobic elements that traditionally have been thought to mediate membrane 
insertion and pore formation (Brogden, 2005). The absence of such moieties in our 
compound implies that alternative mechanisms may play a role in membrane 
disruption in bacterial cells upon exposure to positively charged molecules and the 
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Investigate the mechanisms of bacterial killing by TOP:  
 
The hydrophilic nature of the TOP may not describe the AMPs mechanisms of 
bacterial killing. Current understanding of structure-function relationships and 
mechanisms of AMPs and peptoid-mediated bacterial killing postulates variable 
mechanisms from cell wall disruption and membrane leakage to direct chromosomal 
damage (Coates et al., 2002; Ooi et al., 2010). Since TOP has the sulphanilamide 
group, the killing may involve blocking the production of folic acid synthesis in the 
bacteria and proceed to death (Lascelles and Woods, 1952). However to evaluate 
these mechanisms the TEM and ROS detection strategies were utilised. TEM (Figure 
3.15) visualised the ultra-structural damage of MRSA and PAO1 by TOP. These 
images clearly show bacterial membrane disruption leading to bacterial killing.  
 
Haney and Hancock, (2013) observed similar results with AMPs but the disruption to 
bacterial membrane may or may not be the primary mechanism of killing. Therefore 
the production of ROS has been studied during the killing process. However the ROS 
production also may not be the primary factor for killing but involvement of the high 
ROS production with TOP compared with the other peptoids are very interesting 
results for further investigation (Figure 3.16). It is clear that high ROS production 
with the TOP plays a key role to kill the bacteria and the ROS involved DNA and 
protein damage. Vilchèze et al., (2013) observed ROS production in M. tuberculosis 
to vitamin C lead to DNA and protein damage. However the exact mechanism of 
ROS production in TOP treated bacterial cells are to be investigated but the 
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TOP shows high selectivity on bacteria over mammalian cells: 
 
The selective toxicity of antibiotics means that they must be highly effective against 
the microbe but have minimal or no toxicity to humans. In practice, this is expressed 
by a drug's therapeutic index (TI) or selective ration (SR). These studies demonstrate 
that the TOP shows higher toxicity on bacterial membrane over mammalian cell 
membrane. The MIC and MBC values were used to determine the bacteriostatic or 
bactericidal activity of the TOP. The table 3.2, summaries the MIC and MBC values 
for the TOP.  MIC shows the bacteriostatic values and MBC shows the bactericidal 
values. All seven bacterial strains show MIC values below 80 µM and MBC below 
100 µM. These data indicates that the lower concentrations of TOP confer antiseptic 
properties while higher concentrations show bactericidal activity. However MIC 
values of TOP for different bacterial strains are higher than the previously studied 
antimicrobial peptides (Chongsiriwatana et al., 2008). Balancing high antimicrobial 
activity with low toxicity to the host is fundamental for clinical application and this 
has been quantified using TI or SR (the ratio of the dose causing 10% haemolysis to 
the MIC). Hence the TI was calculated using haemolysis assay data (Figure 3.7) and 
MIC values (Table 3.2) resulting higher TI value for TOP as 100 compared with the 
peptoids described in Chongsiriwatana et al., (2008) was around 20 (Table 3.3). This 
indicates that the TOP has more tendencies to kill bacteria rather than mammalian 
cells.  
 
The table 3.3 summarises the previous publications of MICs of peptoids, AMPs and 
conventional antibiotics on P. aeruginosa. The data show that the TOP shows higher 
MIC value compared to most of the peptoids and AMPs. Kanamycin (100 µM) 
shows higher MIC compared with the TOP but much lower compared with 
Ciprofloxacin (0.4 µM) and Tobramycin (1.6 µM). However according to the 
summary table 3.3 the SR of all the peptoids are lower than the TOP indicating that 
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Table 3.3: Peptoids, AMPs, and conventional antibiotics and their antimicrobial 
activities against planktonic PA14 (Chongsiriwatana et al., 2008; Kapoor et al., 
2011). 
Peptoid, AMP, or 
antimicrobial 
MIC for P. aeruginosa 
(PA 14) (µM) 
Selectivity ratio 
(SR) 
TOP 80 (PAO1 strain) 100 
1                                           12.5 6 
1-11mer                               12.5–25 >3.9 
1-Pro9                                 25–50 20 
1-achiral                              25 Not available 
1-C134mer                            12.5–25 Not available 
14mer >100 Not available 
1-Nssb                              >100 Not available 
LL-37                          25–50 Not available 
Pexiganan 12.5–25 24 
Ciprofloxacin 0.4 Not available 
Tobramycin 1.6 Not available 
Kanamycin >100 Not available 
 
Bacteria and A549 cells co-culture assay shows TOP selective killing bacteria:  
 
The TOP TI value postulated that it can kill bacteria while protecting the mammalian 
cells. To study this outcome in-vitro, co-culture assays were designed to study the 
extra cellular bacterial killing ability of TOP and quantified the bacterial counts 
(cfu/ml) and A549 cell death (sytox-orange). The TOP treated cultures showed less 
bacterial counts (Figure 3.9) compared to non-treated cultures. Further analysis with 
sytox-orange revealed that the TOP treated A549 cell cultures were protected (Figure 
3.10) from invasion of extracellular bacteria and their toxins. The figure 3.10 shows 
the A549 dead cell counts on treated and non-treated cells; less dead cells indicates 
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Bacterial pathogens persist in the intracellular niche and multiply very slowly 
providing residual bacterial counts in the host from which further growth, infection 
and spread (Eltahawy, 1983; Zeiler et al., 1985; Almeida et al., 1996; Bouchard et 
al., 2013). Hence it is very important to treat the intracellular bacteria to have 
complete recovery from the infection. However most antibiotics do not reach the 
intracellular niche to kill the bacteria (Qazi et al., 2004; Yanmin et al., 2010; 
Bouchard et al., 2013). To determine the TOP mammalian cell membrane 
permeability and intracellular localisation, a confocal microscopy study was carried 
out with TOP-TAMRA and TAMRA alone (5, 10 and 50 µM) [Figure 3.11(a) and 
(b)]. The results revealed that the TOP-TAMRA were internalised within 1, 5 and 10 
minutes intervals at 50 µM concentrations. Therefore the activity of the TOP has 
been evaluated by intracellular killing assays (Figure 3.12 and 3.13).  
 
These confocal data [Figure 3.11 (a)] also demonstrated that lysine like peptoids 
enters cells rapidly via endosomal uptake (Peretto et al., 2003; Unciti-Broceta et al., 
2009). The bioluminescence and gfp-fluorescence were measured after 
internalisation of RN6390; S. aureus expressing a gfp-luxABCDE reporter operon 
under the control of a growth-dependent promoter to track bacterial replication 
within mammalian cells in 96-well micro-plate format described by (Qazi et al., 
2004). The results suggest that the TOP internalised into A549 cells and has potent 
activity against internalised RN6390. This also revealed that the TOP continues its 
bacterial killing ability within mammalian intracellular environments ex-vivo. This 
further confirms that the TOP internalised into the A549 cells and acts irrespective of 
cellular conditions like pH interference and salt concentration when using novel host 
defence peptoids.   
 
The potent intracellular microbicidal activity of TOP led to evaluate the microbicidal 
potential of cells pre-loaded with TOP, as a model of prophylaxis and augmentation 
of cellular antimicrobial activity. The previous experiments described above have 
proven that the TOP can kill extracellular and intracellular bacteria without toxicity 
to A549 cells. Subsequent assays have been designed to understand the prophylactic 
clearance of bacteria in-vitro. Prophylaxis treatment of antibiotics has been 
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recommended for high risk patients such as immune compromised patient to prevent 
infection (Capitano et al., 2001). The results show that TOP was retained within the 
A549 cells and the internalised TOP can reduce the intracellular bacterial growth in a 
dose dependent manner (Figure 3.14). Since the lung epithelial surfaces are 
constantly exposed to bacteria and are often a site for persistent bacterial survival, 
the pre-treatment of TOP could prevent epithelial cell death and apoptosis in 
response to bacterial infection and also contribute to pathological damage to the host 
and within the lung leading to compromised barrier function and consequent acute 
lung injury (van Schilfgaarde et al., 1999; Martin, 2008).  
 
TOP induces inflammatory response on neutrophils: 
 
Neutrophils play an important role as antimicrobial innate effector cells recruited to 
sites of acute inflammation and constitute the first line of cellular defence in bacterial 
infection (Haslett, 1999). The appropriate regulation of neutrophils function, death 
and clearance is critical to innate immunity and dysregulation is implicated in disease 
pathogenesis (Li et al., 2009). Therefore it is important to understand the regulation 
of neutrophils activity by TOP. Neutrophils were incubated with TOP at 50 µM and 
100 µM concentrations for 6 hrs and 20 hrs. The data indicated that the TOP can 
induce secondary necrosis at 6 hrs and 20 hrs incubation. A longer incubation TOP 
induces primary necrosis in the neutrophils (Figure 3.17 and Figure 3.18). Primary 
and secondary necrosis by the TOP can be blocked by QVD, the caspase inhibitor 
(Figure 3.19 and Figure 3.20). This indicates that TOP influenced apoptosis and 
secondary necrosis at lower concentrations (50 µM) but at higher concentrations 
(100 µM) it induced primary necrosis and this may be pro-inflammatory. However, 
AMPs like LL-37 induce rapid secondary necrosis in neutrophils and promote the 
resolution of inflammation (Barlow et al., 2006; Li et al., 2009). The low 
concentration (50 µM) of TOP promotes the resolution of inflammation however 
higher concentrations may pro-inflammatory. Therefore modulation of the TOP is 
very important to optimise the bacterial killing while promoting the resolution of 
inflammation in lung infection. However more experiments have to be done to 
investigate the consequence of these secondary necrotic neutrophils on macrophages 
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and their inflammatory responses. (Li et al., 2009) showed that the LL-37-induced 
secondary necrosis did not inhibit neutrophil ingestion by monocyte-derived 
macrophages and was not pro-inflammatory.  
 
TOP shows cytotoxicity activity on A549 lung epithelial cells:  
 
Further studies have been carried out to investigate the TOP-cytotoxicity activity on 
A549 cells (Figure 3.22 and 3.23). Four different peptoids were tested including TOP 
at different concentrations and no significant toxicity was observed among all 
peptoids. This suggests that the TOP shows selectivity between bacterial and 
mammalian cells as observed in previous haemolysis data.     
 
In conclusion, TOP displayed potent antimicrobial activity compared to 13 other 
tested peptoids. It exhibited antibacterial activity against non-dividing and 
multiplying gram negative and gram positive bacteria. A high SR supports further in-
vivo testing of TOP. Extracellular and intracellular bacterial killing and prophylactic 
properties of the TOP are important characteristics which support its further 
development. TOP induces ROS production in bacteria and membrane damage 
whilst remaining nontoxic to A549 lung epithelial cells. At low concentrations TOP 
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This chapter details the cloning, over-expression and purification of PBP2A protein. 
This purified protein has been used to develop aptamer and peptide probes to detect 
MRSA. The gene transcribing this protein is mecA in MRSA and it has been well 
documented that the methicillin resistance in MRSA is due to the presence of this 
gene. The mecA gene has been amplified from genomic DNA of MRSA strains and 
cloned into pET21d(+) vector using restriction enzymes and DNA ligase, 
respectively. The cloned products were sequenced and analysed using restriction 
enzyme digestion to confirm the insert and its right orientation before transformation 
into the over expression E. coli strain BL21. Under the optimum culture conditions 
and the presence of IPTG the protein was over-expressed and purified using Ni-NTA 
columns. The protein purity was analysed by running a protein gel and quantified 
using BCA protein assay. Finally the purified protein was confirmed using Latex 
Agglutination test. The results confirmed that the purified protein demonstrates the 
same functional properties to its native protein present in MRSA but not in MSSA. 
The purified PBP2A protein coated Ni beads were used to develop aptamer and 
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4.2. Introduction 
 
Methicillin resistance in S. aureus is due to the presence of mecA gene, which 
transcribes the PBP2A protein (78 kDa). PBP2A catalyses the formation of peptide 
crosslinks (transpeptidation) between glycan chains of the bacterial cell wall in the 
presence of β-lactam antibiotics (Pinho et al., 2001). Therefore PBP2A is a potential 
bacterial protein for the development of molecular probes. 
 
This chapter details mecA gene cloning, PBP2A protein over-expression and 
purification in order to develop specific aptamer and peptide molecular probes 
against PBP2A protein.  
 
4.3. Bioinformatics data mining 
 
The whole genome of an MRSA strain has been sequenced (Holden et al., 2004). 
The bioinformatics data for mecA gene was obtained from Comprehensive Microbial 
Resource (http://cmr.jcvi.org/tigr-scripts/CMR/CmrHomePage.cgi) and data was 
obtained as mentioned in the materials and methods section (2.2.1). The gene 
sequence and the protein sequence were obtained as mentioned and the mecA gene 
consists of 2007 base pairs (bp) and the transcribed PBP2A protein is 668 amino 
acids (aa) with molecular weight of 78 kDa.   
  
4.4. mecA gene specific primer designing 
   
As described in the Materials and Methods section, the primers were designed to 
remove N-terminal transmembrane region of the PBP2A protein. This removes the 
insoluble part of the protein up to 23aa. The 24aa to 668aa of the protein has been 
over-expressed with His tag at the C-terminus. The primers used in this study are 
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Table 4.1: Oligonucleotide primers used for cloning of mecA gene in this study 
 
The restriction enzyme digestion of mecA gene was analysed using NEBcutter V2.0 
(http://tools.neb.com/NEBcutter2/) to study the suitability of using NcoI and XhoI 
enzymes for cloning (Figure 4.1). The searches indicated that the two restriction 
enzymes are not splicing the mecA gene were suitable to use for mecA cloning. 
 
 
Figure 4.1: The map of the restriction enzyme digestion of mecA gene  
 
4.5. PCR amplification of mecA gene 
 
The mecA gene was PCR amplified using the protocol described in the Materials and 
Methods section (2.2.3) and the agarose gel confirmed that the presence of the mecA 
gene (2007bp) is only observed in the MRSA strains (Figure 4.2). The amplified 







Name Sequence 5’-3’ 
Forward primer- ATAATACCATGGCTTCAAAAGATAAAGAAATTAATAATAC 
Reverse primer-  ATAATACTCGAGTTCATCTATATCGTATTTTTTATTACC 
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Figure 4.2: Agarose gel electrophoresis images; PCR amplification of mecA gene in MRSA. 
Lane 1-MSSA; Lane 2-MRSA Clinical strain; Lane 3-MRSA ATCC252 strain; Lane 4-negative 
control. 
 
4.6. Restriction enzyme digestion and ligation 
 
Both the vector pET21d(+) (Figure 4.3) and the insert (mecA) were cut with 
restriction enzymes (NcoI and XhoI) and run on an agarose gel to confirm the purity 





Non-specific PCR amplification 
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Figure 4.3: The plasmid vector pET-21d(+).The pET21d(+) plasmid vector was used to clone the 






















Figure 4.4: Agarose gel electrophoresis image. Showing restriction digested products; Lane 1- 
Plasmid vector (pET21d+) cut with XhoI and NcoI; Lane 2-Insert (mecA) cut with XhoI and 
NcoI. 
 
4.7. Transformation of cloned plasmid to E. coli BL21 cells 
 
Transformation of the ligated products into BL21 cells was carried out as detailed in 
the Materials and Methods section. Ten colonies were selected after overnight 
incubation in ampicillin (50 μg/ ml) LB plates and colony PCR was carried out on 
ten selected colonies using the same primers. PCR amplification demonstrated that 
the mecA gene was correctly cloned into 7 out of 10 colonies of the pET21d(+) 











Figure 4.5: Agarose gel electrophoresis image investigating the mecA gene amplification in 10 
different colonies of BL21. Colony numbers 5, 6 and 9 were negative for PCR amplification for 
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4.8. Sequencing of cloned plasmids 
 
Four mecA positive colonies were selected from the colony PCR results for further 
studies. Plasmids of these colonies were extracted as mentioned in the protocol using 
Qiagen kits. The plasmids were sequenced using T7 sequencing primers to determine 
the presence of the correct sequence of the mecA gene in the vector pET21d(+). The 
Sanger sequencing results were analysed using ClustalW software. Data showed that 
the mecA gene sequence was present in all four colonies (1 to 4) and these were 















Figure 4.6: ClustalW data showing the alignment of sequenced data (JCK138-34-A) with the 
mecA gene sequence. 
 
4.9. Over-expression and purification of PBP2A protein 
 
Over-expression and purification of PBP2A protein was carried out according to the 
Materials and methods section (2.2.3.10.). Purified proteins were visualised by 
running a SDS-polyacrylamide protein gel and staining with coomassie brilliant blue 

















Figure 4.7: SDS-polyacrylamide protein gel showing the over expressed PBP2A protein and 
purified protein (a) Lane 1, 3, 5 and 7 are the four colonies before over-expression and 2, 4, 6 
and 8 are after PBP2A over-expression with IPTG (1 to 4 colonies were selected-Figure 6). (b) 
Lane 1 (sample-34) and 2 (sample-35) represent the purified PBP2A protein (Two colonies were 
selected). 
 
4.10. Quantification of the protein PBP2A 
 
The BCA assay was performed to quantify the over-expressed protein as detailed in 
the Materials and Methods section. Two samples were chosen numbered 34 and 35 
corresponding to the colony numbers on the plates (Table 4.2). 
 
Table 4.2: Quantification of purified PBP2A protein in sample 34 and 35 
 
Sample 
Absorbance (100 µl) 
Average (Y) X=(Y-0.118)/0.001 µg/ ml mg/ ml 
1 2 3 
34 0.242 0.251 0.242 0.245 127 1270 1.27 
35 0.257 0.258 0.269 0.261 143 1433 1.43 
 
The above data shows that the PBP2A protein is purified (Figure 4.7) and 
concentrations are above 1 mg/ ml of 10 ml (Table 4.2). 
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4.11. Penicillin binding protein (PBP2A) Latex Agglutination test 
 
To confirm the activity of the over-expressed PBP2A protein, Latex Agglutination 
test was carried out. Therefore as mentioned in the Material and Methods section 
(2.2.3.15.) PBP2A antibody binding assay was carried out. The PBP2A latex 
agglutination test (Oxoid, Hampshire, United Kingdom) is a 20-min phenotypic test 
that detects PBP2A in isolated colonies (Doern et al., 1994). This assay showing the 
over-expressed PBP2A protein is responding to the active proteins in the MRSA not 
MSSA (Figure 4.8). 
 
 
Figure 4.8: Latex beads agglutination assay for purified PBP2A protein (a) MRSA and MSSA 
bacterial strains showing the positive and negative results respectively for the latex beads 
agglutination test. (b) Two samples of PBP2A over-expressed protein (34 and 35) respond to the 
test as MRSA. This indicates that the over-expressed PBP2A protein is showing the same 
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4.12. Discussion 
 
MRSA has developed clinical resistance to β-lactam antibiotics by acquisition of the 
mecA gene (Enright et al., 2002) which encodes PBP2A and provides transpeptidase 
activity to allow cell wall synthesis at β-lactam concentrations that inhibit the β-
lactam-sensitive strains (Lim and Strynadka, 2002; Otero et al., 2013). S. aureus 
normally produces four PBPs, (Georgopapadakou et al., 1986) which are susceptible 
to inhibition by β-lactam antibiotics. The irreversible acylation of the active site of 
the PBPs by the β-lactam antibiotics causes the death of the bacteria due to the non-
functional PBPs. However, PBP2A is resistant to all commercially available β-
lactams (Otero et al., 2013) and MRSA has become resistant to almost all 
commercially available antibiotics. Thus the detection of the PBP2A protein is an 
important goal of clinical microbiology. The aim of this chapter work has been to 
produce PBP2A to enable efforts to develop molecular diagnostics in the following 
chapters. Importantly PBP2A is located on the outer surface of the bacterial cell wall 
(Ohwada et al., 1999; Roth et al., 2006). The truncated PBP2A protein has been 
selected for over-expression from the mecA gene coding elements of the membrane 
spanning segment which is lack in the over-expressed PBP2A protein (Wu et al., 
1992). 
 
A 242 bp fragment of mecA gene was amplified by PCR from S. aureus, expressed, 
purified and used to stimulate humoral immune response in a murine model. This 
investigation revealed that PBP2A as a potential to develop vaccine against MRSA 
infection (Haghighat et al., 2013). In another study, PBP2A and PBP2ALGA (PBP2A 
from MRSA strain LGA251) were over-expressed to study the MRSA strain-to-
strain variation in resistance level (Kim et al., 2012). Inactivation of the 
transglycosylase domain and the activation of the transpeptidase domain were 
studied using over-expressed PBP2A protein by (Pinho et al., 2001). Hence similar 
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Holden et al., (2004) sequenced the 2.8 Mbp genomes of two disease causing S. 
aureus strains isolated from hospital-acquired MRSA (MRSA252). The sequence 
data has been obtained using online bioinformatics data base called ‘Comprehensive 
Microbial Resource’ (http://cmr.jcvi.org/tigr-scripts/CMR/CmrHomePage.cgi). 
Using the mecA gene sequence, mecA specific primers were designed to PCR 
amplify the mecA gene. The results of the PCR amplification showed that the mecA 
gene was only present in MRSA. This indicated that my chosen mecA specific 
primers were and could be used to identify MRSA strains in the clinical samples.  
 
The PBP2A latex agglutination test (Oxoid, Hampshire, United Kingdom) is a 20-
min phenotypic test that detects PBP2A in isolated colonies (Doern et al., 1994). The 
PBP2A assay is faster and less complicated than PCR for mecA and has been shown 
to be more sensitive than other phenotypic methods, such as the use of oxacillin 
screen agar (van Griethuysen et al., 1999). The positive results with the purified 
PBP2A protein indicates that the purified protein function as same as native PBP2A 
protein in MRSA and the activity of the protein is remain the same. Finally it can be 
confirmed that the cloning, over-expression and purification of the biologically 
active PBP2A protein was possible and will be used in Chapter 5 and 6 to develop 
molecular probes.   
 
The purified soluble PBP2A protein has been used to develop PBP2A specific 
aptamer and peptide molecular probes to detect MRSA. The Ni-NTA beads were 
coated with His-tagged PBP2A protein. SELEX and the bio-panning assays were 
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This chapter investigates the development of aptamer bio-imaging probes to detect 
bacterial infection. Two different aptamer libraries have been used in this study and 
characterised the best library and the optimum selection buffer conditions for SELEX 
protocol.  Then the PCR conditions for the aptamer amplification have been 
optimised for the number of PCR cycles to have high yields of DNA and low non-
specific PCR amplifications. The preparation of ssDNA from the dsDNA PCR 
products were optimised using biotin labelled primers and streptavidin sepharose 
beads. SELEX protocols have been carried out on whole MRSA bacterial cells and 
PBP2A coated Ni beads to generate MRSA and PBP2A specific aptamer bio-
imaging probes. Fifteen rounds of SELEX were carried out against PBP2A coated Ni 
beads and five rounds of parallel SELEX  carried out on five different bacterial 
strains and A549 cells before Ion Torrent sequencing. The sequenced data have been 
analysed and overlapping sequences between bacteria eliminated to generate unique 
sequences for PBP2A and MRSA. Remarkably these two probes are 50% similar in 
DNA sequence. The PBP2A specific probe shows high specificity towards the 
PBP2A protein over other tested proteins such as FBS, BSA and trypsin in Ni beads 
assay. It also binds to MRSA but shows non-specific binding to other bacterial 
strains in similar manner. MRSA probe shows higher binding capacity towards 
MRSA bacteria over the rest of the bacteria tested. Aptamers show no cellular 
toxicity at 50 µM concentration on 3T3 cells and show potential in-vivo applications. 
MRSA and PBP2A specific aptamer probes were not antibacterial according to 
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5.2. Designing of Aptamer libraries 
 
Aptamers are single stranded DNA or RNA molecules. The length of the molecules 
are variable, typically <100-mer long. In this study eight DNA aptamer libraries have 
been tested. They were made up of two main libraries termed G and M with two 
different primer binding sites. Each G and M library had four sub groups having 
different lengths of variable regions of 30 and 40 nucleotides (shown as -30N- and -
40N-) in the Table 5.1 and Figure 5.1, including G-quadruplex (shown as -GGG-) 
where guanines are located at fixed positions in the variable regions. The prime 
objective of having different libraries is to give higher diversity within the aptamer 
libraries for SELEX protocol. I designed the primer binding sequences for library G 
and library M primer sequences were taken from previous publication (Sefah et al., 
2010). 
 
Table 5.1: Eight aptamer libraries used in this study. 
 
Variable region Library G 













-(30N)- G1 (74bp) M1 (66bp) 
-(40N)- G2 (84bp) M2 (76bp) 
-(NNGGNNNNNNGGNNNNNNG 
GNNNNNNGGNN)- 
G3 (74bp) M3 (66bp) 
-(NNNGGGNNNNGGGNNNNGG 
GNNNNGGGNNN)- 
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Primer sequences:  
Jck11GA- Forward-AminoMod 5’CTACACGACGCTCTTCCGATCT3’ 
Jck11GB- Reverse-biotin 5’ TGCTGAACCGCTCTTCCGATCT 3’ 
 
Jck10MA- Forward-AminoMod 5’ ATACCAGCTTATTCAATT 3’ 
Jck10MB- Reverse-biotin 5’ AGATTGCACT TACTATCT 3’ 
 
5.3. Agarose gel electrophoresis to visualise the aptamer libraries 
 
An agarose gel was run (4%) to visualise the designed aptamer libraries before 
(Figure 5.1.) and after PCR amplification. Agarose gel electrophoresis determined 
the length of the aptamer generated by each PCR round and visualised any non-
specific PCR products amplified during PCR. Agarose gel electrophoresis was 
performed as a quality control for each round of PCR amplification and after 










Figure 5.1: Agarose (4% TBE) gel electrophoresis image showing the products of the naïve eight 
aptamer libraries (1µl/ lane). G2 and M2 contained 40 nucleotides in the variable region whilst 
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Before the SELEX protocol, the libraries were PCR amplified using specific primers 
to determine the optimum PCR conditions for the full amplification of the libraries. 
Figure 5.2 shows the DNA gel after amplification of these libraries showing products 
double the size due to the dsDNA. The optimum PCR amplification used the 
following amplification conditions: hot start 95oC for 2 minutes, denaturation at 95oC 
for 30 second, annealing at 60oC for 30 second, extension at 72oC for 30 second and 










Figure 5.2: Agarose (4% TBE) gel electrophoresis image showing the PCR amplified G and M 
aptamer libraries (5µl/ lane). The negative control has been run with a template sequence and 
the remaining contained 0.1 µl of each ssDNA aptamer libraries (100µM). 
 
5.4. Study of different buffers on the efficiency of SELEX protocol 
 
After optimising the PCR conditions to amplify the aptamer libraries, optimisation of 
selection buffers were studied. Aptamer binding capacity may vary depending on 
buffer components such as pH, solutes conditions (osmolality) and different buffers 
have been used for SELEX screening in different studies. Experiments were 
designed to evaluate how different buffers reacted with the libraries. False positive 
and false negative results occurred under poor buffer binding conditions. Library G 
and M were utilised in this experiment and selection was carried out with bacteria 
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1. PBS (with Ca+2 and Mg+2) 
2. Buffer B (Tris–HCl-25 mM, KCl-50 mM, NaCl-200 mM, EDTA-0.2 mM, 




All of these alone were not optimal giving false positive results (without 1% BSA: 
Data are not shown). PBS and Buffer B gave the most promising results. The 
addition of 1% BSA further reduced the non-specific binding of aptamer to the 
eppendorf tube and optimised the SELEX procedure. Figure 5.3 shows the 
combination of experimental conditions carried out to evaluate the suitability of 














Figure 5.3: Agarose (4% TBE) gel electrophoresis image showing the PCR amplified G and M 
aptamer libraries after first round of SELEX. Lane 9 and 10 represent G and M negative 
controls. Two bands of PCR products show non-specific amplification. 
 
According to the above Figure 5.3, lane 3, 4, 7 and 8 shows PCR products indicating 
that the aptamer can bind to the walls of eppendorf tubes (used eppendorf low 
binding tubes) non-specifically (control) and may give false positive bands. However 
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selection buffer. The non-specific binding of aptamers to non-target objects can be 
reduced by increasing BSA concentrations up to 1% in the selection buffers of Buffer 
2 and PBS (Figure 5.3). These results indicate that the best binding buffer for 
bacterial cell SELEX is PBS with 1% BSA. In addition the G library showed lower 
false positive binding. Therefore the rest of the SELEX studies have been carried out 
using the G library. 
 
5.5. Determination of the number of PCR cycles that yields enough DNA 
without nonspecific amplification 
 
Amplifying nonspecific DNA during the PCR amplification is a major problem in 
SELEX protocol and low PCR cycles also give low yields of DNA for further 
SELEX rounds. Therefore PCR conditions were optimised to have high yields of 
DNA and low non-specific DNA during PCR amplification. To determine the 
number of PCR cycles the library was amplified for three different PCR cycles 10, 
15 and 35 (Figure 5.4). The results show that the number of PCR cycles directly 
proportional to the number of nonspecific PCR products. The results suggest that this 
can be minimised by keeping the number of PCR cycles to 10 while still generally 











Figure 5.4: Agarose (4% TBE) gel electrophoresis image showing the products of the various 
PCR cycles (10, 15 and 35) of selected DNA library amplification. Lane 1- DNA ladder; Lane 2- 
10 PCR cycles; Lane 3- 15 PCR cycles; Lane 4- 35 PCR cycles. More than one band of PCR 




Chapter 5:   Aptamer bio-imaging probe development 
5.6. Preparation of ssDNA from PCR products 
 
It is an important step to prepare ssDNA from the dsDNA for further SELEX cycles. 
Selected ssDNA pools were amplified using biotin labelled reverse primer and the 
forward primer. The PCR products were incubated with streptavidin sepharose beads 
suspension. This allows dsDNA to bind to sepharose beads forming an interaction 
between streptavidin and biotin. Then increasing the pH by adding 200 mM NaOH 
allows the separation of the two strands leaving the biotin labelled ssDNA strand 
behind. The supernatant of the non-biotin labelled (forward primer amplified strands) 
ssDNA were collected by centrifugation at 13,000rpm for 1 minute and diluted into 1 
ml of PBS-T, containing 10 µl of 200 mM monobasic phosphate buffer to adjust the 
pH to 7.5. Finally, the material was heated to 95°C for 10 minutes then immediately 
placed at 4°C until the next round of SELEX. The purified ssDNA samples were run 













Figure 5.5: Agarose (4% TBE) gel electrophoresis image showing the PCR products before and 
after ssDNA preparation. Each lane contains 5µl of DNA samples. In the gel circle shows the 
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5.7. Experimental design of the SELEX procedure 
 
After optimising PCR conditions including 10 PCR cycles, PBS as SELEX buffer 
and ssDNA preparation all these optimum conditions were utilised to perform 
SELEX on MRSA and PBP2A purified protein. The main objective of these 
experiments was to develop MRSA specific aptamer probe. To achieve these goals 
two approaches were developed.  
 
A) Whole bacterial cell SELEX-against MRSA 
B) Purified protein SELEX-against MRSA specific cell division protein PBP2A 
(see chapter 4) 
 
The whole bacterial cell SELEX was successfully carried out in previous 
publications using counter selection against other bacteria to reduce the nonspecific 
binding. However MRSA specific aptamer probes have not yet been discovered 
according to the recent publications (Cao et al., 2009). Therefore a novel approaches 
where no counter selection was involved during the SELEX procedure was used. 
This also reduced the number of SELEX cycles minimising errors during PCR 
amplification and mishandling samples. In my experimental procedure five rounds of 
SELEX were carried out independently against MRSA (ATCC252), MSSA (ATCC 
25923), PAO1-Pseudomonas, Kebsiella pneumonia, Escherichia coli (ATCC 25922) 
and eukaryotic cells A549. This will generate aptamer against individual bacteria and 
eukaryotic cells but they were not specific due to lack of counter selection. These 
ssDNA aptamers were sequenced separately using the Ion Torrent sequencing 
method. Then the elimination of non-specific aptamers was carried out at sequenced 
level where the sequenced data was analysed and common sequences shared with the 
other bacteria were eliminated, resulting in the MRSA specific aptamer molecules.    
 
The second approach was carried out using purified PBP2A protein coated Ni-NTA 
beads where 15 SELEX rounds were successfully carried out before Ion Torrent 
sequencing. Since this approach is on purified protein the counter selection step was 
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not performed against any bacteria involved. Agarose gel was run to quantify and 












Figure 5.6: Agarose (4% TBE) gel electrophoresis image showing the final PCR products before 
sending for Ion Torrent sequencing. Two bands of DNA represent the combination of 74bp and 
84bp aptamer G-libraries also indicate the concentrations of DNA present in the sample. MR-
MRSA; MS-MSSA; PA-PAO1 Pseudomonas; EC-E.coli; KL- Kebsiella pneumonia; 15-PBP2A 
15 rounds of SELEX; A5-A549 eukaryotic cells. 
 
5.8. Ion Torrent sequencing and data analysis 
 
Seven DNA samples were sent to The Institute of Genetics and Molecular Medicine, 
Western General Hospital, Edinburgh, UK for sequencing. The first step in the 
sequencing was to generate a library of DNA fragments flanked by the Ion Torrent 
adapters. This was done by adding the adapter sequences during PCR by designing 
PCR primers with the Ion Torrent adapter sequences at the 5’ end. These PCR 
products were run on a gel to visualise the fragment size for sequencing (Figure 5.7). 
The barcoded samples were analysed on the Agilent bio analyser, which confirmed 





 MR          MS           PA           EC            KL            15            A5 
























Figure 5.7: Electropherogram Summary from Agilent bio analyser; the graphs show (blue 
circles) the size of the DNA fragments after adding adapter sequences and the gel 
electrophoresis showing the dsDNA corresponds to the electropherogram. MR-MRSA; MS-
MSSA; PA-PAO1 Pseudomonas; EC-E.coli; KL- Kebsiella pneumonia; 15-PBP2A 15 rounds of 
SELEX; A5-A549 eukaryotic cells. 
 
Following sequencing the summary results generated the number of bases, reads and 
means of the read length. Table 5.2 shows the summary of the Ion Torrent 
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Table 5.2: The summary of Ion Torrent sequencing showing the number of bases, 
reads and mean read lengths. MR-MRSA; MS-MSSA; PA-PAO1 Pseudomonas; EC-









The quality of the DNA was analysed by the Agilent Bioanalyzer, which provided 
that the size of the DNA, details of contamination and the concentration of the 
samples. According to the data, all the DNA samples used in this study were around 
150bp size and intact DNA was observed on both the gel electrophoresis and 
electrophotogram, indicating that there is no DNA degradation or contamination 
(Figure 5.7). After passing through the quality checks of the DNA samples, they 
were run through Ion Torrent sequencing to obtain the DNA sequences. 
 
The Ion Torrent summary data are shown in the table 5.2 and it shows the statistical 
data of the sequenced samples. The data show that the number of bases, reads and 
mean length of the each sample. The expected mean length of the sequenced DNA 
should be around 150 bp as observed in the Agilent Bioanalyzer because the quality 
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of the samples were already analysed and checked before running the Ion Torrent 
sequencing. However, Ion Torrent sequencing data show that the 7 samples are very 
short lengths (less than 50 bp). This may have been caused by having sequences 
which were difficult to amplify due to long homo-polymer stretches or high GC 
content (Table 5.2). The failure of getting full length of the sequence will lose the 
data required for the analysis and predict the possible aptamer probe.  
 
The summary report (Table 5.2) detailed barcodes aligning with each sample. 
Sample 6 which corresponds to PBP2A (barcoded with barcode 31) looks much 
better than the other 6 samples (there are far fewer short reads). The summary report 
indicated that the number of polyclonal reads was very high (61%), this occurs when 
the software detects that there are two templates per sphere and not just one. Ideally 
we would usually expect this number to be around 30%. The controls indicate that 
there isn’t a problem with the sequencing run itself, other than the high polyclonality. 
 
After removing the truncated primers, the data have been analysed to identify more 
reads by looking for truncated primers which may have been trimmed by the 
software. The analysis was performed using TextWrangler, (text editor software) and 
two probable aptamer probes named PBP2A specific and MRSA specific were 
generated (Figure 5.8). 
 
Sequence alignment between two aptamer probes (randomised region): 
 

















Underlined sequences are the primer binding sites of the probes. 
 
The figure 5.8 shows the hairpin structures of the aptamer probes. Their minus Gibbs 
free energy (∆G) indicates higher stability and higher melting temperatures also 
















 ∆G (kcal/mole) Tm (oC) 
PBP2A-probe -14.35 64.4 
MRSA-probe -15.84 60.7 
 
Figure 5.8: The hairpin structures of MRSA and PBP2A aptamer probes. The minus Gibbs free 
energy (∆G) indicates that the hairpin structures of aptamer probes are stable and the melting 
temperatures are well above room temperature.   
PBP2A-aptamer 
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5.9. Evaluation of PBP2A-aptamer probe binding in-vitro; Ni-NTA beads 
assay 
 
The two lead aptamer probes were re-synthesised with 5’ FITC modification form 
SIGMA-ALDRICH. For the assays, FITC modified PBP2A-aptamer probe was used 
to evaluate specificity of the aptamer candidate on different proteins including 
PBP2A protein. This assay was carried out as previously described in the SELEX 
protocol to develop PBP2A specific aptamer probe. Ni-NTA beads (300 µl) were 
incubated with 100 µg/ ml of PBP2A, BSA, FBS and trypsin separately and unbound 
proteins washed away. These protein coated beads were used as target molecules for 
the PBP2A-aptamer probe and efficacy of binding evaluated by using plate reader, 
confocal microscopy and confocal laser endomicroscopy.   
 
The different imaging modalities were used to quantify and image the PBP2A-
aptamer probe. The plate reader data showed that the PBP2A protein coated beads 
gives much higher fluorescence reads at 488/520 compared with the other three 
proteins and naked Ni beads. This suggests that the PBP2A-aptamer probe binds to 
PBP2A protein at higher efficacy than the BSA, FBS and trypsin (Figure 5.9). 
Another way of analysing this data is to visualise these beads under the confocal 
microscope (Figure 5.9). The images clearly indicate that only the PBP2A coated Ni 
beads are fluorescently labelled with the PBP2A-aptamer probe showing the 









































Figure 5.9: Ni-NTA protein binding assay shows that the PBP2A-aptamer is more specific to 
PBP2A protein compared with the BSA, FBS and Trypsin. A. Transmitted image of PBP2A 
protein coated beads; B. Fluorescent image of PBP2A coated beads; C. Transmitted image of 
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The laser endomicroscopy (Cellvizio) experiments were carried out to prove that the 
FAM labelled aptamer can be used in parallel with the clinically approved Cellvizio 
imaging platform. To achieve this Ni beads were visualised using the Cellvizio mini 















Figure 5.10: Ni-NTA protein binding assay; Cellvizio image analysis. Fluorescent image of the 
sample and the fluorescent intensity of the image. The reduced fluorescent shift to the right on 
the histogram indicates that the FBS beads are not labelled with the PBP2A-aptamer probe. 
 
5.10. Evaluation of MRSA-aptamer probe binding in-vitro Ni-NTA bead assay 
 
The Ni-NTA beads assay was carried out to evaluate probe binding capacity to other 
proteins including PBP2A protein (Figure 5.11). The results indicated that the 
MRSA-aptamer probe also binds to PBP2A protein. This is not unexpected as the 
























Figure 5.11: Ni-NTA protein binding assay shows that the MRSA-aptamer binds to PBP2A 
protein at higher rate compared to FBS and BSA. The confocal image shows that the PBP2A 
coated Ni beads are labelled with MRSA-probe. 
 
5.11. Evaluation of MRSA and PBP2A-aptamer probe binding in-vitro 
bacterial binding assay 
 
The ultimate objective of developing these probes was to detect MRSA specifically 
over other bacterial species. To assess the specificity of these probes, bacterial 
binding assays were carried out and bacterial cells were analysed using flow 
cytometry (Figure 5.12). A panel of bacteria were used at 108 cfu/ml bacteria and 
probes at 100 nM in PBS.  Reassuringly the MRSA-probe showed a trend for higher 
affinity to MRSA compared with the rest of the bacterial panel, yet was not 
significantly increased compared to some strains.   The PBP2A-probe showed no 
specificity towards MRSA though it shows very high specificity to PBP2A protein in 
Ni-NTA beads binding assay. This may be the fact that the aptamer has been 
developed against the whole protein and it may share the similar binding sites with 
the other bacterial proteins as well.  
 
 




















































Figure 5.12: Flow cytometry data showing percentage increased in mean fluorescence intensity. 
Top graph shows the MRSA-probe and the bottom graph shows the PBP2A-probe. MRSA-
probe shows higher binding to MRSA bacteria compared to the rest of the bacteria. However 
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5.12. Aptamer cytotoxicity studies on 3T3 cells 
 
This assay was carried out to investigate aptamer toxicity on mammalian cell line to 
study the feasibility of using these probes in-vivo in murine models. The 3T3 cells 
have been used as a standard cell line to study the cellular toxicity of potential drug 
targets. Mouse 3T3 cells were cultured in 96 well plates overnight and incubated 
with aptamer and H2O2 at 50 µM concentrations separately and the control cells with 
normal cell culture media. After 24 hours incubation, the ATP activity was 
quantified. The aptamers demonstrated no celleular toxicity at the concentrations 
used (Figure 5.13). However more extensive studies are necessary before a 




















Figure 5.13: Aptamer toxicity: The graph shows the ATP derived luminescence after incubation 
for 24 hrs. Below are the light microscopy images of healthy and non-viable 3T3 cells (Panels 
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5.13. Study of aptamer as a therapeutic agent for bacterial infection 
 
Aptamers can be used as a therapeutic agent if they bind to bacterial essential 
proteins leading to killing of bacteria. The protein PBP2A is an essential cell division 
protein in MRSA and it is a potential antibacterial drug target. Blocking its function 
will prevent bacterial cell division. Therefore assays have been conducted to study 
MRSA growth inhibition by PBP2A-aptamer probe and the MRSA-aptamer probe. 
The binding of MRSA-aptamer probe to MRSA essential proteins was evaluated by 
this assay since it has been developed against whole bacterial cells and there is a 














Figure 5.14: MRSA growth inhibition assay in MHB. 1 µM of aptamer has been used for this 
assay in MHB (100 µl) and 106 cfu/ ml bacterial. The growth of bacteria was assessed by 
measuring the absorbance at 600 nm for 16 hrs. The data shows that there is no effect on MRSA 








MRSA growth inhibition assay in MHB
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5.14. Bio-distribution and bio-availability of aptamer in mouse model 
 
Mice have been used to study the bio-distribution and bio-availability of the 
aptamers. Naïve aptamer library was amplified using Cy5.5 conjugated primers and 
aptamer were delivered into mice. Intratracheal (i.t.) delivery shows the aptamers are 
localised in the lung at 20 minutes. In contrast to i.t delivery, intravenous (i.v.) 
delivery shows the distribution of aptamer in the mouse body and higher 
concentrations are present in the kidneys, liver and bladder. This work revealed that 


















Figure 5.15: Optical images of mice injected with Cy5.5 conjugated aptamer library. 125µg/mice 
of Cy5.5 conjugated aptamer were injected. The images show the distribution of Cy5.5 
conjugated aptamer in-vivo mouse model after 20 min (panel A) and 72 hours (panel B).  Organs 
were removed and imaged and then digested and PCR amplification using aptamer specific 
primers to confirm aptamer distribution. Organs are numbered and numbers ascribed to gel 
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5.15. Discussion  
 
This chapter described efforts to develop two types of aptamer probes to detect 
MRSA; (1) whole MRSA cell SELEX aptamer probe, and (2) purified PBP2A 
protein specific aptamer probe. For the first approach five rounds of bacterial cell 
SELEX were carried out on different gram positive and negative bacteria separately 
using the aptamer library G. Then ion torrent sequencing was carried out separately 
and careful analysis of the sequenced results eliminated the common conserved 
sequences among bacterial species, hopefully predicting the MRSA specific aptamer 
sequences unique to the MRSA. For the PBP2A specific aptamer probe development, 
SELEX has been carried out 15 times on purified PBP2A protein (purified the 
PBP2A protein in the previous chapter) and the conserved sequences were elucidated 
from the sequenced data. The probes were analysed using in-vitro assays to evaluate 
the binding affinity towards the purified protein and MRSA. 
 
Five prime (5’) FITC labelled PBP2A and MRSA specific aptamer probes were 
evaluated using in-vitro assay, PBP2A coated Ni beads assay and bacterial binding 
assay. The results show that the two probes bound to PBP2A protein at a much 
higher rate than the FBS, BSA and trypsin. FITC labelled PBP2A aptamer probe 
binding to the purified PBP2A indicates that the aptamer probe shows higher 
specificity towards the PBP2A protein compared to the rest of the proteins tested. In 
a similar manner the MRSA specific probe also shows a trend for higher binding 
towards the PBP2A. Careful analysis of these probes sequences indicated that they 
are 50% similar to each other. Bacterial binding assays were performed to evaluate 
the binding efficacy of these probes towards MRSA (Figure 5.12). However, these 
probes demonstrated no specificity towards MRSA in bacterial binding assays 
carried out. This may be due to the non-specific binding of the probes towards the 
other elements on the rest of the bacteria tested. The in-silico counter selection has 
not been successful, likely due to the far fewer short reads at the ion torrent 
sequencing (see Table 5.2). Shorter sequences may have lost the important and key 
potential aptamer sequences to be determined.  Likewise there are several factors that 
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may contribute to the unsuccessful SELEX and the development of aptamer probes 
(Lakhin et al., 2013).   
 
There is another possibility that the PBP2A specific probe may not recognise MRSA 
due to the low level of PBP2A expression and not sufficient enough protein to bind 
the aptamer probe. This could be investigate in the future studies by culturing the 
MRSA at sub-inhibitory oxacillin concentrations to induced PBP2A expression in 
MRSA and run the binding assay (Rudkin et al., 2014). This may increase the higher 
binding ability to MRSA by the PBP2A specific probe.  
 
Table 5.3 shows that the relative binding pattern of MRSA specific aptamer 
developed by Turek et al., (2013) using fixed bacterial cells. This table summarizes 
the results obtained with the binding assays on clinical strains of methicillin-resistant 
Staphylococcus aureus (MRSA), S. aureus and E. faecalis bacteria. Ten clinical 
strains were tested against the four aptamers developed by them (Table 5.3). 
DTMRSA1 and DTMRSA3 showed the best specificity and appeared to be the best 
candidates for MRSA treatment investigation, DTMRSA1 being the best one of the 
two, while DTMRSA2 and DTMRSA4 bound to all three types of clinical bacteria 
strains. Consequently, the binding ability of these four aptamers was compared in the 
context of different clinical MRSA strains, as well as S. aureus and E. faecalis (Table 
5.3). They observed that the selected aptamers bound to all MRSA clinical strains 
tested except DTMRSA1 with strain MRSA 7. This also indicates that all MRSA 
clinical strains are not sharing the similar surface properties. MRSA, S. aureus and 
Enterococcus are all gram-positive bacteria. Based on their similarities, some 
common binding can be expected by the commonality of proteins among the strains, 
whereas others are more specific to each type of bacterium. DTMRSA1 and 
DTMRSA3 show the best specificity and therefore appear to be the best candidates 
for MRSA treatment investigation, DTMRSA1 being the best one of the two, while 
DTMRSA2 and DTMRSA4 bind to all three types of bacteria. But they have not 
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They also showed that the DTMRSA1-4 collectively represents a powerful tool by 
which to study the membrane structure of MRSA, as well as develop potential 
treatment modalities to combat this pathogen.  
 
Table 5.3: Relative binding of the selected aptamers to various clinical cell lines 
(Turek et al., 2013) 
 
Clinical strains DTMRSA1  DTMRSA2 DTMRSA3 DTMRSA4 
MRSA 2    +++ ++++ +++ ++++ 
MRSA 4    +++ +++ +++ ++++ 
MRSA 6     ++++ ++++ +++ ++++ 
MRSA 7     - ++++ +++ ++++ 
S. aureus 164     - ++++ + +++ 
S. aureus 165     - ++++ + +++ 
S. aureus 166     - ++++ + +++ 
E. faecalis 43    - ++++ + +++ 
E. faecalis 44     - ++++ + ++ 
E. faecalis 45     - ++++ + +++ 
(-) no binding; (+) 0%-25%; (++) 25-50%; (+++) 50%-75%; (++++) 75%-100% 
 
When aptamer technology was first developed almost a quarter of a century ago, a 
suggestion was immediately put forward that it might be a revolutionary solution to 
solve many problems associated with diagnostics and the therapy of diseases. 
However, multiple attempts to use aptamers in practice, although sometimes 
successful, have been generally much less efficient than had been expected initially 
(Lakhin et al., 2013).  
 
To carry out SELEX protocol in this study, two different libraries (G and M) have 
been used initially, with primer binding site variation.  Library G was chosen for 
further studies as it demonstrated reduced non-specific amplification of DNA (Figure 
5.3) with the buffer conditions. To increase the diversity of the aptamer libraries, 
different lengths of the variable region were incorporated (30 and 40 bp) (Table 5.1) 
as previous studies have used variable lengths and no fixed lengths have been 
recommended (Sefah et al., 2009; Shangguan et al., 2006). Some of the libraries also 
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possessed G-quadruplex (shown as -GGG-) regions to increase the stability of the 
aptamers and increase the diversity. A significant proportion of these 
oligonucleotides display G-quadruplex structures that enable molecular recognition 
of their ligands. G-quadruplex structures couple a common scaffold to varying loop 
motifs that act in target recognition (Tucker et al., 2012).  
 
Different buffer conditions were evaluated with the two libraries to establish the 
optimum conditions for the SELEX protocol, minimising the non-specific binding 
and amplification of DNA. Modifying and optimising the selection buffer conditions 
may counter-act or otherwise stabilise the interactions between the target and the 
unselected aptamer pool. With a negatively charged target, decreasing the pH below 
a target’s isoelectric point (pI) will neutralise the negative charge and encourage the 
binding of the negatively charged pool (Stovall et al., 2004).  
 
The SELEX buffer conditions may also vary with monovalent salt(s) identity; 
monovalent salt(s) concentration, and divalent salt identity, divalent salt 
concentration, buffer identity, buffer concentration, and pH. The optimised buffer 
conditions likely increase the probability of a successful selection and therefore 
promote higher ratios of successful aptamer selections against a variety of targets. 
Therefore different buffer conditions were selected and tested on two different 
aptamer libraries with and without bacteria. The best buffer condition was selected as 
PBS (Park et al., 2012; Sosic et al., 2011) with Ca+2 and Mg+2 to eliminate the non-
specific binding and PCR amplification. Throughout the experimental protocol, I 
used DNA low binding eppendorf tubes to eliminate non-specific binding of DNA 
onto the wall of tubes. The BSA concentration in the selection buffer (PBS with Ca+2 
and Mg+2) was increased to 1% to minimise the non-specific binding and increase the 
stringency of the selection.  
 
The number of PCR cycles were adjusted to 10 to get optimum PCR products but 
with low non-specific PCR amplification (Sefah et al., 2010). PCR amplification was 
carried out by using biotinylated primers and the PCR products were incubated with 
streptavidin sepharose beads suspension allowing dsDNA bind to sepharose beads 
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forming interaction between streptavidin and biotin. The increased pH (200 mM 
NaOH) allows the separation of the two strands leaving the biotin labelled ssDNA 
strand behind. The supernatant of the non-biotin labelled (forward primer amplified 
strands) ssDNA have been collected by centrifugation and diluted into 1 ml of PBS-
T, containing 10 µl of 200 mM monobasic phosphate buffer to adjust the pH to 7.5. 
Finally, the material was heated to 95°C for 10 minutes then immediately placed at 
4°C until the next round of SELEX (Murphy et al., 2003). This allows the generation 
ssDNA after PCR amplification and materials for the following SELEX round.   
 
Previous in-vitro assays showed that the two probes were binding to the PBP2A 
protein in a similar manner despite showing non-specific binding to other bacteria in 
bacterial binding assays. However binding of aptamer probes can block the function 
of a protein, e.g. pegaptanib sodium (Macugen) an RNA aptamer directed against 
vascular endothelial growth factor (VEGF)-165, inhibits VEGF-mediated cellular 
responses (Jellinek et al., 1994; Ng et al., 2006). Therefore a growth inhibition assay 
evaluated the effect of the aptamer probe on MRSA killing or the growth inhibition. 
The results indicated that the binding of low concentrations of aptamer to MRSA 
showed no bactericidal or bacteriostatic effect.  
 
Laboratory mice have been used to study the bio-distribution and bio-availability of 
Cy5.5 conjugated aptamer library. The results indicate that the aptamer labelled with 
Cy5.5 is a very good optical molecular probe use in the mouse model since the 
distribution of the aptamer can be detected in in-vivo mouse model.  
 
In conclusion, the PBP2A specific aptamer molecular probe was able to show high 
specificity in in-vitro Ni-NTA beads assay. However, both PBP2A and MRSA 
aptamer probes generated were not specific or efficient enough to detect MRSA over 
other bacteria in bacterial binding assay. This may be due to the several factors 
described above.  
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The phage display technique has been used to develop peptide probes to detect 
MRSA using peptide library (Ph.D. 12) from New England Biolabs (NEB). This 
library consists of 109 different peptide clones expressed on its phage virus particles. 
Whole bacterial cells of MRSA and PBP2A protein coated Ni beads were incubated 
separately with the pool of the phage display library to facilitate binding. The 
unbound phage was washed followed by elution of specifically bound phage by 
disrupting the binding interactions between the phage and the target. The eluted 
phage pools were then amplified in-vitro and the process repeated, resulting in 
stepwise enrichment of the phage pool in favour of the tightest binding sequences 
towards whole bacterial MRSA and PBP2A purified protein. After 3 rounds of bio-
panning and amplification, 120 clones were characterized by DNA sequencing. The 
resulting DNA sequences were translated into an amino acid sequences using 
FinchTV software tool and the corresponding 12-mer peptide sequences were 
analysed using ClustalW online tool. Two different peptide sequences were 
identified as PBP2A specific peptide GLHTSATNLYLH and MRSA bacterial 
specific peptide GWTSVSVHIRGG. For further analysis FAM was conjugated to 
these peptide sequences and binding affinities were evaluated in-vitro using bacterial 
binding selectivity assays. Flow cytometry and confocal microscopy were used to 
evaluate the peptide binding efficacy to bacteria. Antibacterial activity of these 
peptides was also studied on MRSA and MSSA. The developed peptides do not 
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6.2. Introduction 
 
The microbial cell surfaces consist of unique molecular compositions made of lipids, 
carbohydrates and proteins. These molecules may alter the mechanism by which 
peptide molecules might interact with an epitope or receptor, thereby providing 
unique binding sites for peptide interaction (Yarbrough et al., 2011). Phage-
displayed peptides have been successfully used to identify Salmonella typhimurium 
(Goldman et al., 2006; Olsen et al., 2006; Sorokulova et al., 2005), Escherichia coli 
using streptavidin conjugated quantum-dots (Edgar et al., 2006), use of lytic phage 
for specific capture and detection of S. aureus (Balasubramanian et al., 2007) and 
Bacillus anthracis (Sainath Rao et al., 2010). 
 
Phage display has been shown to be a powerful tool to study protein-protein or 
protein ligand interactions (Derda et al., 2011). In this study a commercially 
available random phage-display library was screened against MRSA cells and 
purified PBP2A protein to identify peptides binding to the bacteria. Elucidating 
specific peptides that bind to MRSA can be used as molecular probes to detect 
bacteria and study the antibacterial activity. This study used a 12-mer peptide library 
against MRSA since most of the previous studies used 12-mer library from New 
England Biolabs (NEB).  Bio-panning experiments have been carried out as 
described in the material and method section according to the commercial supplier 
(NEB). The counter selections on MSSA and PAO1 were carried out before bio-
panning with PBP2A coated Ni beads and MRSA whole bacterial cells. The counter 
selection removed any peptides binding to MSSA and PAO1 bacterial strains (Figure 
6.1). Then the supernatant contains unbound phage used for the bio-panning 



















Figure 6.1: This diagram shows the experimental design; four different sets of bio-panning were 
carried out separately using 12-mer peptide library. 
 
The 12-mer phage-displayed peptide library from NEB was used for bio-panning 
against MRSA and PBP2A. In this library, five copies of peptides with 12 amino 
acids were displayed by the phages. The peptides were encoded by random foreign 
DNA insertion in the phage genome. They were linked with phage coat protein pIII 
via a short linker sequence, which was Gly-Gly-Gly-Ser. The library contained 1 x 
1013 plaque forming units per millilitre (PFU/ml) with 1.28 x 109 complexes. The 
library was stored at -20ºC and thawed on ice before being used to avoid heat shock 
reactions. 
 
6.3. Selection of Phage-Displayed Peptides Binding to MRSA and PBP2A 
 
In biopanning, phage titer was determined by counting the number of blue plaques 
formed by individual phage on LB/IPTG/Xgal plate (Figure 6.2). The blue plaque 
forming units indicate that the affinity-selected phages from the bio-panning were 
derived from the library with special lac Z gene insertion. At the same time, the titer 
plate suggested that the phage eluated had no contaminant as no colourless plaques 
were seen. 
 
After three rounds of bio-panning against MRSA and PBP2A protein, 120 phage 
infected bacterial clones were randomly selected for sequencing from each group 
(Figure 6.2). Blue colonies were selected ‘randomly’ but only well isolated and blue 
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colonies were selected to achieve zero contamination for sequencing. Single stranded 
phage DNA was prepared for sequencing and a DNA gel was run to confirm the 
correct size of the plasmid and to determine the purity of the colonies selected 














Figure 6.2: Phage titer of eluted phage on IPTG/Xgal Agar plate. The blue colour indicated 
phage infected bacteria (black arrow). These colonies were selected for sequencing after three 









Figure 6.3: Agarose (1% TBE) gel electrophoresis image showing the phage DNA before 
sending for Sanger sequencing. The size of the viral DNA was correct size. Control DNA, 
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According to Table 6.1, the output titer, which was also the phage eluate titer, was 
ranged in between 105-107 PFU/ ml over the three rounds of biopanning in both 
probe screening. The eluted phage from the first round of biopanning had the lowest 
output titer with 1.3 x 105 PFU/ ml while the eluted phage from the third round of 
biopanning had the highest output titer which is 1.6 x 106 PFU/ ml in MRSA probe 
development. This indicated that the output titer increased from the first round to the 
third round of biopanning. The similar results were observed in PBP2A probe 
development where the output titer increased from 3.0x10-4 PFU/ ml to 1.8x10-3 PFU/ 
ml from first round to third round of biopanning.   
 
The yield of selection (Table 6.1) of phages for each round of biopanning was 
calculated as the percentage of the output titer divided by the input titer. It was 
maintained in between the percentage of 10-3and 10-5. This indicated that only certain 
numbers of the input phage was being selected in the biopanning. The yield of 
selection was increased from the first round (1.3x10-5%) to the third round (1.6x10-4 
%) of biopanning in MRSA probe development. The yield of selection in PBP2A 
probe development also increased from the first round (3.0x10-4%) to the third round 
(1.8x10-3%) indicating that there was an enrichment of peptide sequences during the 
screening. In short, the highest yield of selection was observed at the third round of 
biopanning. A total of hundred and twenty individual phage clones were randomly 
selected for sequencing. 
 
Table 6.1: Yield of selection for three rounds of biopanning. 
Rounds of  
biopanning 
















Yield of  
Selection 
(%) 
1 1x1012 1.3x105 1.3x10-5 1x1012 3x106 3.0x10-4 
2 5x1011 4.8x105 9.6x10-5 1.8x1012 4x106 2.2x10-4 
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6.4. Sequencing results and data analysis after three rounds of enrichment 
 
The Sanger sequencing generated 40 individual results for each four groups of bio-
panning (Figure 6.1). The resulting DNA sequences were translated into an amino 
acid sequences using FinchTV software tool (the DNA sequences are not listed) and 
the corresponding 12-mer peptide sequences were analysed by ClustalW online tool. 
The analysis data are shown below in four groups (Figure 6.4, 6.5, 6.6, 6.7. and 


















Figure 6.4: ClustalW analysed data; 1. Clones from 41 to 60; MRSA with counter selection. The 

























Figure 6.5: ClustalW analysed data; 2. Clones from 61 to 80; PBP2A with counter selection. The 
















Figure 6.6: ClustalW analysed data; 3. Clones from 81 to 100; MRSA no counter selection. The 
























Figure 6.7: ClustalW analysed data; 4. Clones from 101to 120; PBP2A no counter selection. The 
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Table 6.2: The table shows the peptide sequences of four different bio-panning 
procedures. The high to low frequency peptides have been identified using the 
ClustalW analysis from the 40 different colonies.  
 
Sequencing sets Peptide sequences Frequency 



























Table 6.3: The summary table shows the final peptide sequences for MRSA and 
PBP2A bio-panning experiments with and without counter selection generated 
similar peptide sequences.   
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6.5. Bacterial biding assay 
 
In-vitro bacterial binding assays were carried out to investigate the peptide probe 
binding efficacy. MRSA and PBP2A probes were derivatived to detect MRSA over 
other gram positive and negative bacteria. All peptides were FAM labelled. Peptide 
probes were dissolved in DMSO (1 mM) and the working concentration was 10 µM 
in PBS. After incubation with the peptide probes, bacterial cells were washed with 
PBS and binding assessed using flow cytometry and confocal microscopy (Figure 














Figure 6.8: Flow cytometry data showing the FAM-AM3 peptide binding to gram positive 
bacteria. 10 µl of peptides were incubated with 108 cfu/ml bacteria at 37oC for 30 minutes in 
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Figure 6.9: Flow cytometry data showing the AM3 peptide binding to gram negative bacteria. 
10 µl of peptides were incubated with 108 cfu/ ml bacteria at 37oC for 30 minutes in PBS with 
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Figure 6.10: The mean fluorescent intensity of the flow cytometry data. AM3 peptide shows high 
mean fluorescent intensity with all bacteria while the rest of the probes show low intensity.  
 
Live confocal microscopic image analysis was carried out to investigate the binding 
of AM3 peptide to MRSA (Figure 6.11). The results indicate that the high signal 
coming from the AM3 peptide was due to the precipitation effect rather binding to 
the MRSA bacteria.  
 
Figure 6.11: Live confocal microscopic images showing the precipitation of the peptide probe 
AM3 in PBS incubated with MRSA. The precipitation of the probe is the result of false positive 
signalling given with the flow cytometry analysis. However other AM probes (AM1, AM2 and 
AM4) do not precipitate in PBS at 10 µM concentrations.    
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6.6. Discussion 
 
Phage display is a powerful tool for discovering ligands for various targets and the 
technology has been described since 1985. The technique has been used widely in 
basic and applied biosciences to study molecular biology mechanisms involving 
protein-protein (Sidhu et al., 2003) or protein to non-protein interactions (Yu et al., 
2009). A phage display library is a complex mixture of phage clones displaying 
random foreign peptides or protein domains displayed on the phage surface (Smith 
and Petrenko, 1997). Filamentous phages with displayed peptides fused to the N-
terminus of capsid proteins are typically used; however, several alternative phage 
display formats aiming to avoid the limitations of the conventional display system 
are also available. Commercially available phage display libraries based on 
filamentous phage M13 (Ph.D.TM-7, Ph.D.TM-12, Ph.D.TMC7C; New England 
Biolabs) or spherical T7 phage (T7Select®, Merck) are most commonly used 
(Bratkovič, 2010). Large phage populations are screened against target molecules or 
cells called biopanning to yield ligands that exhibit the desired target binding. Phage 
clones from the library are incubated with the immobilized target molecule or in 
solution. Nonbinding virions are removed by multiple washing steps and phage 
bound to the target are recovered by different elution strategies. A typical screening 
procedure involves several rounds of biopanning, until the phage pool is enriched in 
specific binding phage (Smith and Petrenko, 1997). 
 
In this study the Ph.D.TM-12 from New England Biolabs was used to derive MRSA 
and PBP2A specific peptides. A biopanning procedure was carried out in solutions 
for MRSA and PBP2A coated Ni-beads. Two sets of biopanning experiments were 
carried out and one set of biopanning was subjected to counter selection against 
MSSA and Pseudomonas (PAO1) to reduce the non-specific binding and the other 
one carried out without counter selection. Therefore four sets of enriched phage 
populations were generated for sequencing; 1) MRSA-without counter selection 2) 
MRSA-with counter selection 3) PBP2A-without counter selection 4) PBP2A-with 
counter selection. After three rounds of biopanning the enriched phages were 
amplified and sequenced after DNA isolation. Sanger sequencing has been carried 
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out at the University of Edinburgh, at the Gene Pool facility. The analysis of data 
was able to generate two different peptide sequences identifiable to biopanning for 
MRSA (GWTSVSVHIRGG) and PBP2A (GLHTSATNLYLH). These peptides were 
synthesised with a FAM conjugate including two control peptides, using solid phase 
synthesis at the Chemistry department, University of Edinburgh to assess the 
bacterial binding. The bacterial binding assay data showed that the peptides showed 
no binding to MRSA at 10 µM concentration.  
 
Binding success during the screening and the enrichment (first and second rounds of 
screening) was observed by calculating the yield of selections (Table 6.1) and it 
showed the enrichment of phage clones during the screening.  A decrease in titer 
from the input phages to the output phages indicates the selection of phages. The 
weak and non-specific binding phages which contribute mostly to the portion of 
input phages were being washed away during the biopanning. As shown in Figure 
6.1, a decrease in selection from the first to the second round of biopanning could be 
explained by the high portion of non-specific binding phages which were being 
washed away using the washing buffer with higher concentration of Tween-20 in the 
second round of biopanning. Upon each round of selection, the eluted phages were 
amplified prior to the subsequent round of biopanning, and this could increase the 
titer of specific binding phages that was used in later round of biopanning. The yield 
of selection that was increased from the second to the third round of biopanning 
indicates more phages were bound to the target bacteria in the later round of 
biopanning. Thus, it is assumed that the specific binding phage clones were enriched. 
As a result, the clones of phage-displayed peptides that were isolated from the third 
round of biopanning probably had the highest binding affinity and specificity 
towards the target MRSA and PBP2A. After the third round 120 randomly collected 
clones were sequenced to determine the peptide sequences. These were well isolated 
blue colonies to minimise the cross contamination with environmental M13-like 
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All peptide probes were N-terminus FAM conjugated probes where C-terminus was 
free. Since the synthetic peptide did not bind to the target, it is possible that the 
selected sequence requires additional elements from the adjacent spacer sequence for 
binding. During biopanning, the N-terminus of the selected peptide sequence was 
free; the C-terminus was fused to the phage. Furthermore, the C-terminal residue of 
the selected sequence did not have a free negatively charged carboxylate during 
panning. Therefore a simple synthetic peptide with a free carboxy terminus will 
introduce a negatively charged group at a position occupied by a neutral peptide 
bond during panning, which may completely abolish binding. When designing 
synthetic peptides corresponding to selected sequences, it is recommended to add the 
spacer sequence Gly-Gly-Gly-Ser to the C-terminus and aminating the C- terminal 
carboxylate to block the negative charge (Wu et al., 2010). During the chemical 
conjugation of the peptide to FAM, the C-terminal serine can be replaced with 
cysteine (if there are no other cysteines present in the sequence). As these 
recommendations are available in the NEB, the possible sequences can be 
resynthesized and reassessment of bacterial binding performed. 
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Chapter 7: Concluding remarks, limitations and future studies 
 
The increasing drug resistance among gram-positive bacteria is a significant problem 
because they are responsible for one third of nosocomial infections. Drug resistance 
in gram-positive organisms (i.e. staphylococci, pneumococci, vancomycin resistance 
in enterococci, and mycobacteria) has increased in the last 15 years (Johannsson et 
al., 2012; Robert et al., 2005). MRSA is one of the most frequently reported 
nosocomial pathogens in developed countries. MRSA infections are responsible for 
more deaths (20,000 deaths per year) in the U.S. each year than AIDS (Klein et al., 
2007). Therefore developing new antibacterial agents to interfere with unexploited 
bacterial molecular target(s) are important. 
 
Over the last decade there have been few novel antimicrobials reaching the 
marketplace. Linezolid was the first oxazolidinone antibacterial agent for treatment 
of gram-positive bacterial infections in 2000 (Manfredi, 2006). Linezolid was 
approved for the treatment of vancomycin resistant Enterococcus faecium infections, 
and S. aureus (Gales et al., 2006). Daptomycin is a cyclic lipopeptide antibiotic used 
in the treatment of certain CA-MRSA and HA-MRSA infections. It is worth noting 
that daptomycin can not be used for community associated pneumonia as it is 
inactivated by pulmonary surfactant (Anthony et al., 2008). Vancomycin remains the 
choice for the treatment of systemic infection caused by MRSA because it shows 
relatively safe profile and secondly it limited anti-MRSA regimens are available (the 
lack of other approved alternatives). However, the oral absorption of vancomycin is 
very low, and thus, vancomycin must be administered intravenously to control 
systemic infections (Scott, 2007). Thus, treatment of MRSA infection with 
vancomycin can often be complicated, due to its inconvenient route of 
administration. Several newly discovered strains of MRSA show antibiotic resistance 
even to vancomycin and teicoplanin (a glycopeptide antibiotic). These new 
evolutions of the MRSA bacterium have been called vancomycin intermediate-
resistant Staphylococcus aureus (VISA). For the moment, there are limited and rather 
expensive therapeutic options for the infections by S. aureus in the critically ill (e.g. 
chemotherapy with linezolid) (Rayner and Munckhof, 2005).  
 
 201 
Chapter 7:   Concluding remarks and future studies 
Ceftobiprole (a fifthgeneration cephalosporin) has been approved for use in limited 
countries. Ceftobiprole shows activity against systemic MRSA infections when given 
intravenously (Jacqueline et al., 2005) for community-associated bacterial 
pneumonia and acute bacterial skin and skin structure infections including MRSA. 
The high affinity of ceftaroline for penicillin-binding proteins is responsible for the 
potent activity observed against clinically relevant pathogens (Biek et al., 2010).  
 
Therefore the continuing development of currently available antibiotic arsenals to be 
effective against drug resistant bacteria should remain important. This also suggests 
redefining infectious disease therapy, shortening length of therapy, reducing side 
effects profile, and reducing drug resistance profiles of currently available 
antibacterial products. However, the ultimate goal of drug development for MRSA 
infections is to discover novel antibacterial agents which interfere with unexploited 
bacterial molecular target(s).  
 
Therefore my PhD studies were focused on antibacterial drug development coupled 
with attempts to develop molecular diagnostics for bacterial infections. During the 
first part of my work in chapter 3, I investigated the antibacterial properties of 
peptoid molecules for therapeutic purposes against gram positive and gram negative 
bacteria. The latter part of my research, in chapters 4, 5 and 6 investigated the 
development of MRSA specific diagnostic optical molecular probes using aptamer 
and peptide combinatorial libraries.  
 
(a) Study and characterisation of peptoids as novel antimicrobial agents. 
 
The first hypothesis of my study was to investigate the antimicrobial properties of 
lysine monomeric peptoids as a novel class of antibiotics. A library of peptoids were 
synthesised and antibacterial properties were studied on clinically relevant bacterial 
species. TOP demonstrated significant broad-spectrum bactericidal activity out of 13 
different peptoids tested. Therefore further studies were carried out on TOP 
investigating the mammalian cell toxicity and immunomodulatory properties on TOP 
in chapter 3.  
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Therapeutic options for antibiotic-resistant bacterial pathogens remain inadequate 
and new approaches are urgently required. With the introduction of antibiotics in 
1940s and 1950s patients with bacterial infections were handed a ‘golden bullet’. But 
with the over usage of antibiotics throughout the last century and this century, most 
bacteria have become resistant to antibacterial drugs. No new classes of antibiotics 
have been produced in the last 37 years (Bax et al., 1998). Therefore discovery of 
new therapeutic approaches are urgently required. 
 
Cationic antimicrobial peptides (CAMPs) are important components of the innate 
immune systems in all living organisms including bacteria, fungi, plants and animals. 
These peptides are active against bacteria, fungi, viruses, and pests such as insects. 
Peptoids have been generated to mimic the biological functions of naturally 
occurring cationic host defense peptides (Steiner et al., 1981). However peptoids 
have not been used as antibacterials in the clinic. Compared to peptides, peptoids 
have higher stability under in-vivo conditions and have great potential as new classes 
of antimicrobials. Therefore developing peptoids antimicrobials were focused in the 
chapter 3 aiming to discover new therapeutics for multidrug resistant bacteria.   
 
Chapter 3 discussed 9-mer lysine-like peptoid library development and their 
antibacterial properties followed by investigations of mammalian cell toxicity and 
immunomodulatory properties. A library of 9-mer lysine-like peptoid was made to 
determine the structure-activity relationship of these peptoids and peptoid 
derivatives. These peptoids were screened against clinically important gram positive 
and negative bacterial species to determine the antibacterial properties. The 9-mer 
lysine-like peptoid library was made based on the well-known cell penetrating HIV 
Tat protein and the lysine-like cell-penetrating peptoids (Unciti-Broceta et al., 2009, 
Dhaliwal et al., 2012). To determine the structure-activity relationship of these 
peptoids, peptoid derivatives were made by; (i) changing the length of the carbon 
side chain (Figure 1.14); and (ii) N-terminus modifications (Figure 1.15). The three 
different side chain lengths were introduced to a 9-mer which consisted of butyl 
(four-carbon), hexyl (six-carbon) and octyl (eight-carbon) monomers. Further 
structural changes were made to the N-terminus end of the polymer encompassing 
 
 203 
Chapter 7:   Concluding remarks and future studies 
different chemical groups conjugated to the N-terminus end such as H-non modified, 
BnCO-Phenyl acetamide, Tosyl-Toluene sulfonamide, Suc-Succinic amide, Ac-
Acetamide and Fmoc-9-Fluorenemethanol (Figure 1.15 and Table 1.3). A number of 
different bioassays were developed and carried out to study the structure-activity 
relationship on these peptoids on bacterial killing and potential mechanisms. 
 
In chapter 3, it was concluded that out of 13 different peptoids derivatives, only one 
peptoid called Tosyl-octyl-peptoid (TOP) demonstrated significant broad-spectrum 
bactericidal activity. TOP kills bacteria under non-dividing and dividing conditions. 
The MIC values of TOP for S. epidermidis, E. coli and Klebsiella were 20 µM, 
whereas Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-
sensitive Staphylococcus aureus (MSSA) were 40 µM. The highest MIC values were 
observed for Pseudomonas aeruginosa (PAO1) at 80 µM. The selectivity ratio (SR) 
or Therapeutic index (TI) was calculated, by dividing the 10% haemolysis activity (5 
mM) by the median of the MIC (50 µM) yielding a TI for TOP as 100. This TI is 
well above previously reported peptidomimetics TI of around 20. TOP demonstrates 
selective bacterial killing in co-culture systems and intracellular bacterial killing 
activity. TOP demonstrates killing of bacteria in the intracellular and extracellular 
compartments suggesting it could be valuable in both prophylaxis and therapy.  
 
Peptoids have been generated to mimic the biological functions of naturally 
occurring cationic host defense peptides that confer antimicrobial activity including 
cationicity and amphipathic secondary structure where residues are segregated into 
cationic and hydrophobic regions (Chongsiriwatana et al., 2008). The biophysical 
characteristics of cationic host defence peptides have been used to design non-natural 
peptoids with similar properties, termed ‘ampetoids’ (Chongsiriwatana et al., 2008). 
Recent structure/function investigations of these ampetoids suggested a requirement 
for net cationic charge and moderate hydrophobicity for effective antimicrobial 
activity, with high hydrophobicity and strongly amphipathic structures causing 
hemolytic effects (Chongsiriwatana et al., 2008). Balancing high antimicrobial 
activity with low toxicity to the host is fundamental for clinical application, and may 
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be quantified using a selectivity ratio (Chongsiriwatana et al., 2008). Since TOP 
yields a TI of 100, TOP displays favourable characteristics.  
  
TOP has two major components; (i) lysine-like (octyl) 9-mer unit and (ii) N-
substitute-Tosyl (sulphonamide) group. Previous studies have identified that several 
lysine-peptide hybrids have broad-spectrum activity against clinically important 
bacteria and fungi (Ryge et al., 2008). Recent studies on the lysine-peptoid hybrid 
LP5 revealed that it traverses the cytoplasmic membrane of S. aureus without 
causing lethal damage to the membrane and binds to the chromosomal DNA 
inducing bacterial death (Gottschalk et al., 2013). It has been postulated that the 
cationic and amphiphatic nature of AMPs selectively kill bacteria by penetrating the 
negatively charged cell membrane leading to membrane disintegration. However, 
AMPs may also act by other mechanisms without destruction of the cell membrane 
targeting intracellular enzymatic activities such as cell wall synthesis and RNA, 
DNA and protein synthesis (Jenssen et al., 2006; Hale and Hancock, 2007). The 
inhibition of RNA, DNA and protein synthesis in bacteria may result from AMPs 
interacting with DNA repair by collapsing replication forks (Gunderson and Segall, 
2006; Dubois et al., 2013). At higher concentrations, LP5 also targets the cell 
membrane leading to leakage of intracellular compounds like ATP, resulting in cell 
death (Dubois et al., 2013; Gottschalk et al., 2013). 
 
According to the initial screening results with the growth inhibition assay, the 
presence of the sulphonamide groups on octyl-peptoid showed antibacterial activity. 
However, Hexyl and Butyl peptoids with the N-sulphonamide group did not show 
any antimicrobial activity on PAO1 (Tosyl-Butyl and Tosyl-Hexyl) and E. coli 
(Tosyl-Hexyl). But some growth inhibition was observed with MRSA and MSSA 
with Tosyl-Hexyl, indicating that the sulphonamide group synergises with the octyl-
9-mer combination to promote the broad range of bactericidal activity on Gram 
positive and negative bacteria. Previous studies on sulfonamide derivatives revealed 
that the given chain length of the lipophilic moiety and the nature of the hydrophilic 
group substituted at the amino nitrogen of the sulfonamide molecule had a marked 
influence on surfactant properties and mutual lipophilic and hydrophilic groups may 
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have surface activity and an antibacterial effect (Badr, 2008). These studies suggest 
that the proper combination of different groups to the sulphonamide may have 
beneficial effects. 
 
TOP shows less mammalian cell membrane toxicity and less cytotoxicity activity on 
A549 cells at low concentrations, suggesting that the TOP shows selectivity between 
bacterial and mammalian cells. Unlike other antimicrobial peptoids, TOP shows 
higher MIC values tested. It also has higher SR showing higher selectivity over 
mammalian cells. However at low concentrations, TOP induces secondary necrosis 
of apoptotic neutrophils similar to other antimicrobial peptides. In future studies, 
modulating molecular structure of the TOP could increase the bacterial killing 
efficacy and reducing the mammalian cell toxicity.  
 
In conclusion these studies, suggest that the antibacterial activity of TOP may have 
been due to the length of the eight carbon-side chain and the N-terminus 
sulphonamide group combination. Neither individual octyl-9-mer group nor the 
sulphonamide groups are antimicrobial as shown in the results section. Therefore the 
results suggest that the correct combination of different lysine groups with 
modification on the carbon length and the capping groups generates the antimicrobial 
active compound. However further studies are required to elucidate the mechanism 
of action on bacterial killing.  
 
(b) Strategies to develop aptamer and peptide molecules to detect 
bacterial infection. 
 
Current microbiological diagnosis is inefficient, with a minimum lag of 48 hours 
between the isolate reaching the laboratory and accurate organism identification. 
Delay in administering effective antibiotics results in stepwise increases in mortality 
resulting from bacterial sepsis and use of empirical broad spectrum antibiotics in 
patients with severe sepsis will become greater, driving selection of resistant 
microorganisms and exacerbating the problem. Therefore strategies to improve the 
diagnosis of serious infection such as MRSA are important to avoid unnecessary 
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antibiotic exposure. The role for novel diagnostic technologies lies in rapid 
identification of causative organisms with specificity (O'Brien and Gould, 2013). 
MRSA is currently detected using multiplexed PCR primers that detect specific 
genes for S. aureus (e.g. nuc or fem) and mecA for detection of methicillin resistance 
(Turek et al., 2013). The eradication of multidrug-resistant bacteria is very difficult 
and it is essential to look for alternative detection options to identify MRSA 
infection. According to the second hypothesis of my studies, it was focused on 
aptamer and peptide molecular probes and developed as novel diagnostic tools to 
detect MRSA infection. To study this hypothesis MRSA specific extracellular 
PBP2A protein was purified and two different aptamer probes were developed as 
PBP2A specific and MRSA specific based on bacterial cell based SELEX 
procedures.  
 
Chapter 4 discussed mecA gene cloning and PBP2A protein over-expression in order 
to carry out the SELEX and phage biopanning against PBP2A protein. SELEX and 
phage biopanning were carried out separately against the purified PBP2A protein and 
whole bacterial cells and the results were discussed in the chapter 5 and 6. Aptamer 
and peptides are small molecules with potential as tools to enable disease diagnostics 
and treatment. My main target was to develop MRSA specific molecular probes 
using highly diverse combinatorial libraries of aptamers and peptides. These 
molecules y bind with high affinity to targets on the cell surface and are selectively 
displaced by putative ligands. These are the peptide-based phage display and the 
oligonucleotide-based aptamer techniques, respectively. Aptamer libraries were 
designed and ordered from commercial Integrated DNA Technologies (IDT) and the 
phage display libraries were purchased from NEB.  I have screened aptamer libraries 
and peptide libraries against whole MRSA bacteria and purified PBP2A protein. The 
PBP2A protein is a unique membrane protein expressed by MRSA.  I cloned the 
mecA gene and over-expressed and purified the PBP2A protein before testing its 
functional properties to its native protein present in MRSA using the Latex 
Agglutination test. The SELEX procedure was carried out against whole MRSA 
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Chapter 5 described the aptamer bio-imaging probe development using purified 
PBP2A protein and MRSA. Optimizing the selection buffer conditions increases the 
likelihood of producing a good target aptamer. The selection buffer conditions may 
vary as widely as the selection targets, and therefore buffer optimization is helpful 
for effective aptamer selections (Stovall et al., 2004). Therefore different selection 
buffer conditions were adopted during SELEX and optimised to minimise the non-
specific binding and optimise the target molecular binding in PBS (with Ca+2 and 
Mg+2) instead of others buffer tested (Cho et al., 2006). Previous studies suggested 
that the buffer conditions may vary between monovalent salt(s) identity, monovalent 
salt(s) concentration, divalent salt(s) identity, divalent salt concentration, buffer 
identity, buffer concentration, and pH. The optimized buffer conditions likely 
increase the probability of a successful selection and therefore promote higher ratios 
of successful aptamer selections against a variety of targets (Stovall et al., 2004). 
Amplifying nonspecific DNA during the PCR amplification is also a major problem 
in SELEX protocol. Therefore PCR conditions such as annealing temperature and 
number of PCR cycles were optimised to have high yields of DNA and low non-
specific DNA amplification to 10 PCR cycles (Sefah et al., 2010). However many 
other researchers have used more than 10 PCR cycles in their protocols and found no 
nonspecific amplifications due to variable primers, buffer conditions and annealing 
temperatures (Shangguan et al., 2006; Tang et al., 2007; Sefah et al., 2009).   
 
The elimination of the negative DNA strand after PCR amplification is usually 
conducted by either lambda exonuclease digestion of the negative dephosphorylated 
strand (Oh et al., 2011), asymmetric PCR (Berezovski et al., 2008), denaturing 
polyacrylamide gel electrophoresis (Kim et al., 2010), or with streptavidin-coated 
magnetic beads (Tanaka et al., 2009; Sefah et al., 2010), which I have adopted in my 
experiments. However each of these approaches has its own advantages and 
disadvantages which are more broadly discussed elsewhere (Marimuthu et al., 2012; 
Svobodová et al., 2012). In addition, a multitude of sequences present in the 
amplification step of the SELEX procedure make the pool prone to forming non-
fully complementary dimers, which may often lead to the appearance of a product of 
undesired size, mostly larger (Murphy et al., 2003). To prevent this effect, the 
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number of cycles and annealing temperatures for the PCR amplification of the 
selected library has to be strictly monitored and adjusted (Waybrant et al., 2012). In 
my experiments it was set to 10 PCR cycles to minimise larger PCR fragments.  
 
The theory of SELEX is very simple and relies on Darwinian evolution at a 
molecular level. Basically, a vast number (1014–1016) of DNA or RNA 
oligonucleotides with different sequences are subjected to selection for binding to the 
target molecules. While non-binding oligonucleotides are discarded by washing steps 
and counter selection, the bound sequences exhibiting affinity for the target are 
amplified by PCR. Generally, after 8–15 cycles, the oligonucleotide pool is 
populated by the best binding aptamer candidates, which are finally separated and 
identified by sequencing (Vater et al., 2003; Szeitner et al., 2014). However, I 
implemented a novel approach where no counter selection has been practiced during 
the SELEX procedure. This also reduced the number of SELEX cycles minimising 
errors during PCR amplification and mishandling samples (Sefah et al., 2010). As in 
my experimental procedure five rounds of SELEX have been carried out 
independently against MRSA (ATCC252), MSSA (ATCC 25923), PAO1-
Pseudomonas, Kebsiella pneumonia, Escherichia coli (ATCC 25922) and eukaryotic 
cells A549. This generated aptamer against individual bacteria and eukaryotic cells 
but they were not specific due to lack of counter selection. The elimination of non-
specific aptamer was carried out at sequence level called in-silico SELEX. 
Sometimes SELEX fails to identify aptamers that bind to their target with high 
affinity. Thus, post-SELEX optimization of aptamers is required to improve aptamer 
binding affinity. The in- silico maturation is based on a genetic algorithm (Savory et 
al., 2010). In another study, In-silico maturation was performed to improve a VEGF-
binding DNA aptamer (Nonaka et al., 2013). 
 
Implementation of aptamer production is much more complex than its simple, 
theoretical scheme would suggest, and the success of the procedure mainly relies on 
seemingly minor experimental details of the selection. Consequently, following the 
introduction of SELEX, numerous alternative approaches have been explored 
(Gopinath, 2007) with the general intention of increasing the success rate, but also 
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ensuring high speed (Park et al., 2009; Huang et al., 2010), low handled volumes 
(Hybarger et al., 2006), minimal contamination and automation (Mathot et al., 2013). 
 
Chemically synthesized selected aptamer sequences can be labelled directly with (i) a 
fluorophore, such as FITC or cy5 or (ii) biotin. Biotin labelled aptamers are detected 
with streptavidin-conjugated fluorophore, such as Alexa Fluor 488, phycoerythrin or 
phycoerythrin-cy5.5 (Sefah et al., 2010). In this study two aptamer probes were 
resynthesized with 5’ FITC modification from SIGMA-ALDRICH and binding 
assays were carried out as mentioned in the Sefah et al., (2010). Both aptamer probes 
show higher specificity towards the purified protein but no specificity towards the 
MRSA bacteria. However previous publications also show that some of the selected 
aptamers can also bind to the controls and other related cells (Sefah et al., 2010; 
Szeitner et al., 2014). The two aptamer probes may bind non-specifically towards the 
other surface molecules located on the bacteria. Since the counter selection was not 
carried out during the SELEX nor in-silico maturation, therefore the aptamer probes 
may bind to other bacteria in a non-specific manner. It can also be expected that 
some selected aptamers will recognize both target and control cells (Cerchia et al., 
2005; Chen et al., 2008). 
  
Chapter 6 described the development of MRSA specific peptide probes using highly 
diverse phage derived peptide libraries (Ph.D.).  This study used 12-mer PhD peptide 
library against MRSA since most of the previous studies used 12-mer library from 
New England Biolabs (NEB) (Trepel et al., 2008; Zhang et al., 2014). Bio-panning 
experiments were carried out as described in the material and method section 
according to the commercial supplier (NEB). The counter selections on MSSA and 
PAO1 were carried out before bio-panning with PBP2A coated Ni beads and MRSA 
whole bacterial cells. Peptide molecules were developed against viruses (Long et al., 
2014), bacteria (Sainath Rao et al., 2013), cancer cells (Ploss et al., 2014; Sainath 
Rao et al., 2013) and other bio molecules (Jiang et al., 2014) using phage display 
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After 3 rounds of bio-panning and amplification, 120 clones were characterized by 
DNA sequencing and amino acid sequences were analysed using ClustalW online 
tool. However the number of biopanning rounds can be varied from 3-5, although the 
commercial supplier recommends 3 rounds of biopanning (Turnbough, 2003; Dane et 
al., 2006). Two different peptide sequences were identified as PBP2A specific 
peptide GLHTSATNLYLH and MRSA bacterial specific peptide 
GWTSVSVHIRGG after ClustalW analysis. For further analysis N-terminus FAM 
conjugated these peptide sequences were synthesised and binding affinity have been 
evaluated in-vitro with bacterial binding selectivity assays. Similar N-terminus 
conjugations of peptides were reported on cancer cell detection (Dane et al., 2006). 
Flow cytometry and confocal microscopy were used to evaluate the peptide binding 
efficacy to bacteria (Williams et al., 2003). However both probes showed no 
specificity towards MRSA and bound to the control bacteria tested.  These results 
suggested addressing limitations in this study in future work.     
 
Scientists recent have focused their research on screening novel AMPs by using 
combinatorial libraries and computational approaches for antimicrobial drug 
discovery and design. Phage display serves as a valuable tool for the selection of 
peptides binding to surface epitopes on whole cells (Kay et al., 1998; Wang et al., 
2009). Some studies used a 12-mer phage-display library to identify peptides binding 
to the whole cell surface of E. coli. This focused to identify a novel peptide that 
showed binding to E. coli cells. The peptide exhibited antimicrobial activity against 
Gram negative organisms and showed significant bactericidal activity against E. coli 
and P. aeruginosa (Sainath Rao et al., 2013). Therefore the antibacterial activity of 
these peptides was also studied on MRSA and MSSA. The results suggested that 
these peptides did not show any specific binding towards the MRSA and show no 
antibacterial activity. 
 
In this study the two peptides were synthesised as N-terminus FAM conjugated 
probes. However during the biopanning procedure the N-terminus of the selected 
peptide sequence was free and the C-terminus was fused to the phage. Therefore, this 
structural modification may affect the binding ability of these peptides to targeted 
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molecules.  In previous studies structural modification were done to achieve the 
binding of the peptide to the target molecules (Turnbough, 2003; Jinghui et al., 
2014). Further to that when designing synthetic peptides corresponding to selected 
sequences, it is recommended to add the spacer sequence Gly-Gly-Gly-Ser to the C-
terminus and amidating the C- terminal carboxylate to block the negative charge. The 
chemical conjugation of the peptide to FAM, the C-terminal serine can be replaced 
with cysteine (if there are no other cysteines present in the sequence) (Chichili et al., 
2013).  
 
Future perspectives:  
 
In summary, my studies on peptide research have produced some positive outcomes 
and generated more avenues for further studies on peptoid work in the future. I 
demonstrated the biological effects of modulating the peptoid libraries and in-vitro 
experiments were optimised for future research. These peptoids can be evaluated in-
vivo mice models and to have better understanding of peptoid biology and to develop 
drug candidates for bacterial infection.  
 
In future studies, I would like to suggest that the combination of variable lengths of 
lysine like peptoids (e.g. 10-mer, 11-mer or 12-mer) and different capping groups 
may be a very good platform to study the antibacterial peptoid biology. This is not 
only limited to lysine peptoids, we also can study other peptoids derived from amino-
acids combinations. This can change the properties of peptoids such as pH, 
hydrophobicity and hydrophilicity. This study evaluated the efficacy of TOP on 
Gram negative and Gram positive bacterial species including clinically isolated 
bacteria and multidrug resistance strains such as MRSA. However in future work it is 
important to investigate the effect of TOP on other clinically important 
bacterial/fungal/virus strains and species including vancomycin resistant enterococci 
(VRE), Mycobacterium tuberculosis and other multidrug-resistant microbes to study 
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The developed aptamer probes show some degree of specificity to purified PBP2A 
protein (chapter 4). However these probes are not specific to detect MRSA bacterial 
species over other bacteria. This could be due to several reasons as discussed 
previously. The most likely cause of failure, were issues regarding the SELEX 
procedure itself. There are many opportunities to further develop these probes.   
 
It is important to understand the biology and technical pitfalls during the 
development of MRSA specific aptamer and peptide probes. Since I have 
experienced the non-specificity of aptamer and peptide probe development I would 
rather try to repeat previously published aptamer and peptide molecular development 
protocol to familiarise with the techniques as example using thrombin as a molecular 
target (Avino et al., 2012).   
 
Success of aptamer probe development is mainly depend on the careful planning, 
meticulous implementation and tracking of progression of selection (Mencin et al., 
2014). Therefore in future studies monitoring of enrichment could be done after each 
SELEX round using labelled aptamer. Since most papers feature only a single 
aptamer, there is little awareness that the selection process generally results in a large 
number of sequences. Ideally, all selected oligonucleotides need to be evaluated 
individually in terms of their target binding properties to designate the most suitable 
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